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ABSTRACT 
HuR, the ubiquitously expressed member of the ELAV (embryonic lethal abnormal vision) 
family of RNA binding proteins, selectively binds to AREs (AU-rich elements) and mainly 
stabilizes ARE-containing mRNAs, e.g. TNFα, VEGF, c-FOS, favoring specific protein translation. 
TNFα mRNA is one of the most important target mRNA of HuR since the protein encoded by 
this gene mediates the inflammatory response and its overexpression is correlated with 
autoimmune diseases and cancer-related inflammation. Specific drugs are already available 
that can inhibit TNFα protein but cause important side-effects, as insurgence of tumoral 
pathologies, due to high immunodepression. Therefore, inhibition of TNFα mRNA translation 
by specific inhibitors targeting HuR, only in those cells undergoing pathological anomalies, is 
an alternative, intriguing novel therapeutic approach that deserves investigation. By REMSA 
and AlphaScreen assays we identified a family of low molecular weight inhibitors, called 
Tanshinones, among which DHTS-I (Dihydrotanshinone – I) was the most potent. Tanshinones 
are well known in the traditional Chinese Medicine Practice, and these anti-inflammatory 
agents possess the ability to prevent HuR-RNA complex formation in vitro. We further 
identified structural determinants of HuR and DHTS interaction using RRM1&RRM2 tandem 
domains. EMSA and AlphaScreen experiments, with truncated ΔRRM1 and mutants revealed 
that DHTS is a competitive binder of HuR with respect of target RNA. To ameliorate the 
solubility of DHTS, we synthesized a number of DHTS analogs, of which the most potent and 
soluble compound was named MFM49. We evaluated the anti-inflammatory potential of 
DHTS and DHTS analogs and the HuR-dependent mechanism of action, revealing that, at least 
in part, DHTS and DHTS analogs rely on HuR to exert their mechanism of action. Influence on 
NF-kB activation by DHTS and MFM49 upon LPS co-stimulation was not seen in 
immunofluorescence studies. So here, we disclose a previously unrecognized molecular 
mechanism of action exerted by DHTS, and anti-inflammatory potential of DHTS analogs 
opening new perspectives to therapeutically target the HuR mediated, post-transcriptional 
control in inflammation and cancer like anomalies. 
 
 
 
 3 
 
 
 
 
 
 
 
 
ORIGINAL AUTHORSHIP 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declaration 
 
I Preet Lal, confirm that this is my own work and the use of all material from 
other sources has been properly and fully acknowledged. 
 
 
 
 
 
 4 
 
CONTENTS                                             #Page 
ABSTRACT…………………………………………………………………………………………………………………………….2 
ABBREVIATIONS .................................................................................................................... 9-10 
INTRODUCTION ....................................................................................................................... .12 
Elav-like genes a conserved family in vertebrates………………………………………………………………..12  
HuR structural feature………………………………………………………………………………………………………..14 
Signals that converge to HuR…..…………………………………………………………………………………………………..16 
p38 MAPK Pathway influence on HuR and TTP……………………………………………………………………18 
NF-kB pathway……………………………………………………………………………………………………………………19 
ROLES OF HUR .......................................................................................................................... 20 
HuR in pre-mRNA processing . ……………………………………………………………………………………………..20 
HuR in Cancer .......................................................................................................................... .23 
HuR in Inflammation ............................................................................................................... .26 
Nuclear or Cytoplasmic: Does it endow any prognostic role? .................................................. 30 
Current state of the art on the Pharmacology of HuR and Small Molecules Inhibiting HuR….32 
 
Focusing on Tanshinones/DHTS to target HuR in vitro and in vivo……………………………………….35 
Why to inhibit HuR………………………………………………………………………………………………………………38 
MATERIAL AND METHODS ...................................................................................................... 41 
RESULTS .................................................................................................................................... 49 
DHTS is an Inhibitor of HuR-RNA Interaction ........................................................................... 50 
DHTS binds to M1M2 domains of rHuR…………………………………………….………………………………….51 
DHTS selective profile against other RBPs…………………………………………………………………..…….….53 
Inter-domain linker region of HuR structure is crucial for binding to target RNA and therefore  
for DHTS activity………………………………………………………………………………………………………………….54  
Single point mutations in the HuR-DHTS interacting region abolishes DHTS efficacy………….…57 
Single point mutation causes dimerizing aggregation behavior of Muteins…………..………………60 
 5 
 
DHTS downregulates TNFa and VEGF in breast cancer cells…………………………………………………61 
DHTS efficacy depends upon HuR expression……………………..………………………………………………64 
DHTS is effective on HuR positive models invitro and invivo…….…………………………………………….64  
BIOCHEMICAL CHARACTERIZATION OF DHTS ANALOGS………………………………………………..………..66 
 
MFM49 is most potent inhibitor of rHuR-RNA interaction invitro……………………………………..68
  
DHTS analogs are the potential inhibitors of HuR RNA: Complex formation………………..………..69 
MFM49 and DHTS do not influence nucleocytoplasmic level of HuR in MCF-7 cells……………....71 
MFM49 and DHTS do not influence substantial nucleocytoplasmic level of NF-kB and HuR in 
RAW264.7 cells…………………………………………………………………………………………………...................73 
ANTI-INFLAMMATORY PROPERTIES OF DHTS ANALOGS………………………………..…………..……….75 
Cell Viability assays………………………………………………………………………………………………..……………75 
DHTS analogs down-regulates LPS induced cytokines in RAW264.7 cells……………….……….…..76 
DHTS downregulates TNFa and TTP levels…………………………………………………………………………..78 
Down regulation of major cytokines by DHTS and MFM49 is HuR-dependent……………………..79  
 
TNFa down-regulation by DHTS and DHTS analogs is independent of TTP in TTP-KO 
macrophages………………………………………………………………………………………………………………………80 
 
Preliminary Results…………………………………………………………………………………………..………………..81 
NF-kB activation is not influenced by DHTS analogs in RAW264.7 cells …………………………………..81  
 
 MAPK pathway activation upon co-treatment our with compounds…………………………………..84 
Analysis of p38 MAPK pathway in TTP-KO cells……………………………………………………………………85
  
Polysomal analysis in RAW264.7 upon LPS stimulation………………………...…………….………………85
  
Effect on mRNA Stability after transcriptional inhibition with Actinomycin D……………………….87  
OTHER DHTS ANALOGS…………………………………………………………………………………………...........88 
DISCUSSION…………………………………………………………………………………………………………………….91 
CONCLUSIONS ........................................................................................................................... 98 
REFERENCES… ........................................................................................................................... 99 
 6 
 
APPENDIX……………………………………………………………………………………………………………………..112 
Acknowledgements……………………………………………………………………………………………………….144 
 
LIST OF FIGURES 
Figure 1 Schematic representation of the biological processes where HuR plays crucial role…14 
Figure 2 (i)  Crystal structure of free RRM1/2……………………………………………………………………….15 
Figure 2 (ii) Dynamic properties of RRM1/2…………………………………………………………………………15 
Figure 3 MAPK signalling pathways affecting properties of cytokine mRNAs………..………………17 
Figure 4 Schematic of regulation of TNFa mRNA and TNFa release by p38 and MK2/3…….……18 
Figure 5 Schematic of NF-kB pathway and the Mechanism of NF-kB action…………………………20 
Figure 6 HuR function in controlling cell fate by controlling mRNAs…………………………………….25 
Figure 7 Schematic diagram of HuR target and their influence in cells…………………………………..26 
Figure 8 The immunostaining of HuR from histological and cytological specimen ………….....32 
Figure 9 Schematic representation of Synthesis HuR-FNP preparation………………………….……...34 
Figure 10 Chemical structure of tanshinones……………………………………………………………………....37 
 Figure 11 Densitometric comparision of Tanshinones activity by EMSA ………………..…….........38   
Figure 12 Biochemical screening and characterization of DHTS in-vitro.................................. 50 
Figure 13 DHTS interfere with HuR-RNA complex and lowers the cell viability...................... 51 
Figure 14 Effects of DHTS on RRM1/2 and RRM2/3………………………………………………………………51 
Figure 15 Limited effects of DHTS on individual RRMs…………………………………………………………..53  
Figure 16 Determination of selective profile for DHTS in panel of other well-known RBPs..……53 
Figure 17 EMSAs using individual RRMs and ΔRRM1 to dictate probe binding upon DHTS 
addition………………………………………………………………………………………………………………………………56  
Figure 18 Single point mutations in the HuR-DHTS interacting region abolish DHTS efficacy 58 
 7 
 
Figure 19 CD and NMR spectra of TNFa……………………………………….……………………………………….59 
Figure 20 Calculation of Kd of muteins by AlphaScreen assay……………………………………………….59 
Figure 21 Calculation of Kd for RRM1/2, and positions of mutated residues in HuR…………….60 
Figure 22 Aggregation of HuR muteins…………………………………………………………………………….....61 
Figure 23 DHTS downregulates TNFα and VEGF in breast cancer cells………………………………….62 
Figure 24 Efficacy of DHTS is HuR dependent ……………………………………………………………………..63 
Figure 25 DHTS efficacy relies on HuR presence in vivo…………………………………………………..65-66 
Figure 26 Screening of other potent HuR inhibitors……………………………………………………………..67 
Figure 27 MFM49 is most potent inhibitor of rHuR-RNA interaction………………………………68-69 
Figure 28 AlphaScreen assays to evaluate DHTS analogs activity………………………………..………70 
Figure 29 Nucleocytoplasmic levels of HuR upon MFM49 and DHTS treatment………………72  
Figure 30 Nucleocytoplasmic levels of HuR & NF-kB upon co-treatment with LPS and DMSO, 
MFM49, DHTS and ActD ………………………………………………………………………………………………...73-74 
Figure 31 Dose Response curve for DHTS analogs and DHTS………………………………………………..76  
Figure  32 DHTS analogs down-regulates cytokines produced after LPS stimulation………76-77 
Figure 33 DHTS downregulates TNFα and TTP levels…………………………………………………………….78 
Figure 34 Down regulation of major cytokines by DHTS and MFM49 is HuR-dependent…79-80 
Figure 35 TNFa levels counteracted by DHTS analogs independent of TTP in TTP KO cells……..81 
Figure 36 NF-kB activation is not influenced by DHTS analogs in RAW264.7 cells ………………..82 
Figure 37 Activation of p-MK2 and α-TTP levels in RAW.264.7 cells…………………………………….83 
Figure 38 Analysis of p38 MAPK pathway in TTP-KO cells…………………………………………………...85 
Figure 39 RT-qPCR analysis of actin and TNFα mRNA levels in Polysomal Profile…………………86 
Figure 40 Influence of DHTS and MFM49 on the stability of major cytokines in LPS-exposed 
RAW 264.7…………………………………………………………………………………………………………………………..88 
 8 
 
Figure 41 Cell viability assays done on various cell line using HuR inhibitors………………………….89 
Figure 42 (1 & 2) Cytokines levels upon DHTS and MFM49 treatment...………………………………114 
 
LIST OF TABLES 
TABLE 1 K(obs) values for HuR and its isoforms in FP…………………………………………………………..56 
TABLE 2 Ki values obtained for DHTS Analogs by Alphascreen assay……………………………….70-71 
TABLE 3 IC-50 values for DHTS and its analogs……………………………………………………………………112  
TABLE 4 qPCR Primer sequences………………………………………………………………..……………………..112 
 TABLE 5 HuR RRMs Primer and HuR muteinsPrimers…………………….……………..……………..…..113 
 
 
 
 
 9 
 
ABBREVIATIONS 
Act D                                                                                                                                          Actinomycin 
D ALEs                                                                                                                                          Alternative Last Exons 
AREs                                                                                                                                    AU-Rich Elements 
ATP                                                                                                                       Adenosine Tri-Phosphate 
Bi-TNF                                                                                                                                 Biotinylated TNF 
BMDMs                                                                                               Bone marrow derived macrophages 
CALM-2                                                                                                                                Calmodulin 2 
CCL                                                                                                                     C-C Motif Chemokine Ligand  
CD                                                                                                                                       Circular Dichroism 
CENPN                                                                                                                        Centromere Protein N 
Chk2                                                                                                                               Checkpoint Kinase 2  
cIAP-2                                                                                                           Cellular Inhibitor of Apoptosis 
COX-2                                                                                                                                  Cyclooxygenase 2  
CSF-2                                                                                                                 Colony Stimulating Factor 2 
CXCL                                                                                                       The chemokine (C-X-C motif) ligand 
CXCR-4                                                                                                 C-X-C Motif Chemokine Receptor 4 
DHTS-I                                                                                                                            Dihydrotanshinone-I 
Dlst                                                                                                Dihydrolipoamide-Succinyl transferase 
ELAVL-1                                                                                     Embryonic Lethal Abnormal Vision like-1 
EMSA                                                                                                  Electrophoretic Mobility shift Assay 
FNP                                                                                                                                Folate Nanoparticles 
GATA3                                                                                                                        GATA-Binding Factor 3 
HDACs                                                                                                                           Histone deacetylases 
HuR                                                                                                                                      Human Antigen R                                                    
IC50                                                                                                                   Inhibitory Concentration 50 
i-CLIP                              individual-Nucleotide Resolution UV Crosslinking and Immunoprecipitation 
IFN-γ                                                                                                                                           Interferon- γ     
MAPK                                                                                                  Mitogen Activated protein Kinases 
MK-2                                                                                               MAP kinase-activated protein kinase  
 10 
 
 
 
 
MMPs                                                                                                                 Matrix Metalloproteinase 
NF-1                                                                                                                                  Neuro Fibromin-1 
Ni-NTA                                                                                                                        Ni-Nitrilo Triacetic Acid  
NMR                                                                                                               Nuclear Magnetic Resonance 
OSCC                                                                                                             Oral squamous cell carcinoma 
PAR-iCLIP           Photoactivatable ribonucleoside-enhanced Crosslinking and Immunoprecipitation  
PCR                                                                                                                        Polymerase Chain Reaction 
p-gp                                                                                                                                           p-Glycoprotein 
 Pro-Tα                                                                                                                                   Pro-Thymosin A 
qPCR                                                                                            Quantitative  Polymerase Chain Reaction 
RBP                                                                                                                                    RNA binding Protein 
RIP                                                                                                                         RNA-Immunoprecipitation 
AUBPs                                                                                                                     AU-rich Binding Proteins 
RRMs                                                                                                                          RNA recognition motifs 
SDS-PAGE                                             Sodium Dodecylsulphate-Polyacrylamide Gel Electrophoresis 
SIRT                                                                                                                                 Deacetylase Sirtuin 
SNPs                                                                                                         Single Nucleotide Polymorphisms 
SPR                                                                                                                    Surface Plasmon Resonance 
TGF-β1                                                                                                Transforming Growth Factor beta 1  
TIA -1                                                                                            T-cell restricted Intracellular Antigen -1 
TIAR-1                                                                  T-cell restricted Intracellular Antigen 1-related protein 
TNFa                                                                                                                            Tumor Necrosis Factor 
TRA                                                                                                                                         T-cell Receptors 
TTP                                                                                                                                             Tristetraprolin 
 
 
u-PA                                                                                                        Plasminogen Activator, urokinase 
VEGF                                                                                                      Vascular Endothelial Growth Factor 
α-KGDH                                                                                           Alpha-Ketoglutarate Dehydrogenase 
 
 11 
 
 
CHAPTER 1 
 
 
 Introduction 
 12 
 
INTRODUCTION 
Thousands of RBPs have been found to evolve during evolution, possessing unique properties 
to process newly formed RNA elements within eukaryotic cells regulating post-transcriptional 
gene expression. RNA molecules with RNA binding proteins (RBPs) further comprise 
ribonucleoprotein (RNP) complexes. These complexes play vital roles in cellular processes 
such as stability, splicing, transport, polyadenylation, cellular localization, and translation [1]. 
RBPs contains distinct RNA binding domains (RBDs), categorized in RNA recognition motifs 
(RRMs) or RNP domains,  K Homology (KH) domain, Zinc finger (mainly C-x8-C-x5-C-x3-H type), 
DEAD/DEAH box, Pumilio/FBF (PUF) domain, double-stranded RNA binding domain (DS-RBD), 
Piwi/Argonaute/Zwille (PAZ) domain, Sm domain, and few others. These domains usually 
consist of 90-100 amino acids domains which bind to pre-mRNA, mRNA, pre-ribosomal RNA 
(rRNA), and small nuclear RNAs (snRNA) [2].  
Many RNA binding motif indicates the molecular function of the RBP, e.g., DEAD/DEAH box is 
responsible for RNA helicase activity, PAZ domain binds to short single-stranded RNA in RNAi 
or microRNAs processing, and Sm domain binds to snRNA during splicing and also involved in 
tRNA processing. However, for other RBPs their RNA binding domains doesn’t indicate the 
aspect of RNA metabolism they engage [3]. 
One key feature of these RNA motifs is the RNP consensus sequence which is mainly 
composed of hydrophobic conserved amino acids distributed in each motif. These amino acids 
are well conserved and play an important role in the RNA binding function of these numerous 
RBPs. Most of the RBPs bind to multiple RNA types and these multi-RNA binding domain 
proteins possess amino acids at the terminal region of the RBDs are highly conserved and 
indicate that they are responsible for sequence-specific RNA contacts [2]. 
Elav-like genes a conserved family in vertebrates  
Eukaryotes employ many posttranscriptional mechanisms to regulate gene expression [4]. A 
distinct family of genes encodes proteins that have RNA binding domain or RNA recognition 
motifs, which binds RNA and regulate their post-transcriptional function. The elav embryonic 
lethal abnormal vision like / Hu-protein family of RBPs is one of them, which is neuronal 
specific and is necessary for differentiation and maintenance of neurons in Drosophila 
melanogaster. It was identified after characterization of fly mutants of lethal embryonic with 
abnormal vision phenotype, suggesting that the gene function during embryogenesis is pivotal 
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for normal neuronal differentiation [5] [6]. Later human ELAV orthologues have been 
discovered after the elav gene has been found to be linked with small cell lung carcinoma and 
paraneoplastic encephalomyelitis (elavl1 and elavl4) [7]. Similar genes have been found in 
other species Xenopus laevis, zebrafish, frogs, mouse and classified into elrA, elrB, elrC, and 
elrD [8]. 
ELAV-like or Hu antigens caused autoimmune response leading to numerous neurological 
defects in human also known as Hu-syndrome [9].  In mammals these four proteins are HuA 
(erlA), HuB (erlB), HuC (erlC) and HuD (erlD) shows homology of 70-85% between themselves. 
HuB (erlB), HuC (erlC) and HuD (erlD) are confined to be expressed in the neuronal tissue and 
generally localized in cytoplasm whereas the HuA (erlA) or HuR  is ubiquitously expressed in  
and localized in nucleus as was found in fly Drosophila [10] [11]. However, in the presence of 
nucleo-cytoplasmic signals, HuR can shuttle between nucleus and cytoplasm.   
Ma et al., in 1996 first cloned and characterized Human HuR protein showing tight binding to 
AREs present in c-fos, n-myc, c-myc and IL3 mRNAs. HuR mainly binds to AU rich (ARE) sites at 
the 3' prime of the mRNA of several cell-cycle regulators, growth factors, and transcription-
regulating proteins and transports the mRNA to the cytoplasm for protein translation. 
Localization of the HuR was confirmed on to human chromosome 19p13.2. Protein 
corresponds to 326 amino acid with molecular weight of 36 kDa [11]. 
HuR regulates many transcripts based on their AU-sequences available at the 3´or 5´UTR 
sequences. Excessive dysregulation of these transcripts via this protein can cause 
inflammation and further physiological dysregulation [12]. Comparing the sequence identity, 
AU-rich 3' UTR was found to be conserved in most of the cytokine and oncogenic mRNA [13]. 
It was also shown that the ARE of TNF mRNA is important for regulating its expression, is one 
of the targets of HuR and plays a crucial role in causing chronic inflammatory diseases [14]. 
Specifically, HuR-dependent stabilization was evident at the pre-mRNA level, suggesting that 
HuR-binding is a very early step in the life of an mRNA. HuR is a major player in regulating the 
post-transcriptional regulation of thousands of transcripts (Figure 1). Considering this fate, it 
has been proposed that the stabilization of pre-mRNA by HuR ensures proper mRNA 
processing, akin to the effect of Pol II transcription which was HuR mediated [15]. 
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Figure 1 Schematic representation of the biological processes, where HuR plays the crucial roles, i.e., in splicing 
of pre-mRNA, nucleo-cytoplasmic export, stabilization, and recruitment of bound transcript on active translating 
polysomes [16]. 
HuR Structural Features 
HuR protein has three RRMs (RRM1, RRM2, and RRM3), the N-terminal RRMs are arranged in 
tandem (RRM1–RRM2), whereas RRM2 and RRM3 are joined by a hinge region. First two 
regions were shown to bind tightly to target RNAs [17]. RRM3 has been demonstrated to bind 
to poly-A tail and further involved in oligomerization [18] [19]. Crystal structure of the first 
two HuR domains was solved by Wang, H. et al., 2013, both in RNA free and RNA bound form. 
By comparing both structures of RRM1/2, was revealed that it undergoes conformational 
changes after RNA binding. A region exists between two domains called as inter-domain linker 
comprised of 12-residue (Tyr95–Ala106) forming a short helix and maintains the distance 
within the two RRM motifs with a length of 13A⁰. RRM1 can recognize at least 4 or 5 
consecutive uracil’s (U) residues, which further confers strong binding affinity towards RNA, 
inter-domain linker was also found to interact with 1 or 2 uracil residues.  To further confirm 
this they have done mutational analysis in RRM1/2 domains, and CD experiments revealed 
that two structures of those mutants changed as compared to WT RRM1/2. The open (RNA-
free form Figure 2 (i)), and closed (RNA bound- form), however the protein folding are same,-  
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Figure 2 (i) crystal structure of free RRM1/2 [20]. 
  
 
 
 
 
 
 
 
 Figure 2 (ii) Dynamic properties of RRM1/2 a) HuR RRM1/2–RNA bound structure, RNA-interacting residues 
(bases) are labeled accordingly. b) The RNA is shown in a positively charged cavity formed upon conformational 
changes in HuR RRM1/2. c) Schematic view of RNA element covered with a 2Fo-Fc electron-density map 
contoured at 1𝜎. The RNA is represented as ball-and-stick representation. d) Super positioned structure of RRM1 
in bound and free form together with RRM2 [20]. 
-but there were dramatic changes in tertiary protein structure as represented by the attached 
figure above. Conformational changes were noticeable upon superimposition, as RRM2 has 
undergone a rotation of 137.3 rad, to form an RNA binding cleft [20]. 
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Signals that converge to HuR 
Mechanisms regulating HuR expression are still unknown. However, HuR functions primarily 
related to its subcellular localization [21]. Generally, HuR is present in the nucleus of 
unstimulated cells, where it binds to other protein ligands such as SETα/β, pp32, and APRIL, 
but can be transported to the cytoplasmic compartment in response to stress stimuli. In the 
presence of leptomycin increased binding with pp32 and APRIL was observed along with 
increased crosslinking of HuR to nuclear Poly (A) mRNA, suggesting ligand binding stabilized 
HuR’s association with ARE bearing mRNAs. Heat-induced activation of HuR has resulted in 
the cytoplasmic export of the hsp70 mRNA and importantly through its association with 
protein ligands pp32 and APRIL [17]. Moreover, AMPK (AMP-activated protein kinase) activity 
decreased the abundance of HuR vice versa and led to HuR dependent regulation of mRNA 
targets [22].  
MAPK cascades as the sensor of stress-activated pathways have been already found to 
regulate the abundance of cytoplasmic HuR and RNA complex formation activity in stimulated 
cells (Figure 3) [23] [24]. Activated MAP kinases p38 and ERK has enhanced the stability of 
uPA and p21 mRNAs along with an abundant cytoplasmic accumulation of HuR confirming the 
role of HuR in these signaling pathways [24] [25]. Accordingly, MAPK activation by ionizing 
radiation resulted in upregulation of the cyclin-dependent kinase inhibitor p21Cip1 and 
following arrest of cell cycle at G1 phase leading to accumulation of p21Cip1 mRNA. This was 
due to phosphorylation of HuR on Thr118, causing cytoplasmic accumulation of HuR and 
enhanced binding to the p21Cip1 mRNA [26].  
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Figure 3 MAPK-signaling pathway affecting properties of cytokine mRNAs via phosphorylation of HuR, different 
MAPKs and consequent mRNA stabilization and translation mediated by their interaction with distinct 3' or 5' 
UTR elements is shown. AUG start codon; UAA stop codon; CDS, coding sequence; UTR, non-translated region; 
(A)n, poly(A) tail of variable length; ARE, AU-rich element, class I, II, and III; CDE, constitutive decay element; pA, 
polyadenylation signal; miR, miRNA-binding site; XYZ, any other element such as cytoplasmic polyadenylation 
element (CPE), differentiation control element (DICE), CU-rich or an upstream sequence element (USE), and 
others; pre-miR, precursor miRNA (Figure adapted from Tiedje et al, 2014 [23]. 
 
Phospho-regulation at the HuR RRMs notably at S88 in RRM1, S158 in RRM2, and S100 in hinge 
region; strongly affect the binding to mRNA. However, there was no influence in the general 
structure of HuR [27]. 
Cyclins are the central engines of the cell cycle machinery, which interacts with cyclin-
dependent kinases (cdks) to form the cyclin-cdk complexes. It has been found that important 
cyclin A2 (for progression through the S and G2 phases) and cyclin B1 (for progression through 
G2/M phases) interact with HuR in human, mouse cells and cancerous cells thus can play a 
critical role in growth progression, at least in part by mediating the cell cycle-dependent 
stabilization of these mRNAs. It is known previously that HuR phospho-regulation by cdk1 at 
S202 within hinge region is necessary for increased association with 14-3-3 and causes its 
nuclear retention. In case of cell cycle residue S242 phosphorylation causes HuR's cytoplasmic 
accumulation with enhanced cyclin expression, modulating cell proliferation thus suggesting 
an important role of HuR in cell division [28] [29]. Chk2 (checkpoint kinase 2) also 
phosphorylate HuR at S88, S100, and T118,  leading to dissociation of HuR from the target 
RNA probe, further triggering the growth arrest with enhanced cell survival [30]. In in vitro 
kinase assays HuR serines (Ser) 158, 221 and 318 have been identified as targets of protein 
kinase C (PKC), further validation by phosphomimetic mutation at S221D and data from 
electrophoretic mobility shift assays indicated that S221 is not relevant for binding to target 
mRNAs. Whereas S158D and S318D have shown specific binding to all ARE-RNA types, 
suggesting the differential binding of HuR upon phosphorylation by PKCs [31]. Protein arginine 
methyltransferases (PRMTs) or member of PRMTs family, protein coactivator-associated 
arginine methyltransferase (CARM1/PRMT4) has been shown to methylate HuR protein, at 
arginine 217(R217) under the influence of LPS in macrophages and in HeLa cells, by stabilizing 
the stability of mRNAs encoding cyclin A, cyclin B1, c-fos, SIRT1, and p16 [32] [33]. Increased 
ubiquitination of the HuR at K182 was associated with tumor suppressor esophageal cancer-
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related gene 2 (ERCG2), upon DNA damage. In this report, XIAP, an inhibitor of apoptosis 
whose expression levels were decreased as the HuR was degraded [34]. Thus HuR activity with 
in cells is influenced by all these major upstream regulators in cellular pathways.  
 
p38 MAPK pathway influence on HuR and TTP 
p38 MAP kinase pathway is essential during the stress responses, e.g., heat shock, UV 
radiation exposure, LPS- stimulation, etc. [35]. Regulation of TNFα biosynthesis mediated via 
AU-rich element (ARE) post-transcriptionally under the influence of p38 MAPK pathway [14] 
[36]. p38 MAPK kinase targets various RNA binding protein including TTP, hnRNP, KSRP, PABP1 
[37][40]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Schematic of the regulation of TNF mRNA and TNF release by p38 and MK2/3. TTP expression is 
induced upon LPS treatment followed by activation of p38 and MK2/3 kinases. MK2 phosphorylates downstream 
targets TTP and PABP [37], [40] and [41]. p38 and MK2 phosphorylate HuR directly and get distributed in its 
subcellular localization from the nucleus (n) to the cytoplasm (c) [24] [42]. HuR involved in translation of ARE 
bearing mRNA, whereas on the opposite phosphorylation of TTP by MK2/3 leave TTP unable to compete with 
cytoplasmic HuR (right side of picture).  Non-phosphorylated TTP competes with HuR and stops the translational 
initiation by competition with eIF4G binding to PABP1 or by blocking association of the 43S pre-initiation 
complex. Therefore TTP interferes with expression of AU rich -containing mRNAs [43]. 
 
HuR and other RBPs are mainly involved in the control of the cytokine production under the 
control of p38 pathway [44] (Figure 4). HuR an RBP takes part in the nuclear and cytoplasmic 
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stabilization of ARE-mRNAs[45], [46]. HuR has been found to be associated with the 
translation of control of ARE bearing mRNA and has been shown as a negative 
posttranscriptional modulator in inflammation [47] [48]. MAPK MK-2 as an inducer of HuR 
function, after subjecting cells to oxidative stress, activated p38 MAPK pathway resulting in 
phosphorylation of HuR and consequently enhanced HuR binding to AREs of uPA in BT-549 
and MDA-MB-231 cells [24]. TTP in p38 MAPK pathway plays an opposite role to that of HuR, 
via deadenylation of colony-stimulating factor or other ARE bearing mRNA, including its own 
mRNA [37] [49]. MK-2 phosphorylates TTP which further binds with 14-3-3 proteins and TTP 
is not able to degrade target mRNA [40]. p38 MAPK pathway activation and influence on TTP 
protein level has been checked in normal and TTP-KO RAW264.7 cells, upon LPS co-
stimulation with DHTS and DHTS analogs has been monitored and described in the result 
section (Figure 37 and 38). 
 
NF-kB Pathway: 
The inflammatory response is a coordinated program, which through several proteins come 
into the function via the specific use of DNA elements that can be selectively recognized by 
the transcription factors [50]. Nuclear factor (NF) kB belongs to the family of seven homologs 
vertebrate transcription factors that usually serve in various combinations in response to 
external stimuli and move from cytoplasm to the nucleus in macrophages and T-cells, e.g., 
cytokines, ROS, bacterial lipopolysaccharides, viral infection and DNA damage. This family has 
Rel Homology domain (RHD) of 300 amino acids which displays homology 35-61% between 
themselves. RHD decides IkB binding to DNA with identical or others members of the family 
[51]. The Rel/NF-IkB are grouped into two classes: one comprised of p105 and p100 precursor 
protein, which proteolytically changed to p50 and p52 forms [52]–[54]. Second class contains 
c-Rel, v-ReI, Rel A (p65) and Rel B proteins [55] [56]. First class members are known as weak 
or inert gene activators whereas dimeric forms NF-kB containing at least one form of subunit 
from a second-class function as a strong activator of gene expression in human [57]. 
In recent studies, NF-kB has been indicated as the primary mediator of vascular inflammation, 
cardiovascular hypertrophy, and cellular stress responses [51]. HuR has been found as a direct 
transcription target of NF-kB and its activation in gastric cancer cell lines strongly linked with 
phosphatidylinositol 3-kinase/AKT signaling. HuR activation of this pathway has led to 
increased nucleo-cytoplasmic shuttling and subsequent proliferation of the tumor cells and 
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transition from the G1 phase to the S phase, finally showing the anti-apoptotic behavior of 
the gastric cancer cells [58]. Influence on the translocation of NF-kB upon LPS co-stimulation 
with DHTS and DHTS analogs has been checked and described in result section (Figure 30 and 
in preliminary results Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Schematic of NF-kB pathway and the Mechanism of NF-kB action. The NF-kB, a heterodimer of Rel and 
p50 proteins, is usually found in cells in an inactivated state located in the cytoplasm complexed to IkBa the 
inhibitory protein. Membrane receptors, through a variety of extracellular signals (stress, UV, TNF) can activate 
the enzyme IKK, which phosphorylates, IkBα inhibitory protein, which later degraded via ubiquitin-mediated 
proteasomal degradation. The NF-kB components Rel A and p50 together shifted to the nucleus where it binds 
to RE (Response Elements) of DNA particular sequence, where other coactivators and RNA Polymerase proteins 
are involved in the transcription of the same DNA elements and further active translation of the transcripts on 
the polysomal translation machinery, which further determine the cell fate. [51], [59] [60] and [61]. 
 
Roles of HuR 
HuR role in Pre-mRNA processing: 
Genome-wide analysis has revealed that a maximum number of human pre-mRNAs undergo 
RNA processing [62]. Hu Protein’s nuclear function was also discovered by Hui Zhu et al. in 
2006 as they function as RNA processing regulators in the nucleus, moreover they found that 
these proteins halt the activity of TIA-1/TIAR at the exon junction of several mRNAs. In 2008 
they reported that Hu proteins check the production of short protein NF1, in this case by 
blocking the inclusion of 23a NF1 exon by the TIA-1/TIAR proteins. In vitro experiments done 
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using nuclear extract showed that Hu protein block the binding of U1 and U6 snRNPs at 5’ 
splicing site, on the opposite TIA-1/TIAR increased this binding [63].  
Proteomic analysis of assembled pre-mRNA revealed that HuR was found for the first time 
with spliceosome complex, ENSEMBL Accession number ENSGALG00000000726) [64]. HuR’s-
role in splicing was confirmed by in vitro splicing assays in which in vitro produced fas mRNA 
containing sequences between 5 and 6 including a 30 nucleotides sequences were incubated 
with extracts from HeLa cells, along with splicing machinery, so there was the inclusion of 
exon 5 and 6 in an ATP dependent manner. On the other hand, when recombinant HuR was 
transfected into cells, the cells extract didn’t show any accumulation of exon 5 and 6 splicing 
product, to further confirm this recombinant TIA-1 and TIAR were added to reaction mixture, 
and again it rescued exon 5 and 6 from skipping. Exon 6 skipping by splicing of fas transcript 
further produces soluble form of its protein which is apoptosis receptor and is engaged in 
preventing programmed cell death [65]. 
Zhao et al., 2014 showed that HuR is also involved in splicing of SIRT1, which is also known as 
histone 3 deacetylases (HDACs), by skipping exon 8 from the spliced SIRT1 transcript. Here 
they measured the levels of SIRT1-FL and SIRT1-ΔExon8 by PCR and qPCR based experiments, 
in HuR overexpressing cells HEK293T cells. They found an increase in the level of SIRT1-ΔExon8 
and in HuR ablation conditions apparently this event was not observed at all, similar 
experiments were also done in the U251 cells, and the same pattern of outcomes was seen. 
Previously it was known that HuR regulates the SIRT mRNA and stabilize it upon HuR 
phosphorylation by Chk2  but how it is regulated was discovered by Wenhui and colleagues 
[67].  
PAR-CLIP and RIP-Chip Seq analysis have shown that HuR was involved in regulating the fate 
of transcripts by binding to intronic and 3' UTR of many sequences. Further investigation to 
confirm this specific probes to the intronic region, considered as HuR binding sites were 
correlated with their stabilization [15]. 
In a transcriptome-wide analysis of the HuR interactome, almost 26,000 binding sites were 
identified, and specifically, most of them were found in the intronic region. They also showed 
that HuR binds ssRNA preferentially and having no preference for Hairpins, by 
computationally folded HuR binding motif in almost 30 UTRs and resulting base pairing 
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probabilities were averaged. These studies confirm that HuR finely binds to transcripts 
immediately after or during transcription and further cooperate in splicing, cytoplasmic export 
of the target RNA, in this regard, it further stabilizes these mRNA transcripts [68]. 
Dutertre group in 2013 elucidated the nuclear function of HuR and its consequent role in 
alternative splicing. Upon doxorubicin treatment, alternative polyadenylation pattern 
changed and led to the inclusion of intronic poly (A) sites, normally HuR was responsible for 
binding to the conserved region which was repressed by doxorubicin and resulted in reduced 
production of CENPN, MBD1 mRNAs. These transcripts are thought to be involved in the G2/M 
passage and DNA damage response. On the other hand, it was observed that HuR translocate 
to the cytoplasm and get engaged in 3'UTRs binding and stabilization of various mRNAs. 
Therefore Internal ALEs in a subset of human premature mRNAs depend on HuR binding for 
inclusion in matured mRNA. Upon DNA damage, this unique binding is inhibited and results in 
isoforms like CENPN-pA12 [69]. 
Naipauer J. et al., 2013, explained about the short and full-length mRNA encoding the β1 
subunit (Itgb1) based on alternative functional cleavage and polyadenylation site which 
yielded a new Itgb1 mRNA isoform corresponding to 578 bp shorter than that previously 
discovered. These forms are expressed in a variety of tissues. β1 integrins play a significant 
role in the maintenance of mammary gland tissue integrity and function. Itgb1-S (short) 
isoform was decreased during the pregnancy and lactation where Itgb1-L (long) isoform 
remained unchanged, Actinomycin D chase experiments revealed that Itgb1-L was more 
stable as compared to Itgb1-S isoform, in differentiating and proliferating HC11 cells. This was 
probably due to the presence of AUBPs (AU-rich Binding Proteins) at Itgb1-L 3' UTRs. 
Meanwhile, the level of HuR correlated to the increased level of the Itgb1-L, both at mRNA 
and protein levels. To confirm the role of HuR in all of these events transfection of HC11 cells 
with the HuR siRNAs after following Act D treatment was performed and the mRNA levels of 
Itgb1-L mRNA isoform were measured by RT-PCR. As expected the level of the Itgb1-L were 
decreased in the Si-HuR as compared to control [70]. Munoz, MD et al., 2015 showed that 
HuR is required for the normal B-cell antibody response, besides this they also explained the 
B-cells transcriptome regulation by HuR.  Using i-CLIP it was discovered that HuR dependent 
splicing had affected thousands of transcripts, one particular gene they have described was 
Dlst (Dihydrolipoamide-S-succinyltransferase) which is a subunit of the 2-oxoglutarate 
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dehydrogenase (a-KGDH) complex. In HuR KO mice B-cells defective mitochondrial 
metabolism was observed along with abundant secretion of ROS, leading to B-cell death. 
Splicing alteration which has occurred upon HuR deletion was retention of intron 10 and 
followed by alternative inclusion of a cryptic exon linking exons 10 and 11. To explore this 
matter mechanistically they further analyzed the i-CLIP data, which verified that 75% of the 
HuR crosslinking sites were related to the intronic region. So merely HuR cross-linked at the 
exon-intron boundaries indicating that HuR specifically binds to introns 3' UTR primarily bond 
within branch point and 3' splice site [71].  
All these data together suggest that HuR might be a splicing regulator, regulating all events 
described above. 
Further, HuR was also exploited for its participation in alternative splicing of the TRA2β gene 
in human colon cancer cells under the oxidative stress. TRA2β is a splicing factor transformer 
2, and it produces 5 mRNA isoforms (TRA2β 1 to -5) via alternative splicing. In HCT116 colon 
cancer cell line, Chk2 and p-38 MAPK kinase were induced by sodium arsenite treatment, and 
further phosphorylated HuR at positions S88 and T118, this caused HuR to bind to TRA2β at 
exon 2 and resulting in TRA2β4 isoform that bears exon 2 with multiple stop codons. Upon 
deletion or HuR Chk2/p38 MAPK double knockdown and after following sodium arsenite 
stimulation came out with TRA2β and in return protein levels of TRA2β. These results were 
validated further by using mutant HuR S88A, S100A, and T118A as expected this obstructed 
association of TRA2β4 with HuR and consequently TRA2β4 generation [72]. 
HuR in Cancer 
In cancer-like conditions, RNA binding proteins function is perturbed, notably TTP (zfp36) and 
HuR are involved in these pathological conditions. Overexpression of AU-rich sequences is 
coupled to low activity or deficiency of Tristetraprolin (TTP, zfp36), and high activity of HuR in 
controlling the fate of these numerous transcripts and causing irrelevant pathologic 
conditions (Figure 6). This was confirmed in TTP-KO mouse fibroblasts, in this context HuR-
zfp36 has been correlated with cancer invasive gene expression. Moreover, miR29a 
specifically target TTP and miR29a expression is usually higher in breast cancer, when it was 
inhibited by the permeable miR29a inhibitor, rise in the TTP activity was seen especially 
towards the HuR 3'UTR, this further affected the expression of mRNAs, uPA, MMP-1, MMP-
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13 which are known as cancer-causing invasive factors. This point was highlighted for 
potential therapeutic approach, focused on TTP-HuR axis [73]. In cancer pathology, HuR is 
usually correlated with its cellular localization. HuR was overexpressed in seven human cancer 
cell lines SW480, Caco-2, SW707, HT-29, HRT-18, CX-2, and LoVo, and its localization and 
expression investigated by immunoblotting and quantitative RT PCR. HuR was found 
predominantly inside the nucleus of all these lines however after overexpression, HuR 
cytoplasmic accumulation was observed and correlated with increased COX-2 expression [74]. 
Robert Calaluce et al., 2011 by using RIP-ChIP assay to find systematic HuR target genes in 
breast cancer cell lines MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen 
receptor negative, ER-), among many subsets of HuR target, they found two unique HuR 
targets CD9, CALM2, which were previously not known among the HuR targets. These targets 
were further verified by pull-down assay and qPCR analysis. Quantification of HuR protein 
levels in both cell lines showed that more or less same level of HuR were seen, however, the 
cytoplasmic levels of HuR in MDA-MB-231 was higher than in MCF-7 Cells [75].  
Nevertheless, HuR expression was also seen in non-tumorous immortalized epithelial cells for 
e.g.,  Epithelial HB2, HMT-3522-T4-2, epithelial ductal carcinoma T47D, epithelial carcinoma 
BT-20, Hs578T cells and in epithelial adenocarcinoma SKBR-3 cells [76]. Further, in 2010, 
Lauren A. and colleagues showed that HuR is involved in mediating the post-transcriptional 
processes of GATA3 mRNA, upon HuR silencing, GATA3 levels were significantly lowered, 
biotin pull-down experiment confirmed that GATA3 3'UTR is the target binding site of HuR. 
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Figure 6 HuR function in controlling the fate of the mRNA involved in various cellular processes. In each case 
when the respective transcripts levels are altered lead to mentioned pathologic and cancer like conditions [16]. 
Also, cellular proliferation rate upon inhibition of either HuR or GATA3 were decreased to by 
35 and 44%, in MCF-7 cells suggesting the possible role of HuR and GATA3 in invasion and 
progression of breast cancer [77]. In OSCC, cleavage of HuR was interfered via the increased 
COX-2 expression by caspase 3. Cyclooxygenase-2 (COX-2) was overexpressed rigorously, 
which was one of the reason for resistance to paclitaxel treatment within oral cancer cells. 
After successfully inhibiting the COX-2 via its known inhibitor celecoxib lead to apoptosis in 
the same cells, which confirmed the cleavage of HuR in resistant oral cancer cells [78]. Baldan 
et al., 2016, determined the level of HuR in thyroid cancer cells and found the huge altered 
level of HuR, based on this finding they performed RIP seq and compared the HuR regulated 
transcripts in tumorigenic and non-tumorigenic cancer cell line, almost 114 mRNA were found 
bound to HuR, which were absent in non-tumorigenic cell line [79]. 
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Figure 7 Schematic diagram of HuR targets and their influence in cells, mediated by HuR in breast cancer cells. 
HuR is depicted as a rectangle in the middle of the arrowheads. The upper part of the diagram from the depicted 
HuR are drugs, miRNA, factors modulating HuR expressions and in lower are the HuR target and their fate upon 
HuR regulation [76]. 
In breast cancer, most of the genes modulated by HuR are involved in cellular processes such 
as migration, proliferation, and invasion along with tumor and angiogenesis Figure 7. 
demonstrates the link between HuR and these cellular processes and its role in breast cancer 
[76]. 
HuR in Inflammation  
HuR is the central modulator of inflammation as it is pivotal in the regulation of cytokine 
synthesis and coordinates the activity of other AREs binding proteins. Cytokines and 
chemokines secreted by the immune cells exert inflammation and most of them carry 3’ UTR 
ARE sequences and are supposed to be regulated by HuR. The key mediators of inflammation 
such as TNF, IL-4, IFNγ, and COX2.have already been described to be involved in inflammatory 
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pathways. However inflammation is a critical component of the immune system, it allows cells 
to repair the damaged cells by recruiting factors which further cooperate in the recovery of 
damage but on the other side excessive uncontrolled inflammation can exacerbate tissue 
damage [80]. Conditional KO mice for HuR has been already tested for the role of HuR in 
regulating the expression of Gata3, IL4 and IL13 mRNAs with decreased steady-state level and 
least changes at the protein level [81]. HuR expression in myeloid lineages is important, so as 
to limit the expression of inflammatory cytokines. Conversely, HuR KO myeloid cells induced 
systemic inflammation with increase in the levels of pro-inflammatory cytokines TNF, IL-6, 
CCL2, iNos and IL-10 mRNA. Most of cells expressing abundant IL-12 and IFN-Y resulted in 
severe colitis. RIP on activated macrophages confirmed that Ccl2, IL10, and TNFa mRNAs 
interact with HuR whereas other cytokines such as IL12, Ccl7, and IL6 mRNAs did not [82]. This 
shows the systemic preference of HuR in myeloid lineages. 
On the other hand, where HuR is considered as an inducer of inflammation evidenced from 
the above examples, HuR was also recognized as suppressor of the inflammatory responses 
in vivo in murine macrophages. HuR overexpression caused the translation inhibition of 
specific cytokine mRNAs without promoting any symbolic effects upon their turnover. 
Katsanou, V. et al., 2005 demonstrated in a model of abnormal ARE function, that HuR is not 
inducing any accumulation of ARE transcripts in the absence of destabilizing protein zfp36, 
besides cooperate with translation silencing protein TIA-1 to decrease the level of cytokines 
mRNA. Further to explore about the HuR associations they have performed IP analysis for the 
target mRNA TNFα, COX-2, and TGF-β and IL-1b in RAW 264.7 cells. Upon LPS induction the 
TNFα level were found associated with HuR whereas COX-2, IL-1b were constitutively present 
besides their increased mRNA pool, the same fashion was also observed in the Tg632 
macrophages, in which they suggested that transgenic HuR can directly alleviate the levels of 
TNFα, COX-2, and TGF-β but not of IL-1b. Also, actinomycin D chase experiment confirmed the 
level of TNFα and COX-2 half-life increased in transgenic macrophages whereas this behavior 
was not observed for the TGFβ. Conversely 40% reduced level observed for TGFβ1 transcript 
produced in induced transgenic cultures, whereas TNFα, COX-2 remained unaffected. 
Polysomal analysis showed reduced levels of TNFα, COX2, and TGFβ1 in macrophages whereas 
IL-1b and actin showed the same distribution over the polysomes, this was further clarified as 
these mRNA TNFα, COX2 share the same ARE-III type, and showed same response to HuR 
 28 
 
overexpression. Altogether the results showed HuR targets only specific mRNAs, and 
overexpression can inhibit the translation of certain inflammatory transcripts, besides 
differential alteration on their mRNA level, these differences by HuR can be explained on the 
basis of sequence diversity of different transcripts [48]. 
Giammanco, A. et al., 2014 also showed HuR role in intestinal homeostasis, by generating 
HuR-KO mice and confirming that deletion of HuR in intestinal tissues reduce the burden of 
small intestinal polyposis. They also demonstrated that HuR-KO mice after injection of 
azoxymethane and dextran sodium sulfate (AOM-DSS), the level of the tumor was three fold 
lower than the control mice. These two models came to the conclusion that intestinal removal 
of HuR protected mice against the tumorigenesis by inducing the apoptosis, and regulating 
the intestinal specific mRNA bearing anti-apoptotic HuR target sequences. They also 
confirmed that prolonged deletion of HuR for over one year didn't have any impact on the 
phenotype in fact aged HuR-KO showed similar phenotype to that of control.  Despite all 
these, however, the proliferation of small intestine was not reduced in aged HuR KO mice, 
also the expression of RNAs (Olfm4, Tp53, and CcnB1) which are involved in the homeostasis, 
cell growth and survival were unaltered [83]. 
HuR was also implicated in the IL-17 induced act-1 mediated chemokines (CXCL1 and CXCL5) 
transcripts stabilization, the absence of HuR markedly lowered the levels of these chemokines 
which were induced by IL-17 through Act-1 (U-box E3 ubiquitin ligase) ubiquitination of HuR 
further leading to binding and stabilization. Consequently, HuR deletion has lowered the level 
of these cytokines. The role of IL-17 is critical as it is involved in organizing local tissue 
inflammation and further inducing secretion of important chemokines and cytokines IL-6, 
CSF2, TNFα, IL-1, CXCL1, CCL2, CXCL2, CCL7, and CCL20, and subsequent release of monocytes 
and lymphocytes including neutrophils in inflamed areas. Upon IL-17 induction HuR was found 
ubiquitinated, to confirm this they transfected HeLa cells with HA-tagged ubiquitin and then 
Induced with IL-17. IP experiments revealed the association of HA-ubiquitin with HuR after 
the western blotting. To test further if Act1 was directly ubiquitinating HuR they have 
performed in vitro poly-ubiquitination assay, interestingly Act1 used Ubc13/Uev1A E2 
complex to ubiquitinate HuR, merely acting as E3 ubiquitin ligase to HuR, considering all these 
observations it was noted that HuR’s ActD mediated HuR poly-ubiquitination is important for 
its stabilizing activity on CXCL1 and CXCL5 mRNAs. Accordingly, polysomal analysis also 
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revealed that upon IL-17 induction, Act1-HuR were found shifted to actively translating 
polysomes and were responsible for the translation of ARE-bearing transcripts [84]. 
Auto-immune disease encephalomyelitis was found mainly due to HuR pathology, as HuR was 
involved in stabilization and translation of the IL-17 mRNA which otherwise was reduced upon 
HuR ablation [85], [86]. Moreover it was experimentally proved that HuR directly binds to the 
IL-17 mRNA at 3’UTR by RIP and pull down assays. Th17 cells which are third subset of Th 
family and are responsible for pathologies in inflammatory and autoimmune diseases for e.g. 
encephalomyelitis, arthritis and asthma [87] [88]. Jin Chen et al in 2013 used an adoptive 
transfer model HuR-deficient Th17 cells and found delay in onset and less in severity of EAE 
(Experimental autoimmune encephalomyelitis). They developed EAE by adoptive transfer of 
MOG-specific CD4+ T cells into naive mice, WT and KO mice. After repeated adoptive transfer, 
they found significant differences in the onset of encephalomyelitis in WT and KO mice, WT 
developed encephalomyelitis on the 11 day after transfer and reached extremity at day 23, 
while in HuR KO, all these onset were delayed. After isolating the monocytes from the CNS 
and finding the frequency of IL-17 secreting cells by Flow cytometry, this analysis also showed 
the decreased level of CD4+ and IL-17 positive cells, within HuR KO mice. On the other hand 
CD4+, T cells proliferation rate from KO and WT mice revealed that cells from KO mice have 
reduced proliferation rate as compared to WT under Th17-polarization conditions. [85] 
Skliris et al., 2014 demonstrated that as HuR is expressed in both neuronal and non-neuronal 
tissues, it can help in promoting the renewal of neuronal progenitor's cells. They highlighted 
a neuroprotective role of HuR which was revealed upon genetic ablation of HuR. Conditional 
KO mice for HuR in the Hippocampal neurons were briefly investigated for the role of HuR in 
neuronal functionality. Upon kainic acid (KA) administration which is potent agonist of a 
subtype of glutamate receptors that could lead to epileptic seizures when administered 
systemically. Seizure rating extent was different in CN-KO mice, as compared to control, where 
it was increased in 10 min and peaked around 20 or 30 min in control mice, whereas seizure-
rating in, female CN-KO mice showed significant decrease in seizure magnitude and sudden 
muscle convulsion leading to death, this confirmed the participation of HuR in the excitation 
and elicitation of the epileptic seizures. Further to assess the degree of permanent neuronal 
damage in both control and CN-KO mice Hematoxylin/eosin and Nissl staining revealed 
additional KA-induced hippocampal lesions than in control [89]. 
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Taken all this together, HuR coordinates defensive network of RNAs post-transcriptionally to 
neutralize oxidative metabolism by lowering the expression of potential hazardous genes and 
further protecting neurons from degradation and necrosis, e.g., Bcl2, NQO1 and Ppargc1a 
mRNAs and its role in inflammation as explained above cannot be ignored. In our experiments, 
we have checked HuR-dependent influence on the TNFα, CXCL2 and CXCL10 levels, of our 
compounds upon treatment with DHTS and MFM49. (Figure 34) 
Nuclear or cytoplasmic: does it endow any prognostic role? 
In last two decades, a lot of studies focused on the role of nuclear and cytoplasmic localization 
of HuR and further its clinical prognostic outcome in cancer types. Predominantly HuR is 
localized in the nucleus, but upon external stimulus (stress) to various stress stimuli, including 
oxidative stress, heat shock, hypoxia, UV light, amino acid starvation, polyamine depletion, 
and staurosporine, it shuttle from nucleus to the cytoplasm, here it binds to target RNAs and 
further recruits them on ribosomes for their active translation [90]. HuR interacts with various 
other proteins such as set PP32 (phosphoprotein-32), APRIL (Acidic protein rich in leucine), 
and SETα/β. These proteins are believed to be involved in HuR export from the nucleus, 
modulating its affinity towards its target probes. Further P21 increases expression upon 
exposure to UV was found to correlate with HuR association with RNPs and silencing of HuR 
resulted in low level of P21 in RKO colon carcinoma cells. All of these events occurred in the 
cytoplasmic presence of HuR [91]. 
Upadhyay, R. et al., 2012 demonstrated about the polymorphism of ELAVL1 (HuR) with poor 
survival in African-American patients, interestingly ELAVL1 gene has been found with more 
than 400 SNPs. Most of the SNPs function is still to be exploited; however, some they have a 
role in as discussed earlier in RNA stability, microRNA recognition and in splicing regulation, 
moreover HuR was neither found mutated in all studied tumors [92].  
In another study, HuR was implicated in carcinogenesis in renal cell carcinoma (RCC), an 
increase in cytoplasmic HuR and RCC associated survival was poor in the patients who 
expressed HuR and COX-2 in their tumors. Here they have treated the cell line with siRNA 
targeting HuR and further reduced the expression of HuR and COX-2. Nevertheless, in 
esophageal squamous cell carcinoma (ESCC), HuR was proposed as a potential prognostic 
marker. Immuno-histochemical analysis and clinicopathological studies revealed that 
 31 
 
metastasis in lymph node, invasive tumors with an advanced stage was positively associated 
with HuR. Patients with cytoplasmic HuR had cumulative five years survival rate of 25%, on 
the other side it was 43.8% for patients with negative cytoplasmic HuR expression [93]. HuR 
was also found to be associated with the cellular inhibitor of apoptosis (cIAP2) in oral 
squamous cell carcinoma (OSCC). In this case, HuR was seen overexpressed cytoplasmically in 
8 oral cancer cell lines. Consequently in OSCC HuR and cIAP2 expression levels were 
determined and cIAP expression except for 4.2% specimen cIAP levels overexpressed in 95.8% 
of OSCC specimens, similarly altered cytoplasmic expression was also found to confer 
increased expression of COX-2 in OSCC [94].  
In gallbladder carcinoma, results showed that increased nuclear HuR expression was related 
to high tumor number followed by vascular invasion, univariate analysis performed verified 
that patients with high nuclear expression had poor disease-free survival [95].  
A major obstacle in cancer chemotherapy is the HuR induced overexpression of P-glycoprotein 
(P-gp) in human breast cancer. Immunohistochemistry revealed overexpressed HuR in the 
cytoplasm, so patients with high cytoplasmic HuR had poor survival as compared to a low 
expressed level of HuR, as inference cytoplasmic HuR expression was found to be negative 
prognostic measure in patients with breast cancer [96]. HuR was also found 
abundantlyexpressed in non-tumorous immortalized epithelial cells for e.g. Epithelial HB2, 
HMT-3522-T4-2, epithelial ductal carcinoma T47D, epithelial carcinoma BT-20, Hs578T cells 
and in epithelial adenocarcinoma SKBR-3 cells [76] (Figure 8). 
Concerning the above findings, we evaluated the influence of DHTS and MFM49 on the 
nucleocytoplasmic abundance of HuR within MCF-7 breast cancer cell line (Result Section: 
Figure 29). 
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Figure 8 The immunostaining of HuR from the histological and cytological specimen taken from breast cancer 
patient. Showing the cytoplasmic abundance of HuR and is primary cause of cancer. [76] 
Current state of the art on the Pharmacology of HuR and Small Molecules Inhibiting HuR 
 
Since HuR has been predicted as a druggable target, lot of researchers published their 
research outcomes in recent years. In this regard Chae et al., 2009 showed the role of chemical 
inhibitors and their efficacy toward HuR, they screened around 179 chemicals, and identified 
three with IC50 below 10 µM e.g., for quercetin, b-40, and b-41 were 1.4 µM, 0.38 µM, and 
6.21 µM, against the binding of HuR and TNFα in  in vitro EMSA and filter binding assay. Also, 
they found that Quercetin and b-40 compounds were not effective on zfp36 and TNFα binding. 
In RAW264.7 LPS-induced TNFα which is a HuR target, levels were lowered in Act D chase 
assay. Using our compound we have also determined the half-life of the LPS induced TNFα 
and other cytokines in RAW264.7 cells (Figure 40). 
Meisner, N. et al., in 2007 screened 50,000 natural compounds and found most potent, 
Dehydromutactin, naphthofuranone MS-444, and Okicenone. Mechanistically, MS-444 bound 
HuR protein within first two RRMs and prevented HuR homo-dimerization, thus further block 
HuR translocation to the cytoplasm, where it is known for its stabilizing function.  
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D'Agostino et al., 2013 demonstrated a novel assay, to assess HuR and probe binding in vitro, 
and has screened 2000 small molecules, inhibiting the HuR-RNA complex formation, further 
verified by EMSA assays. He found Cetylpyridinium chloride mitoxantrone, a small molecule 
abrogating HuR-RNA complex formation [98].  
Later on, D'Agostino et al screened 107 commercially available anti-inflammatory compounds, 
searching for their inhibiting specificity on rHuR-RNA complex formation in vitro. Eight 
potential compounds (DHTS, hydrocortisone acetate, amiprilose, flurbiprofen, deracoxib, 
fluocinolone, triamcinolone and dexamethasone) from 107 compounds came out to be 
potential inhibitors, but the most potent hit was given by DHTS (CHEMBL227075 ID in ChEMBL 
database), which belongs to tanshinones family [99]. 
Further Wu, X. et al., 2015 screened and validated HuR inhibitors from a group of 6000 novel 
compounds using FP HTS based assay, after finding lists of potential disruptors they 
consequently validated them by using AlphaLISA (Amplified Luminescent Proximity 
Homogeneous Assay), surface plasmon resonance (SPR), ribonucleoprotein 
immunoprecipitation (RNP-IP) and luciferase reporter assays. These disruptors e.g. CMLD1–6 
and NC1-3 were tested on colon cancer cell line HCT-11, pancreatic cell line, MiaPaCa 2, and 
normal fibroblast cell line WI-38. Among these NC2, was most potent with IC50 of 13.5±0.5, 
9.2±1.5 µM in HCT-11 and MiaPaCa2 cell lines. CMLD-1 and CMLD-2 were also analyzed for 
their blocking function on HuR and its target mRNAs i.e. for, stability of Bcl-2, Msi1, and XIAP 
mRNAs in HCT-116 cells, by using the Actinomycin D experiments, they significantly decreased 
levels of these mRNAs. Consequently protein levels of these targets were also lowered 
indicating that HuR failed to recruit these transcripts on the polysomes in the presence of 
these molecular disruptors. In addition, the CMLD-2 compound was recognized as potential 
HuR-mRNA disruptor, with a Ki of 350 nM [100]. Zhonghua and colleagues by using 
Fluorescence polarization (FP) assay also screened 1597 compounds. They used NMR 
spectroscopy demonstrating some hit given by potential compounds which disturbed HuR 
oligomerization in vitro [101].  
Resveratrol found in the red skin of grapes was found to decrease induced gene expression in 
T-cells, in a HuR dependent manner. Resveratrol regulated the 3'UTR sequences of the 
transcripts via favoring KSRP interaction and replacing the HuR from the 3' UTR sequences 
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hence changing the stability of the transcripts [102]. Figure 9, represents the study of folate-
based nanoparticle which was transduced with siHuR sequences, forming HuR-FNP (folate 
nanoparticles) spherical structure giving a protective shield to siRNA from degradation. The 
most interesting fact with FNP system was the moderate and controlled distribution of siRNA 
at physiological pH, this was supposed to prolong the efficacy of the treatment and therefore 
reducing the chances of further treatments [103] (Figure 9). 
 
 
 
 
 
 
Figure 9 Schematic representation of synthesis HuR-FNP preparation. Nanoparticles are complemented with 
siRNA for HuR and further inserted via 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino 
(polyethylene glycol)-2000] or DSPE-PEG-FA Mediated delivery  [103]. 
 
R Muralidharan et al., 2015 used CXCR-4 antagonist AMD3100, together with HuR silencing 
sequences coupled to FP nanoparticles. This showed repressed CXCR-4 levels and inhibition 
of cancer cell metastasis. Co-treatment resulted in cell cycle arrest at G1 phase followed by 
decreased cell viability. Moreover, their physicochemical studies showed that HuR-FNPs were 
positively charged having zeta potential of 4.3 mV were almost 300 ± 10 nm in size. Cells used 
for this study were folate receptor (+) positive H1299 lung cancer cells, and the uptake of the 
FNP was via endocytosis, as they were folate-targeted and were efficient in delivering siRNA 
into the cells [104].  
Jiawei Guo et al., 2016 found a synergistic effect of cisplatin, doxorubicin, vincristine, and 
oxaliplatin together with a FDA-approved anthelmintic drug, pyrvinium pamoate. In this study, 
this drug appeared to be a novel HuR inhibitor that inhibited HuR cytoplasmic accumulation 
in a dose-dependent manner. Combined effect enhanced the cytotoxic effect together with 
the repressed growth of tumor derived from patient's bladder xenografted in mice. Further 
 35 
 
investigation confirmed pyrvinium pamoate supported nuclear import of HuR along with 
inhibition of Chk/Cdk kinase pathway, with these findings this novel compound also 
downregulated the level of DNA ligase IV and BRCA2, leading to genetic instability and cell 
death [105]. MPT0B098 is an indoline-sulfonamide compound, a microtubule inhibitor, has 
the potential to interfere with the HIF-1a in several cancer cell lines, e.g., H460, A549 and 
H1299 Non-small cell lung carcinoma (NSLCs). It mainly decreased HuR translocation from the 
nucleus to the cytoplasm, and efficiently suppressed tumor growth and microvessel density 
of tumor specimen in vivo in low IC50 values, i.e., from 70-150 nmol/L [105]  [106]. In another 
study N-Benzylcantharidinamide a novel cantharidin analog, decreased cytosolic translocation 
of HuR, resulting in lower mRNA level of matrix metalloproteinase-9 (MMP-9), in a dose-
dependent manner. MMP-9 causes invasion and metastasis of hepatocellular carcinoma 
HepG3 cells [108]. 
Tripterygium wilfordii, a member of the Celastraceae plant family, in Chinese medicine 
practice, its extract triptolide inhibited COX-2 mRNA and its expression in NSLC A549 cells, 
when induced with TNFα by suppressing nucleocytoplasmic shuttling of HuR [109]. Previously 
triptolide has been shown to, impairs dendritic cell migration by inhibiting COX-2 and CCR7 
expression through NF-kB and phosphatidylinositol-3 kinase (PI3-K)/Akt pathway [110]. 
Similarly, natural compounds from Green tea and Kalopanax pictus has been shown to down-
regulate TNFα and MMP9 mRNA stability and protein trafficking by increasing the anti-
inflammatory protein TTP [111]–[113]. Finally, a new class of anti-inflammatory 
methoxyphenolic compounds has been shown to inhibit CCL2, CCL5, IL-6, IL-8, ICAM-1, MIF, 
CXCL1, CXCL10, and Serpin E1 mRNA levels in Human airway cells when stimulated with TNF-
α. This has been confirmed by the specificity of methoxy compound towards HuR-mRNA 
binding, and the hence have been indicated for their HuR dependent post-transcriptional 
influence [114]. 
 
Focusing on Tanshinone/DHTS to target HuR in vitro and in vivo 
Tanshinones are diterpenes extracted from plant root of Salvia miltiorrhiza, also known as red 
sage, tanshen or danshen. The chemical compositions of tanshinones have been well studied 
extensively over the last 75 years. They are classified based on their structure, e.g. tanshinone-
I has aromatic furan ring, Dihydrotanshinone-I (DHTS) has a reduced dihydrofuran on the right 
side of the molecule, together with cyclohexane rings [115] (Figure 10). According to 
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differences in their structural, chemical/physical properties, tanshen constituents have been 
classified into two groups, I) first groups contains water-soluble phenolic acids such as 
lithosphermic acid B and salvianolic acid. II) The second group has lipophilic diterpene 
quinones such as tanshinone I, tanshinone IIA; B, Cryptotanshinone etc., where each of them 
contribute to their biological activities [116].  
These Tanshen are well known in Chinese traditional medicine practice for the treatment of 
the coronary heart diseases such as myocardial infarction and angina pectoris. Besides this 
they also have been suggested for the treatment of hemorrhage, swelling, insomnia, 
miscarriage, and dysmenorrhea, as well as inflammatory diseases such as edema, endangitis, 
and arthritis. Tanshen analogues were tested for their cytotoxicity in KB, HeLa, Colo-205 and 
Hep2 Carcinoma cell lines. Interestingly they were effective in conc. <1 µg/ml [117]. 
Moreover, in LPS activated RAW 264.7 macrophages, Tanshinone IIA inhibited iNOS 
expression and synthesis of TNF-α, IL-1β and IL-6 protein levels [118]. Besides this Tan IIA has 
been shown to inhibit tumor cell proliferation, intervening tumor cell cycle, initiating tumor 
cell apoptosis, and suppressing tumor cell invasion and transfer in human lung cancer cell lines 
[119]. 
In in vitro and in vivo experiments tanshinone-I exhibited anti-migrating, invasiveness with 
reduced tumorigenesis and metastasis in human lung adenocarcinoma and severe combined 
immunodeficient mice. RT PCR, EMSA experiments confirmed that tanshinone-I reduces IL-8 
intracellular levels, a major factor involved in the angiogenesis and cancer metastasis and thus 
further blocking DNA binding activity of AP-1 and NF-kB [120]. 
15, 16 Dihydrotanshinone has been found to inhibit the collagen-induced aggregation of 
rabbit platelets with an IC50 lower than that the active green tea ingredient Catechin. Besides 
this DHTS inhibited intracellular calcium levels, suppressed collagen-induced liberation of 
Arachidonic acid and thromboxane B2 from rabbit platelets. Here DHTS exerted potent anti-
platelet activity via suppression of Ca2+ mobilization and arachidonic acid liberation and hence 
possess anti-inflammatory activity [121].  
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Figure 10 Chemical structures of tanshinones. (Adapted from D’Agostino et al., 2015) 
Tanshinone I, Tanshinone IIB, Cryptotanshinone, and DHTS has been shown to possess 
antibacterial against the broad range of Gram positive bacteria as they generated superoxide 
radicals, anti-inflammatory, anti-allergic and anti-oxidant properties [122]. DHTS induced 
autophagy and apoptosis through caspase activation and p53 independent pathway, as well 
as via intracellular generation and accumulation of ROS, which showed the pro-apoptotic 
activity of DHTS in colon carcinoma cells [123], [124]. Tumor cells adapt and proliferate in the 
presence of hypoxia-inducible factor-I (HIF-I), whose protein translation was inhibited by 
DHTS in HeLa and its xenograft tumor model in vivo mice model. Conclusively the HIF-1a 
protein synthesis was blocked via downregulation of the mTOR/p70S6K/4E-BP1 and MEK/ERK 
pathways [125]. NF-kB transcription factor which controls many physiological processes e.g., 
immunity, inflammation, apoptosis, and angiogenesis, was significantly suppressed by DHTS 
upon TNFα induction in a dose-dependent manner. DHTS also inhibited TNFα induced 
phosphorylation of IkBα and p65 and subsequent nuclear translocation of p65. Additionally, 
DHTS induced the apoptosis and suppressed the TNFα-induced expression of NF-kB target 
genes, cIAP-1, COX-2, MMP-9, VEGF and major inflammatory cytokines such as TNFα, IL-6and 
MCP1. The in vivo model also indicated that Dihydrotanshinone I inhibited the growth of HeLa 
cells in a xenograft tumor models [126]. Altogether, these findings suggest that 
Dihydrotanshinone I could be a valuable candidate for therapeutic intervention in the cancer 
patients. Also among tanshinones, tanshinone-I was found to be most potent, but due to its 
low solubility and crystal forming property, Dihydrotanshinone-I was better soluble and was 
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further able to disrupt rHuR-RNA complex formation in in-vitro binding assays, e.g., EMSA 
(Figure 11) [99].   
 
 
 
 
 
Figure 11 Densitometric comparison of tanshinones activity from EMSA (EMSA Image not shown) for 
disassociation of HuR–RNA complex formation upon incubation with IC50, 0.2, 0.5 and 1 µM of DHTS, Tan I, Tan 
II, Cryptotanshinone and  IC50 conc. of DHTS [99].  
Why to inhibit HuR? 
HuR could be a drug target for cancer therapy and its inhibition simultaneously down-
regulates multiple oncoproteins resulting in reduced cell migration and  tumor progression 
[127]. Considering HuR is a regulator of many biological pathways responsible for growth, 
metastasis, tumor formation which contribute to chemo-resistance mechanisms to 
therapeutic drugs for e.g., tamoxifen thus now it's important that HuR could be considered as 
a therapeutic target for cancer therapy. Hence, targeting HuR would attenuate the onset of 
multiple cancer related pathways or delay in disease progression by using the small molecules 
that act on or via HuR. 
 We further tried to contribute to the list of potential HuR inhibitors, by testing a specific 
library of commercially available anti-inflammatory compounds [98], [99]. One potential hit 
compound was used as a model inhibitor to synthesize further and characterize set of other 
synthetic analogs and their ability to prevent the rHuR-RNA complex formation, in biochemical 
and cell-based assays. Also because, these tanshen are widely used in clinics in China, and the 
exact mechanism behind therapeutic basis is still unknown [128]. Thus to exploit the 
mechanism of action of DHTS we rigorously worked on our experimental models and 
published our work as D’Agostino et al., 2015 and Lal et al., 2017 [129] [130]. 
Regarding above task: 
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The Aim of my PhD thesis project is “Characterization of small molecules inhibiting the RNA 
binding protein HuR”. 
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CHAPTER 2 
 
 
 
 
Materials and Methods 
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Materials and Methods 
Media and bacterial strains used 
LB (Luria Bertani) broth was used as the medium to grow bacterial strains. The bacterial strain 
used was Nebα strain of E.coli for obtaining the recombinant clones. For prokaryotic 
expression, the Rosetta BL-21 strain of E. Coli was used. For amplification of the desired motif, 
primer used were forward primer with NdeI restriction site and the reverse primer with XhoI 
restriction site for the RRM1/2 and akin for RRM2/3 but with different primer sequences. All 
Primer used are listed in Table 4. 
Protein expression and purification 
pET-42a vector containing the full-length sequence of HuR was used as a template for PCR to 
produce all the individual RRMs [99],  including the ΔRRM1, Primers used for ΔRRM1 are listed 
in Table 5. All four mutants were produced by using Q5® Site-Directed Mutagenesis Kit, 
following the instructions are given by the manufacturer. Primers used are S94A, N107A, 
I133A, and N134A are listed in Table 5.  
Expression of the all the RRMs, i.e. RRM1, RRM2, RRM3, RRM1/M2, and ΔRRM1 were done at 
37°C for initial growth to reach the OD at 0.5, and then were induced by 0.1mM IPTG at 18°C 
for at least 6 hrs. Cells were centrifuged at 5000g and later pellets were dissolved in 
equilibration buffer (20mM Tris-Cl pH 8.0, 100 mM NaCl, 3 mM MgCl2, 0.5 Mm DTT and  1X 
Protease inhibitors) and sonicated at 95 kHz amplitude with 7' Pulse ON and 30' OFF for 9 
cycles. Centrifuged the lysed solution for 30 min at 13000 rpm, separated the supernatant by 
filtering with the 0.2 µM filter. While centrifugation aliquoted 1 ml of the Ni-NTA resins, and 
centrifuged at 1800 rpm for 30 sec removed the excess 20% ethanol and added 1 ml of the 
equilibration buffer with imidazole (5mM), inverted the tube gently 2-3 times and centrifuged 
again at 1800 rpm. Repeated this at least for 3 times. Dissolved the resins in the same buffer 
(0.5 ml) and transferred to the supernatant, incubated on rotating shaker at the 4°C for 4 hrs. 
After 4 hrs centrifuged the supernatant (1800 rpm for 1 min) and separated the protein bound 
resins and dissolved the resins gently in 1 ml of wash buffer (20mM Tris-HCl Buffer pH 8.0, 
100 mM NaCl, 2mM MgCl2,  0.5 Mm DTT and 20 mM Imidazole). Incubate for 10 minutes on 
rotating shaker at 4°C (cold room). Repeated the wash twice with wash buffer containing 250, 
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350 mM NaCl and 25 mM Imidazole, now discard washes but keep 50 µl for coomassie gel 
analysis. Added the elution buffer 1 (equilibration buffer with 100 mM Glycine and 30 mM 
Imidazole) 0.3 ml to the microfuge tube containing the resins incubated rotating again for 20 
min at 4°C. Repeated the second elution using elution buffer 1 with 60 mM Imidazole and 
collected in fresh Eppendorf tubes. To both elutions added the glycerol to 10% final 
concentration. 50 µl aliquots of all the elution, wash, and add laemlli buffer to 1X final 
concentration. Expression and purification of WT-HuR and mutants were similar as described 
above, except for the induction which was done at 30°C with little modification of 20mM 
imidazole in equilibration buffer and wash buffers with 50 mM, 100 mM and 110 mM and 
100mM NaCl in all three washes. All samples of each purified proteins were run on 15% SDS-
PAGE gel for RRMs and 12% SDS-PAGE gel for HuR and its mutants. Stained with the 
Coomassie blue staining solutions for 2 hrs and destained using destaining solution (40% 
methanol, 10% acetic acid and 50% water), the gels were analyzed in Odyssey® Infrared 
Imaging System. 
REMSA assays 
EMSA was done using the equimolar concentrations, i.e., 0.2 µM of the recombinant proteins 
and RNA probe (FAM labelled-AUUAUUUAUUAUUUAUUUAUUAUUUA), DHTS or DHTS 
analogs were dissolved in the 1X REMSA buffer to have the required final conc. of the 
compound in the reaction mixture.  After mixing the all the reagents, the vials to incubate for 
30 min at room temperature  1 µl of 100% glycerol was added to each reaction mixture before 
loading on the native 4% PAGE gel. The native PAGE gel was made in the 0.5x TBE buffer. Now 
the mixture was loaded on the 4% Native polyacrylamide gel (18 µl) was run at 80 V constant 
voltage for about 60 minutes in 0.5X TBE at 4⁰C (cold room).  All the reaction mixtures were 
run without using the bromophenol loading dye. This is to avoid the interference of the dye 
while reading the gel, on the other hand, I have used one well with bromophenol loading dye, 
to check the running front of the free probe. The running apparatus was covered with 
aluminum foil to avoid direct light exposure. The gel image was developed in Typhoon scanner 
at high resolution for FAM probe at 488nm or Licor odyssey infra-red apparatus if using DY-
681 labeled RNA probe depending on the area the gel was occupying on the gel instrument 
surface, with high resolution for at least 10 min and then exported and analyzed for the 
results.  
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AlphaScreen Assay 
In Amplified Luminescent Proximity Homogeneous Assay (Alpha) Donor and acceptor beads 
were at the concentration of 20 ng/µl, in 20µl reaction volume Specific ARE used in bearing 
sequence at 3’ UTR of TNFα mRNA were biotinylated single-stranded Bi-TNF (5’-Bi-
AUUAUUUAUUAUUUAUUUAUUAUUUA-3’), were ordered from Eurofins MWG Operon. 384-
well white OptiPlates (PerkinElmer; 6007299) were used with a final total volume of 20 µl. 
Hooking point of proteins were determined by using the gradient of protein concentration in 
the nanomolar range. The “hooking point” refers to quenching of the starts signal due to an 
extra binding of probe and protein partner, and was optimized for both binding partners. Kit 
used was AlphaScreen c-His detection kit (PerkinElmer; 6760619C) and binding buffer used 
was (25 mM HEPES pH 7.4, 100 mM NaCl, 0.1% BSA). The volume of each reactant used was 
4 µl and five-time more concentrated so that it reaches 1x in 20 µl final volume. The donor 
and acceptor beads were dissolved in 1x Alpha binding buffer. 4 µl of this beads mixture with 
100ng/µl was added to the reaction mixture to reach 20 ng/µl conc. of each beads.  DHTS or 
DHTS analogs were dissolved in the 1X Alpha binding buffer to have the required final conc. 
of the compounds in the reaction mixture in the nanomolar range. The gradient of the each 
compound conc. used in triplicate with DMSO control. Biotinylated RNA probe was dissolved 
in RNase free water to 250 nM conc., and then 4 µl volume was added at the end, when beads, 
compounds, and protein were already added to the reaction mixture. The reaction mixture 
was incubated to stand at RT with shaking for 60 minutes, to allow them to reach equilibrium. 
Enspire plate reader instrument (PerkinElmer; 2300-001A) was used to read the plate, and 
specific binding was determined by normalizing the signal of background control (absence of 
protein or probe using elution buffer of protein) with alpha signals of test obtained. The Kd 
and Ki values were calculated using the GraphPad Prism version 6 with nonlinear regression 
function in analysis tab and choosing the one site-specific binding or One site-specific Ki 
function. For the Ki, the Kd value of the HuR protein and final conc. of the probe used was 
needed to put in order to obtain the specific Ki for each compound.   
Crosslink Experiments 
Bacterial culture expressing recombinant mutants proteins and WT protein were directly fixed 
in the LB (Luria Broth) culture with 2% Formaldehyde (HCHO) for 15-20 min at RT and were 
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then collected at high-speed centrifugation, sonicated, and supernatants collected were used 
directly or loaded with Ni-NTA beads for 3-4 hrs and were eluted in elution buffer (20Mm Tris-
HCl, 100mM NaCl, 3 mM MgCl2 and 250 mM Imidazole), respective proteins were lysed with 
Laemmli buffer and were loaded on 12% gel with 0.05% SDS. The separated proteins were 
then transferred to the nitrocellulose (0.45 µM) membrane, using standard wet transfer 
protocol. The blotted membrane was then incubated with 5% BSA for 1 hr and followed by 
Incubation of membrane with the mouse ant-HuR primary antibody (Santacruz (1:1000) 
overnight at 4°C. Next day after washing three-time (10 min each) membranes with 1x PBST 
was incubated with secondary antibody (HRP-anti-Mouse IgG) for 1 hr. The membrane was 
again washed for 3 times (10 min each) with 1X PBST and developed under BioRad ChemiDoc 
instrument using commercial developing solutions. Image obtained were then analyzed for 
the outcomes. At least three independent experiments repeated to confirm the dimerization 
of muteins. 
Western blot analysis 
Whole cell lysates were collected using Laemmli buffer, afterward separated by running on 
12% SDS-PAGE gels and transferred to PVDF membranes. Membranes were incubated with 
the following primary antibodies: anti-HuR (Santa Cruz biotech), anti-zfp36 (NE2.2/1), anti-p-
MAPKAPK-2 T222 (MK-2), anti-MAPKAPK-2 D1E11 (p-MK-2), anti-NFkB, p-IkB-alpha S32/36, 
anti-pp38-T180/Y182, anti-ATF2, (Cell Signaling) and anti EF2, anti-Actin (Santa Cruz biotech) 
all were used at dilution 1:1000. The peroxidase-labeled secondary antibody (Santa Cruz 
Biotechnology) was detected using ECL western blotting reagents from GE Healthcare and 
were developed under the Bio-Rad developing apparatus. 
Fractionation experiments 
RAW 264.7 cells (1x10 cm plate) were washed with 1x PBS (4°C) and resuspended in 300 µL 
Buffer A, collected and transferred to a 1.5ml tube and were put on ice for 15 min. Then Igepal 
CA 630 (0.5 % (v/v)) was added and vortexed for 10s. Nuclear fraction was isolated by spinning 
at 4°C for the 20s at 6500 rpm. The transferred supernatant (cytosolic fraction) to a new tube 
and kept on ice. Added 150 µL Buffer B to the Pellet (nuclear fraction). Rocked this fraction 
for 30 min at 4°C in an overhead tumbler. Centrifuged for 10 min at 13000rpm at 4°C to 
separate the nuclear fraction from the cell debris. Nuclear fraction was in the supernatant. 
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Blot for cytosolic (GAPDH/Actin/Tubulin) and nuclear markers (H3/ATF-2) to control 
fractionation. 
Polysomal analysis 
10x106 Cells were seeded in 15cm per plate and next day treated with compounds (DHTS, 
MFM49, GD041, MB11v) and co-stimulated with 1 µg/ml LPS, for 3 hrs, after 3 hrs cells were 
washed twice with 10 ml 1X PBS containing 0.1 mg/ml of the CHX further cells were collected 
in on ice and the pellets obtained were stored at -80°C. On the same day gently made the 
gradients as was mentioned in protocol, stored the gradients at 4°C and next day lysed the 
cells in lysis buffer vortexed properly put on ice for 10 min and centrifuged them at a 13000 
rpm at 4°C for 10 min collected the supernatant and transferred the clear supernatant on top 
of the  gradient made, now weighed them accurately in very high sensitive weighing balance 
and then proceeded for centrifugation at 40,000g for 2 hrs 45 min, after the centrifugation 
separated each monosomal and polysomal fraction numbered 1 to 12, store on ice in a 
polysome separating at UV visible spectrum in gradient separator instrument . To each 1 ml 
fraction obtained added 100 µl of sodium acetate and 900 µl absolute isopropanol stored at -
20°C. RNA was extracted as explained by [43],  then followed by qPCR analysis of each fraction. 
RT qPCR Experiments 
PCR conditions and Primers conc. for the target sequences were used according to the 
Mastermix manufacturer instructions. The reaction mixture was prepared with the primer of 
each target to be tested without the cDNA template. The reaction mixture of the each target 
added to 96 or 384 well Biorad qPCR plate. At the end diluted cDNA template was added in 
nanomolar range to each well 96-well plate for q-PCR analysis. The CFX 96 or CFX384 biorad 
machines were used for quantifying the target levels. The program used for the qPCR analysis 
was 2 min initial denaturation at 95°C, 10 sec second denaturation at 95°C and 30 sec 
annealing and extension time at 60°C. This cycle from second denaturation was repeated 40X 
times to see the differences in the level of each target in each test and control. On completion 
of the program after 1 hr 9 min, data obtained were analyzed by averaging 3 technical 
replicates, Ct values were obtained by using formula 2e-ΔCt. The mean Ct of the each replicate 
were exported to MS-excel and then normalized to housekeeping genes GAPDH or 18S or 
beta-actin gene. Fold enrichment changes were then normalized to DMSO or not treated Ct 
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values obtained. The standard deviation for each replicate was calculated in MS-Excel and 
then normalized to the mean of the DMSO control. Primers used for qPCR analysis are listed 
in Table 4. 
Circular Dichroism  
All experiments have been done by using a final 10 μM concentration of TNF-ARE and 10 μM 
DHTS, 10 mM sodium phosphate buffer pH 7.3, was used to dilute RNA and DHTS. CD spectra 
were recorded in a JASCO-700 Spectrophotometer at 240-350nm range (DMSO interfered 
below 240nm), at 100nm/min speed. The TNF-ARE probe was produced by using AmpliScribe-
T7 High Yield Transcription Kit following the manufacturer's instructions. The primer 
sequences used for the IVT for the TNF probe were: 
Forward, 5’-TAATACGACTCACTATAGATTATTTATTATT  
Reverse, 5’-TAAATAATAAATAAATAATAAATAATCTA 
RNA Immunoprecipitation experiments 
5x10^6 cells per sample for each RIP experiment were used and followed accordingly as 
explained in Peritz et al., 2006 [131] without cross-linking step. The cells were treated with 
DMSO and reference compounds for 3 hrs and then collected in Lysis buffer as given in Peritz 
et al., 2006 [131]. The anti-HuR antibody or of mouse IgG isotype (negative control) 
concentration used were 1 μg/ml. TRIzol was added directly to the beads for isolation of HuR-
bound RNA. Data were analyzed by averaging technical triplicates. Fold enrichment changes 
were calculated by the following formula: (X–IgG) / INPUT, where X is the Ct value of the target 
of interest obtained from the immunoprecipitated RNA bound to HuR; IgG is the Ct value of 
the same RNA sequence obtained from the RNA immunoprecipitated with an IgG antibody 
(background) and Input is the Ct value obtained from the total RNA before 
immunoprecipitation. 
RTCA proliferation assays 
xCELLigence RTCA DP Instrument (Roche) was used to perform the Proliferation assays by 
plating 5,000 cells/well at time zero (t0) in E-Plate-16 format. Experiments were run for 72 
hrs. The cell proliferation rate was automatically recorded on the xCELLigence System (Roche) 
in real time every 15 minutes by an electronic cell system. The doubling rate of the cells was 
calculated in accordance with cell index. The cell index is an arbitrary measuring unit which 
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displays impedance. Treatment of the cells was performed by replacing medium with DHTS 
dissolved to 1 and 10 µM concentrations or DMSO (v/v) under the same working conditions. 
Since this system measures the impedance-based sensitivity system, optimization of the cells 
seeding number was followed before starting the main experiments. 
Immunofluorescence experiments 
MCF-7 8,000 cells/well in 96 well plate in triplicate and treated with 1 µM DHTS, MFM49 5 
µM and ActD 2 µM for 3 hrs, were fixed with 100 µl 4% paraformaldehyde (PFA) for 15 min at 
RT. Cells were washed with 1X PBS two times. Now Cells were treated for 10 minutes with 100 
µl permeabilization buffer (200 mM sucrose, 0.2% Triton X-100) followed by one tme wash 
with 1X PBS and then blocked for 15 min with 100 µl blocking buffer (3% Bovine Serum 
Albumin in PBS). Primary antibody anti-HuR 1:300, Anti-NF-kB 1:300 (50 µl) were prepared in 
3% BSA and allowed to incubate for 1 hour at RT. Now washed twice or thrice with 100 µl 1X 
PBS. Secondary fluorophore-conjugated (Alexa 594 Red and Alexa 488 Green) antibody 
(1:500, 50 µl) were diluted in PBS + BSA 0.6% and incubate for 1 hour. Washed 3 times with 
1X PBS (100 µl) and then 100 µl of DAPI Blue (1.5 μg/ml) in PBS was used and incubated for 2 
minutes. After this followed 3 washes with 1X PBS again and let the labelled cells stay in 200 
µl 1X PBS solution overnight or until the image analysis. PerkinElmer image plate reader, 
Operetta was used for image and evaluation by selecting 13 fields/well. Intensity of HuR and 
NF-kB in nucleus and cytoplasm were measured.  Nucleocytoplasmic ratio of HuR/NF-kB 
protein analyzed and plotted in comparison with DMSO control. Clear representative images 
along with DAPI were selected and used for further visual description along with the graph 
showing N/C ratio. 
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RESULTS 
In 2013, a novel high-throughput AlphaScreen biochemical assay was developed in our 
laboratory to evaluate HuR protein-RNA complex formation in vitro [98]. Based on this 
strategy, in 2015 again we screened 107 commercially available anti-inflammatory 
compounds for their potential to target rHuR-RNA complex formation in vitro specifically. Out 
of 107, eight potential positive hit giving compounds named DHTS, hydrocortisone acetate, 
amiprilose, flurbiprofen, deracoxib, fluocinolone, triamcinolone, dexamethasone, were 
additionally screened by EMSA. DHTS was the most potent compound (CHEMBL227075 ID in 
ChEMBL database) among these molecules. Also DHTS did not alter the electrophoretic 
running behavior of the RNA probe in in-vitro REMSA experiments [99].  
Considering this molecule as model HuR inhibitor, we further characterized this molecule 
biochemically in vitro and in a panel of breast cancer cell lines, specifically focusing on post-
transcriptional role of DHTS, in a HuR dependent manner. With the kind support of our 
collaborator, for synthesizing new DHTS analogs, from University of Milan, Prof. Pierfausto 
Seneci and others, we further continued progress of characterizing more precise inhibitors in 
the context of targeting post-transcriptional control of HuR, in breast cancer cell lines, human 
monocytic cell line, and in murine macrophage cell lines via in vitro biochemical, cytotoxic and 
proliferation experiments. 
Together with DHTS, and its analogs we started testing efficacy of those compounds in our 
experimental models systematically. All the results collected are reported below. 
DHTS is an inhibitor of the rHuR-RNA interaction 
We screened a set of anti-inflammatory compounds by using High-throughput AlphaScreen 
assay [98]. Among 107 tested anti-inflammatory compounds DHTS gave the most potent hit 
in term of preventing the HuR-RNA complex formation in vitro indicated with arrowhead 
(Figure 12 A), it showed a Z-score of -2.69. The chemical structure of the DHTS shows the 
reduced dihydrofuran ring, on the right side while on left side planar aromatic methyl-
substituted cyclohexane ring. Dihydrofuran ring was claimed to be the potential body in this 
interfering process. 
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A.                                                                               B.    
      
 
 
 
 
                                                                                                                 
 
 
 
 
 
 
 
 
 
Figure 12 Biochemical characterization of DHTS in-vitro A) HTS AlphaScreen carried for 107 anti-inflammatory 
compounds using 50 nM of each compound with 1 nM of rHuR, 50 nM of Bi-TNF RNA probe. B) EMSA showing 
inhibition of 0.5 μM of rHuR and 0.5 μM of Cy-3 RNA probe at equilibrium with DHTS compound in vitro, 
reference DHTS concentration used was 100 µM. Mean±SD refers to three independent experiments (n = 3). 
(Experiment has been performed by Dr. Vito D’Agostino, published in D’Agostino et al., 2015). 
 
DHTS apart from its interfering property further did not alter the electrophoretic mobility of 
the Cy-3 labelled RNA probe, even at 200 fold more concentration (100 µM), Anti-HuR 
antibody was used to confirm the shift acquired, was by HuR itself Lane 3 (Figure 12B). To see 
the DHTS efficacy we have performed competitive binding saturation experiments by using 
either EMSA or Alphascreen assays.  IC50 values obtained for EMSA and AlphaScreen were 
149±34 nM, 68±16 nM. Ki value, i.e., equilibrium dissociation constant (Ki) calculated for DHTS 
by AlphaScreen assay was 3.74±1.63 nM, after using the Kd 2.5 nM [98] (Figure 13A and 13B).  
These values depend upon the different concentration of the constituent used.  
 A)                                                                                  B) 
 
 
 
 
                              
IC
50 
: 68 ±16 nM 
Ki:     3.74±1.63 nM 
R²:    0.983 
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Figure 13 DHTS interfere with HuR-RNA complex and lowers the cell viability. A) Titration of the HuR with a 
gradient of DHTS concentration showing saturation binding. B) Evaluation of the DHTS activity in low nanomolar 
or micromolar range. Ki values was calculated using the GraphPad Prism version 6 with nonlinear regression 
function in analysis tab and choosing the one site-specific binding or one site-specific Ki function. For the Ki, the 
Kd value [98] (2.5 nM) of the HuR protein and final conc. of the probe used (50 nM) was needed to put in order 
to obtain the specific Ki Mean±SD refers to three independent experiments (n = 3). (Experiment has been 
performed by Dr. Vito D’Agostino, published in D’Agostino et al., 2015 [99]). 
DHTS binds to M1M2 domain of the rHuR  
In HuR main remnant responsible for recognizing the AU-rich RNA elements, are present in its 
RRMs (RNA recognition motif), we constructed and purified recombinant HuR isoforms 
containing two different arrangement of HuR RRMs (Figure 14A). Since we know that RRM1 
and RRM2 are rate-limiting domain of HuR for RNA binding activity [20], the RRM1/2 construct 
was supposed to copy the ability of FL-HuR to bind the target RNA probe, as expected it was 
the target of the DHTS for its ability to interfere in RNA binding activity in HuR RRM1/2 motifs. 
 
                                   A.  
 
                  B.                                                     C.                                                
 
 
 
 
 
 
Figure 14 Effects of DHTS on RRM1/2 and RRM2/3 A) Schematic representation of strategy used to exploit the 
DHTS efficacy in HuR RRMs. B) EMSAs showing inhibition of RRM1/2 binding to TNFa probe, the concentration 
of protein and probe used were 0.5 µM respectively. C) EMSA for RRM2/3, DHTS could not inhibit the binding of 
RRM2/3 binding to TNFa probe, conc. of protein and probe used were same as in figure B. Representative 
REMSAs were repeated with atleast three independent protein purification. (Experiment has been performed by 
me and published in D’Agostino et al., 2015 [99]). 
 
Consequently RRM1/2 isoform reported Kd value 2.66 nM, more or less similar to FL-HuR. 
DHTS was found to be working on the first two domain RRM1/2-RNA complex formation with 
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Ki = 4.12 ± 0.81 nM, when titrated with DHTS to upto 5 µM concentration resulted in complete 
abrogation of the HuR and its ARE binding was observed (Figure 14B) (Ki and Kd graphs not 
shown). 
Moreover RRM2/3 HuR isoform was purified and noted to be a labile protein concerning its 
stability, and represented higher Kd value of 24 nM and only minimal effects of DHTS were 
seen upon, titration with DHTS in a similar fashion as is done for RRM1/2 (Figure 14C).  
Additionally each individual motifs (RRM1, RRM2 and RRM3) were constructed and purified 
from E. coli cells (Figure 15A). RRM1 and RRM3 were stably expressed at RT, whereas RRM2 
showed labile, low expression pattern at RT, lately optimized and was expressed at 16 0C, this 
may be due to its low molecular weight ≥ 10 kDa or labile conformations (Coomassie gel not 
shown).  
They were analyzed for their binding to FAM labelled AU-RNA probe, in the absence (DMSO 
only) and presence of DHTS gradient ranging from 0.31-10 µM, remarkably individual RRMs-
RNA was strong and was not abrogated by DHTS at reference doses. As expected from RRM1, 
where it’s binding with RNA probe was slightly interfered with 20% displacement observed 
after densitometric analysis by Image J (Figure 15B). Altogether, these results show that DHTS 
interfere with RNA binding activity of HuR. A correct clarification could be given for DHTS 
interference with allosteric alteration in conformation of RRM1/2, therefore disturbing the 
additional association formed with inter-domain linker region during RNA-complex formation 
[20].                                                B. 
A.                                                                                                                                             
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Figure 15 Limited effects of DHTS on individual RRMs A) Schematic of the RRMs constructs used for DHTS 
interference analysis (On left). B) RRMs western blot, and densitometry of each RRMs from EMSA. (Upper and 
lower pictures, left hand side), Representative EMSAs showed no inhibition by DHTS on individual RMMs, even 
at 10 µM, except at for RRM1 (On Right). Mean±SD refers from atleast 3 independent protein purification 
independent experiments. (Experiment has been performed by me, published in D’Agostino et al., 2015 [99]). 
 
DHTS selective profile against other RBPs 
Since we know that DHTS interferes with HuR-RNA interaction, in vitro characterization of the 
selective profile of DHTS was necessary [99]. For this purpose we selected four RNA binding 
proteins (RBPs), i.e., HuD/ELAVL-4, TTP, Lin28 and TDP-43, having structural homology of 78%, 
50%, 35%, and 24 % with HuR. HuD which selectively expressed in brain and tumor tissue 
possess 78% homology as it also contains RNA-Binding Domains [7]. In vitro HuD-RNA complex 
formation was interfered by DHTS at 5 µM concentration, whereas on contrary Lin28b has a 
cold shock domain and a pair of CCHC zinc finger domains [132]. TTP (Nup475) has two 
tandemly arranged cysteine and histidine sequences of new heavy metal-binding domain and 
is known to bind Zn2+ and TDP-43 protein has NTD (N-terminal domain, two middle RNA 
recognition motifs (RRMs) followed by a C-terminal glycine-rich fragment [133]. All protein’s 
except HuD, binding to target probe was not abrogated by DHTS (Figure 16A, 16B, 16C, 16D). 
A.                                    B.                                         C.                                     D.   
 
Figure 16 Determination of selective profile for DHTS in panel of other well-known RBPs A) EMSA for HuD, 
DHTS interfered at reference doses. B, C & D) EMSA for TTP, Lin28b, TDP-43, no interference by DHTS at reference 
doses, in all RBPs were detected. Representative REMSAs were repeated with at least three independent protein 
purification. (Experiment has been performed by me, published in D’Agostino et al., 2015 [99]). 
 
5  2.5  µM 
TTP HuD 
2.5  5  µM 
Lin28b 
2.5  5  µM 
TDP-43 
2.5  5  µM 
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Taken together these set of experiments further led us to determine the DHTS mediated 
aftermath in in vitro and cell model with highest efficacy of the DHTS among other tested 
compound encompassing a selective profile towards a group of 4 RBPs. We further decided 
to characterize DHTS additionally in a different set of biochemical experiments which are 
explained in the following result section. 
Inter-domain linker region in HuR structure is crucial for binding to target RNA and therefore 
for DHTS activity.  
We have shown DHTS is somehow interacting with HuR, as it was displacing bound RNA from 
HuR in low mircomolar range, we got a positive hint from the EMSA experiments done in 
RRM1/2 domains that our DHTS specifically binding in the RRM1/2 domain and inhibiting the 
RRM1/2-RNA complex formation (Figure 14A). Already first two domains of HuR, has been 
proved experimentally, and are responsible for binding to target RNA probe in a dynamic 
fashion [20]. To know exactly the amino acid residual information interacting with DHTS, we 
have done NMR studies on RRM1/2 and DHTS binding with combined efforts of our 
collaborators Prof. Marco Fragai, from University of Florence.  
Surprisingly, NMR studies revealed participating HuR aa residues in binding to DHTS, which 
lies in the first two domain in β-sheets of HuR protein. They are Thr20, Asn21, Ile52, Ser94, 
Tyr95, Ala106, Asn107, Leu108, Ile133, Asn134, Val137, Leu138, Arg147, Ile152, Phe154, 
Asp155, and Lys182 respectively. Further after conducting molecular modeling followed by 
“tandem” docking calculations and molecular dynamics (MD) simulations in order to know the 
mechanism of action of DHTS compound, consistently again DHTS was found interacting at 
the region within RRM1/2 i.e. from Ser 94 aa of RRM1 to N107aa of RRM2. This region is also 
called inter-domain linker region and together with these RRMs, forms binding cleft of HuR, 
responsible for binding to target probe [130]. 
To support NMR and molecular modeling that addressed a specific interacting region on HuR, 
we produced HuR protein domains made of the first RRM domain (RRM1), second RRM 
domain (RRM2), RRM1-RRM2 wild-type RRM domains, RRM1 lacking 14 amino acids at the C-
terminus ΔRRM1, missing residues from Ser94 to Asn107 and performed in vitro RNA binding 
experiments. Some of these residues belong to the inter-domain linker (Ser99–Asp105) and 
the others to the β-platform regions of the two domains, where some amino acids 
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experienced decreased intensity in the presence of DHTS (Ser94–Tyr95 in RRM1 and Ala106–
Asn107 in RRM2). HuR domains were produced in Escherichia coli using the pET42 plasmid 
[99]. We obtained the same purity for all the protein isoforms Figure not shown). As single 
domains lose RNA-binding activity very quickly, the in vitro activity of the single protein 
domains and their combination was evaluated by REMSA, mixing equimolar concentration of 
each, freshly prepared, with 0.2 µM of the FAM-ARE ssRNA probe (Figure 17A). The RRM1-
RRM2 isoform was used as a positive control because it displayed a similar Kd (2.62 ± 0.6 nM) 
[99] to the FL HuR protein, and because it was used in the NMR experiments [101]. RRM1 
retained the capability to recognize mRNA substrates [20], however with a lower affinity 
compared to the RRM1–RRM2 construct, probably indicating a change in the stoichiometry of 
cooperative protein binding (Figure 17A) [134][20]. 
Importantly, the RRM1–RNA complex was still sensitive to DHTS. REMSA performed with 
RRM2 and in vitro complementation of the two domains RRM1 + M2 did not provide 
information about the contact region of DHTS.   After removing 14 amino acids, the binding 
capacity of ΔRRM1 to RNA was slightly reduced (∼20%) in comparison with the RRM1 domain 
(Figure 17A). Conversely, ΔRRM1 became resistant to DHTS, suggesting that this region is 
essential for DHTS inhibitory activity (Figure 17B).  
By using fluorescence polarization, we analyzed the binding kinetics of proteins (200 nM) 
toward the FAM-ARE RNA probe (100 nM). We confirmed that full-length HuR and RRM1-
RRM2 tandem domains behave almost similarly (average Kobs ∼4 min), reaching equilibrium 
after 10 min. On the other hand, the RRM1 domain rapidly recognized the substrate (Kobs ∼1 
min), but this affinity was significantly impaired in the ΔRRM1 construct (Kobs of ∼8 min) 
(Figure 17C; TABLE 1). All these results together explain the importance of interdomain region 
of HuR for RNA and for DHTS efficacy.  
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A.                                                                                B.     
                                                                                    
             
 
 
 
 
      
 
 
 
C.  
   
Figure 17 EMSAs using individual RRMs and ΔRRM1 to dictate probe binding upon DHTS addition. A) 
Representative REMSAs of at least three independent protein preparations of recombinant RRM1 + RRM2 (M1 
+ M2) domains, RRM1 (M1), RRM2 (M2), RRM1–RRM2 (M1M2) HuR proteins. REMSAs were performed with 0.2 
µM of protein, 0.2 µM of Cy-3 RNA probe and DMSO or DHTS at indicated doses. B) On right Representative 
REMSA performed with 2.5 µM of ΔRRM1 and 75 fM of probe RNA titrated with DHTS (concentration as shown 
in the legend). Densitometric quantification plotted below represents specific HuR–RNA binding challenged by 
DHTS. C) Kinetic saturation binding experiment by fluorescence polarization. 200 nM wild-type protein or 
mutants were incubated with FAM-ARE RNA probe (100 nM). Full-length HuR and RRM1–RRM2 tandem domains 
(M1M2) have similar Kobs. RRM1 (M1) is binding faster (Kobs of ∼1 min), but deletion of the inter-domain region 
abolishes the binding properties of RRM1 (_M1) (Kobs of ∼8 min). Mean ± SD refers to three independent 
experiments (n = 3, * indicates t-test P-value < 0.05). (All experiment has been performed by me, published in 
Lal et al., 2017 [130]). 
Table 1  
K (obs) Values for HuR and its isoforms in FP 
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Single point mutations in the HuR–DHTS interacting region abolishes DHTS efficacy  
Consistent with NMR data, and therefore considering the NMR aa residual information given, 
as a putative DHTS binding site, we produced mutants of FL-HuR, belonging to the inter-
domain region. Together with another participating residues from RRM2, which forms the 
beta sheets secondary structure in HuR, these mutants were mutated at S94A, N107A, I133A, 
and N134A. These muteins were produced by site directed mutagenesis, and later purified 
from E.coli cells accordingly [98] [134] (Figure 18A). After quantification of the each mutein 
protein concentrations by densitometry (data not shown), we performed EMSA of these 
muteins, with 200 nM of each mutein or FL-HuR and 200 nM FAM labelled ARE-RNA probe, as 
expected we did not see interfering function of DHTS at 5 µM concentration, whereas in WT 
FL-HuR dissociation of the RNA probe, was clearly noticed. In addition, we observed a 
differential qualitative binding behavior of each muteins, which can be seen in the binding 
profile of FL-HuR alone. From this experiment we found three distinct super-shifts (indicated 
as arrow head with number 1, 2 and 3) given by individual mutein or possessed fully by FL-
HuR, depending on the molecular size on EMSA gel. These single point mutants N107 and 
N134A possessed noticeable supershift 3. However, S94A and I133A has given supershift 
similar to that of FL-HuR control. Nevertheless partially they also possessed slight enrichment 
of supershift 3 explaining the likelihood of these muteins with greater oligomerizing and RNA 
recognition function compared to FL- HuR, this is also evident from the amount of free RNA 
probe, both in case of muteins and FL-HuR running front in native EMSA gel (Figure 18B). 
Moreover to find if DHTS interacts with RNA probe we performed, Circular dichroism (CD) 
experiments at 10 µM concentration of both reagents similarly 50 µM RNA + 150 µM DHTS in 
NMR measurements. The results obtained ruled out the putative interaction between DHTS 
and RNA as didn’t observe any difference in the spectra obtained (Figure 19A and 19B).  
Additionally in AlphaScreen assays we found 100 folds lower Kd values i.e. an increased 
affinity in saturation binding experiments concerning wild-type HuR, when titrated with 
biotinylated probe’s final concentration 3.12, 3.12, 0.78, 1.78 for S94A, N107A, I133A and 
N134A respectively. Notably the Kd values obtained were 0.22 with R2 = 0.84, 0.067 with R2 
=0.82, 0.31 with R2 = 0.93 and 0.030 with R2 = 0.99 for S94A, N107A, I133A and N134A (Figure 
20A, B, C, and D), Consistently RRM1/2 has given the Kd value of 2.55±0.744, similar to the kd 
obtained by D’Agostino et al., 2013, 2015 (Figure 21A) [98], [99]. This shows the critical 
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importance of first two motifs for RNA binding activity. The relative Kd values shown by the 
N107A and N134A is consistent with previous finding in EMSA experiments (Figure 20B, 20D 
and Figure 18B), showing enhanced enrichment of aggregation upon RNA probe addition, 
considering this profile of binding, we have optimized the RNA probe conc. to be used in these 
assays which were significantly lower as compared to FL-HuR (50 nM). Accordingly when 
Ser94, Asn107, Ile133 and Asn134 are mutated into Alanine, DHTS does not bind to any 
mutein. The four residues are thus crucial in providing the required flexibility to HuR for its 
mRNA binding function. 
A.                                                                                             B.                                                              
                                                                                             
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Single point mutations in the HuR–DHTS interacting region abolishes DHTS efficacy.  A) Coomassie 
for purification of muteins, M = Marker, Lanes S94A Lanes 1 and 2, N107A Lanes 3 and 4, I133A Lanes 5 and 6, 
N134A Lanes 7 and 8, BSA 350ng and 450ng Lanes 9 and 10, supernatant of muteins S94A, N107A, I133A, N134A 
Lanes 11, 12, 13 and 14. Two lanes for each muteins represents the elution  with 250 and 500mM imidazole 
containing elution buffer B) RNA and DHTS-interacting amino acids are crucial for DHTS and RNA binding, and 
for protein dimerization. Representative REMSAs of at least three independent protein preparations of 
recombinant full-length HuR and indicated muteins. REMSAs were performed with 0.2 µM of protein, 0.2 µM of 
Cy-3 RNA probe, and DMSO or 5 µM DHTS. Muteins are insensitive to DHTS and show different binding patterns 
to the RNA probe. Indicated arrows (1, 2 &3) shows the binding behavior of FL- HuR (DMSO), which is represented 
by each muteins. Representative REMSA were repeated with at least three independent protein purification. 
(Experiment has been performed by me, published in Lal et al., 2017 [130]). 
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B.
 
Figure 19 A) Circular Dichroism spectra of TNFα RNA (10 µM in 200 µL of buffer indicated as Green line) showing 
no binding to DHTS (10 µM in 200 µL Buffer with DMSO indicated as Red line). B) 1D 1H NMR spectra of TNFα 
RNA (50 µM) acquired at 298 K on a 950 MHz spectrometer in the absence (black) and the presence of DHTS 
(150 μM, red). (Figure A :Experiment has been performed by me, published in Lal et al., 2017 [130]) (Figure B 
:Experiment has been performed by our collaborator from University of Florence, published in Lal et al., 2017 
[130]).  
 
 
 
A.                                                                                B. 
 
 
 
    C.                                                                                        D.  
  
 
 
                                                                                            
Figure 20 Calculation of kd of Muteins, by AlphaScreen assay. (A) S94A, (B) N107A, (C) I133A and (D) N134A. 
Differences in the scale used in all Kd’s graphs is due to different concentrations of the Bi-RNA probe used to 
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obtain the respective lowered kds. Mean ± SD refers to three independent experiments (n = 3) (Experiment has 
been performed by me, published in Lal et al., 2017 [130]). 
A.                                                                                  B.  
 
 
Figure 21 Calculation of Kd for HuR isoform RRM1/2, by AlphaScreen assay. A) Kd value obtained for RRM1/2 
B) Schematic showing the position of Mutated residue to Alanine in FL-HuR. Mean ± SD refers to three 
independent experiments (n = 3) (adapted from Venigalla, RKC et al., 2012). (Figure A: Experiment has been 
performed by me). 
Single point mutation causes dimerizing aggregation behavior of Muteins   
As evident from the previous experiments presented in figure 20 and 21, we further 
performed cross-linking experiment to analyze the constitutional pattern of each muteins 
deeply. To establish this, we followed direct fixing of the E. coli cells expressing FL-HuR and 
muteins with 2% HCHO (Formaldehyde) in LB growth medium for about 15 minutes, after 
purification of the cross-linked protein by Ni-NTA beads, were run on 12% SDS-PAGE with 
0.05% SDS in the running gel. Notably again N107A and I134A showed the abundant level of 
both monomer and dimer with particular mol. size (36 and 75kDa) (data not shown). REMSA 
in vitro binding assays confirmed the significant N107A and I134A, more likely aggregating 
behavior as compared to other muteins (Figure 22A and 22B). However, S94A and I133A have 
shown binding differently similar to WT HuR (Figure 22 C). This behavior could result from a 
higher efficiency in recognition and dimerization along the mRNA substrate, or alternatively 
from an aggregation-prone tendency of muteins that therefore aggregate on the same 
molecule of RNA probe. Indeed, mutants showed significantly lower Kd values, i.e., an 
increased affinity in saturation binding experiments with respect to M1M2 (Figure 20 and 21). 
FL-HuR 
Point mutations 
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All these experiments notify that these muteins altogether aggregates due to mutation, also  
DHTS showed negligible efficacy, and this confirms that these residues are important for RNA 
binding activity of HuR and therefore, for pure efficacy of DHTS. 
 A.                                                                                                                                                                 
 
 
 
       
B.                                                                             C.                                                                                                                                                                                                                                 
 
 
Figure 22 Aggregation of muteins. Representative REMSAs of at least three independent protein purification 
performed with increasing concentration of WT and HuR single point mutants as indicated in the legends A) WT 
HuR and N134A B) WT HuR and N107A and C) S94A and I133A with 75 fM of probe RNA. Representative REMSAs 
were repeated with atleast three independent protein purifications. (Experiment has been performed by me, 
published in Lal et al., 2017 [130]). 
 
DHTS downregulates TNFα and VEGF in breast cancer cells 
As tanshinones were found to inhibit the HuR and TNFa binding, confirmed in vitro via 
biochemical experiments [97], we checked the levels of HuR targets TNFα (tumor necrosis 
factor) and VEGF (vascular endothelial growth factor) in breast cancer cell lines, following 
treatment for 24 hrs with DHTS (shown in legend as DT). As noted earlier DHTS as strong HuR 
inhibitor in vitro, we observed 50-60% significant decrease in the levels of TNFa in MDA-MB-
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231 and SKBR-3 cell line (Figure 23A). Another HuR target VEGF (vascular endothelial growth 
factor upon DHTS treatment for 24 hrs, was also downregulated to upto 40%. (Figure 23B). 
A.                                                                                   B. 
 
 
 
 
 
                               C.  
                                  C. 
   
 
 
 
 
 
Figure 23 Intracellular effects of DHTS on HuR targets A) TNFa level in MDA-MB231 and SKBR3 cell lines after 
24 hrs, TNFa level were normalized to actin. B) VEGF levels in MDA cell line, normalized to actin. C) RNA 
immunoprecipitation, in MCF-7 cell line, the treatment was for 3 hrs, with LPS (1 µg/ml), DHTS (1 µM). Mean±SD 
refer to n= 3 experiments and analyzed by one-way ANOVA. * P≤0.05, ** P≤0.01 and *** P≤0.01. (Figure A & B 
contributed by me) (Figure C contributed by Dr. Vito D’Agostino published in D’Agostino et al., 2015 [99]). 
Further, we checked whether DHTS is affecting post-transcriptional control mediated by HuR, 
using RNA immunoprecipitation (RIP). We co-induced cells with LPS, DHTS and another 
LPS+DHTS (1 µM) and DMSO or mock as an independent control. qPCR analysis showed that 
LPS stimulated the TNFa level, whereas our DHTS has counteracted this increase by lowering 
TNFa level comparable to mock control. The strong increase observed in LPS-induced cells 
 
*** 
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further explain the important role of HuR, in controlling post-transcriptionally the fate of TNFa 
mRNA (Figure 23C). Nevertheless, this post-transcriptional control of HuR is not limited to 
TNFa, but RIP analysis of another HuR regulated transcripts, ERBB2, VEGF, and CCND1 bound 
copy number, the presence of DHTS is controlled to a different extent (data not shown), but 
to significant level, with respect to control. 
A.                                                                    B.      
 
     
 
 
 
C.                                                                        D. 
 
 
 
 
 
Figure 24 Efficacy of DHTS is HuR dependent A) MTT assays on the silenced/overexpressing HuR MCF-7 cells 
treated with DMSO OR DHTS for 24 hrs. B) Relative level of the viable cells in silenced/overexpressing HuR MCF-
7 cells treated with DMSO or DHTS for 24 hrs. C) Real time cell analysis (RTCA) proliferation assays, done in 
normal and silenced HuR MCF-7 cells with indicated doses of DHTS in legends. D) Real time cell analysis 
proliferation assays (RTCA), done in normal and overexpressing (OE) HuR MCF-7 cells with 1 µM of DHTS. 
Mean±SD refers to three independent experiments (n = 3). (Experiment contributed by Dr. Vito D’Agostino 
published in D’Agostino et al., 2015 [99]). 
 
 
               IC
50
 
siHuR:    0.45±0.14 µM 
HuROE: 1.30±0.12 µM 
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DHTS efficacy depends upon HuR expression 
After following the string of biochemical experiments, we also exploited the DHTS influence 
in HuR silenced or overexpressing HuR transiently in MCF-7 breast cancer cells. To establish 
this, we started with dose-response assays on HuR silenced or overexpressing MCF-7 cells. 
After 24 hrs exposure of DHTS to these cell lines, differential level of sensitivity was revealed 
for siHuR MCF-7, IC50 = 0.45 µM or for OE-HuR MCF-7, IC50 = 1.3 µM as compared to scramble 
or vector MCF-7 cells. This information explained the compensatory effect overexpressing 
HuR versus DHTS in case of siHuR MCF-7 and, OE-HuR MCF-7 (Figure 24A). HuR absence 
increased the sensitivity of MCF-7 cells in DHTS dose dependent manner, from the figure it is 
clear that even at 1 µM DHTS concentration, siHuR MCF-7 cells viability decreased to 50% as 
compared to mock, however we also observed 20% lower viability rate in case of non-treated 
siHuR cells after 24 hrs. At higher concentrations undoubtedly DHTS killed the cells surpassing 
the fact of either silenced HuR or OE-HuR in MCF-7 cells (Figure 24B). Real-time cell analysis 
assays were done in a similar manner but in different set of experiments to study the effect 
of DHTS on MCF-7 rate i.e. firstly we checked the proliferation rate of siHuR MCF-7 cells 
together with proliferation normal MCF-7 cells. The anti-proliferative effect of DHTS was 
evident at low doses, i.e., at 1 µM, in normal cells, after 12 hrs of treatment time, indicated 
as the arrowhead. In HuR silenced DHTS completely blocked the cell proliferation, at higher 
doses, i.e., at 10 µM cytotoxic effects of DHTS emerged in this experimental system, later on, 
were confirmed by MTT. (Figure 24C). Secondly, we also checked the proliferative potential 
of HuR overexpressing MCF-7 cells in the presence of 1 µM DHTS concentration, in this case 
also markedly 1 µM DHTS has shown the anti-proliferative potential, further indicating that 
HuR levels can counteract or modify the phenotypic response of OE-HuR MCF-7 cells at low 
doses of DHTS. (Figure 24D). 
Taken all together these results shows that HuR can rescue phenotypic effects of DHTS, for 
example viability, proliferation arrest of cancer cells. This further explain that HuR is a central 
target of DHTS, and collectively effects of DHTS on HuR targets could be demonstrated by 
blockade of HuR-RNA binding activity.  
DHTS is effective on HuR-positive models in vitro and in vivo 
To evaluate this mechanism of action, in which a limited displacement of RNAs from HuR may 
be effective in HuR-dependent tumor growth, we studied tumor growth in vitro and in vivo. 
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HCT116 colon cancer cells were used as a model, based on high endogenous levels of HuR and 
their sensitivity to HuR inhibition [136]. These experiments were performed by our 
collaborator in the laboratory of Prof. Dan Dixon from University of Kansas Medical Center, 
Kansas USA. Creation and characterization of CRISPR/Cas9-mediated knockout of the ELAVL1 
gene in HCT116 cells were accomplished as described in Lal S. et al., 2017[137]. HCT116 and 
HuR-knockout cells (HCT116ΔHuR) were grown under anchorage- and serum-independent 
conditions to facilitate tumor spheroid growth, and HuR was observed to be needed for 
tumorsphere growth. In the presence of DHTS, the growth of HCT116 spheroids was 
attenuated 2-old, whereas DHTS did not impact HCT116ΔHuR sphere growth (Figure 25A and 
25B). To test the effects of DHTS on tumor growth in vivo, mice bearing HCT116 cell xenografts 
received IP injections of DHTS (10 mg/kg body weight) or vehicle every 48 h. Over the course 
of the experiment, DHTS was well tolerated, and mice did not display any signs of acute 
toxicity and maintained similar weights. Significant anti-tumor effects of DHTS were observed, 
with approximately a 4-fold reduction in tumor size (Figure 25C and 25D).   
A.                                                                                   B. 
  
 
 
 
 
C.                                                                                  D.      
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     E.                                                                                           F.     
 
 
 
 
Figure 25 DHTS efficacy relies on HuR presence in vivo. A) The spheroid growth of parental HCT116 (HCT116) 
and HuR-knockout cells (HCT116ΔHuR) treated with DHTS (10 µM) or vehicle. DHTS was added after 3 days of 
culture in spheroid growth medium on ultra-low adherence substrate, and spheroid growth was tracked by 
imaging for 15 days. P-value is **<0.01, ***<0.001, n.s. = not significant. B) Representative tumorsphere images 
from day 0 and day 15 of DHTS treatment. Scale bar = 100 µm. C) Tumor growth of parental HCT116 and HuR-
knockout cells (HCT116_HuR) xenografts in nude mice treated with 10 mg/kg DHTS or vehicle control every 48 
h. P-value is ***<0.001, n.s. = not significant. D) Representative tumors excised at day 31 are shown. E) HuR-
knockout cells (HCT116ΔHuR) were transfected a HuR-expression construct (+HuR), along with empty vector 
transfected parental HCT116 and HCT116ΔHuR cells. Cells were treated with DHTS (10 ΔM) or vehicle, and cell 
growth was assessed 6 days after the treatment using MTT assay. Cell survival was normalized to the respective 
control and are the average of three experiments. P-value is **<0.01, ***<0.001. F) Western blot showing HuR 
complementation in HCT116ΔHuR+HuR cells and absence of HuR in HCT116ΔHuR cells. Actin was used as a 
loading control. (Experiment has been contributed by our collaborator from University of Kansas Medical Center, 
published in Lal et al., 2017 [130]). 
 
Additionally, the efficacy of DHTS was strictly dependent on the presence of HuR. 
HCT116ΔHuR cells grew significantly more slowly and formed smaller tumors, but were 
completely insensitive to DHTS. Furthermore, this decreased growth sensitivity of DHTS in 
HuR deficient cells could be restored with expression of HuR in HCT116ΔHuR cells (Figure 25E 
and 25F). These results indicate that DHTS has significant antitumor activity in vitro and in vivo 
without major systemic toxicity, along with demonstrating the specificity of HuR inhibition. 
 
Biochemical Characterization of DHTS Analogs 
 As mentioned earlier at the beginning of result section, I am also involved in characterizing 
another DHTS analogs which we regularly receive from our collaborators. A peculiar property 
of these analogs is that these are more potent or specific for interfering with binding of HuR-
RNA complex formation. Moreover, on the other side, these molecules showed differential 
cytotoxicity in a panel of model cell lines. Although we had a long list of DHTS analogs, we 
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started with nine (9) analogs (which are named as MFM49, MB11V, VB062, GD041, MB37, 
MB39, MB40, MB42, and MB44) by checking their in vitro specificity for HuR-RNA binding 
complex formation. The nomenclature given is random and is meant to identify them 
structurally, the difference in their RNA binding activity and the most important thing to note 
is that we could not show the chemical structures of these DHTS analogs due to a confidential 
agreement with our collaborators.  
Nevertheless, we saw their biochemical activity on rHuR and FAM-ARE. We freshly purified 
rHuR from E.coli cells and used to a final concentration of 250 nM along with 25 nM FAM-ARE.  
As evident from the picture, most potent hit was given by MFM49 and MB39, lanes 4 and 9 
(Figure 26A). However to be more precise densitometric analysis has confirmed this 
impression for activity of MFM49 and MB39, where 60-70% displacement of the bound FAM-
ARE RNA was observed. Simultaneously other analogs showed displacement of the RNA, but 
to lesser magnitude than MFM49 and MB39. Looking accordingly, degree of displaced FAM-
ARE RNA from rHuR- RNA complex, GD041, VB062, and MB42 showed inhibition activity in 
decreasing order, for their ability to displace target bound RNA (Figure 26A lanes, 7, 6 and 
11). Notably, they decreased the binding significantly to 60, 55, and 50% as DSMO control 
100%. (Figure 26B).   
A.                                                                              B.  
           
 
Figure 26: Screening of other potent HuR inhibitors A) Representative EMSA for evaluating the activity of DHTS 
analogs using 250 nM of rHuR and 25 nM of FAM-RNA probe, the concentration of each compound used is 5 µM. 
Lanes RNA only (1), rHuR+DMSO1 (2), rHuR+DMSO2 (3), rHuR+MFM49 (4), rHuR+MB11V (5), rHuR+VB062 (6) 
rHuR+GD041 (7), rHuR+MB37(8) rHuR+MB39 (9) rHuR+MB40 (10), rHuR+ MB42 (11) and rHuR+MB44 (12). B) 
Densitometry of figure A to quantify the level of displaced and bound FAM-RNA probe. (Experiment has been 
performed by me).  
 68 
 
Minor inhibition activity were shown by MB40, MB37, MB44 and MB11V, again in a decreasing 
order for their ability to halt the RNA-binding activity by rHuR, (Figure 26A lanes, 10, 8, 12 and 
5) with 30, 20, 15, and 15 percent decrease after quantification by Image J (Figure 26B).  
Taken all together these results shows that differences in structural moiety can have the 
significant impact on their ability, to bind or recognize or fit into the RNA binding site of HuR, 
which selectively bind to the ultimate small molecules possessing the ability to participate at 
the upfront of binding cleft. 
MFM49 is the most potent inhibitor of rHuR-RNA interaction. 
 I came across a more specific rHuR-RNA complex inhibitor while screening three compounds 
received together from our collaborators. These inhibitors were soluble in DMSO, firstly we 
checked by the REMSA for its inhibition function using 0.5 µM of Cy3-ARE-RNA probe, 400 nM 
of rHuR protein together with DHTS inhibitor at its IC-50 as positive control lane 2 and 3. Lanes 
5 and 6, represented the MFM49 activity at 80 and 160 nM, surprisingly, it showed significant 
displacement of rHuR-RNA complex formation. Among these we also loaded, reaction mixture 
for MFM62 and MFM75 incubated with rHuR-RNA, MFM62 showed displacement of rHuR-
RNA complex formation, but with less significant level, lanes 7 and 8; whereas MFM75 showed 
negligible inhibition of rHuR-RNA complex formation function, lanes 9 and 10 (Figure 27A). I 
also checked these compound's activity in AlphaScreen assays described in previous 
experiments, consistent with EMSA data, these compounds showed, similar efficacy towards 
rHuR-RNA complex formation, as said earlier the most potent compound is MFM49 which 
showed Ki of 12 nM (Figure 27B). 
A.                                                                         B.                                                       
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    C.                                                                                D.      
 
 
 
 
 
Figure 27 MFM49 is the most potent inhibitor of rHuR-RNA interaction. A) Representative EMSA showing the 
most potent activity of MFM49 among other analogs. B) Alphascreen assay carried out using 25nM of rHuR and 
50 nM of biotinylated probe together with 20 ng/µl of donor and acceptor beads to evaluate the Ki of MFM49. 
C) Competitive saturation binding EMSA assay with gradient concentrations as shown in legend  for MFM49 with 
0.5 µM of Cy3- ARE-RNA probe and 500 nM of rHuR protein. D) Densitometric analysis to quantify the proportion 
of Cy3-RNA displaced upon MFM49 addition in reaction mixtures. Mean ±SD refer to at least 3 independent 
experiments. (Experiment has been performed by me). 
 
Consequently complete repeal of the rHuR-Cy3 ARE-RNA formation in competitive binding 
assays, using equimolar concentration of both ligands with MFM49 as indicated in the 
legends, was also observed (Figure 27C, D). Taken all together these results suggest that 
MFM49 is most potent compound, based on its preference to displace rHuR-RNA complex 
formation significantly. Further, this also may suggest that it occupies ARE-RNA binding cleft 
of HuR tightly and prevent further HuR biochemical function in vitro. To test further MFM49 
for intracellular effect on HuR targets, we have tested this compound together with DHTS in 
different cell line models. Results obtained for few of them are described below in coming 
result sections.  
DHTS analogs are the potential inhibitors of HuR RNA:Complex formation  
REMSA binding assays confirmed the specificity of these potent inhibitors, nevertheless we 
also checked this potency in AlphaScreen assays [98], the relative inhibition profile of these 
inhibitors, as expected these molecules interfered with the apparent binding behavior, to a 
significant measures, at low nanomolar range (nM). I selected five compounds among 9 
compounds, previously known for their potential from EMSA binding assay (Figure 26). Also 
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taking into account their color which could interfere or give false alpha count while plate read, 
as this assay is based on fluorescence emission events given by close proximity of donor and 
acceptor beads, specific for the biotinylated probe or His-tagged rHuR protein. 
     A.                                                                        B.       
 
 
 
 
        C.                                                                            D. 
 
 
 
                                           E. 
                                                                                                                     
 
 
Figure 28 AlphaScreen assays to evaluate DHTS analogs activity, showing Ki curve for, in low nanomolar range 
or micromolar range A) MB11V, B) GD041 C) VB062, D) MB39 and E) MB42 Mean ±SD obtained from refer to 
atleast 3 independent protein purification. (Experiment has been performed by me). 
 
TABLE 2 Ki values obtained for DHTS Analogs 
         DHTS                     MB11V       GD041        VB062       MB39       MB42 
     logKi nM 1,689                     ~3,442 1,909 ~ 5,742 2,462 2,116 
              R²  0,9200                        0,7896 0,9112 0,7396 0,7365 0,8453 
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I firstly optimized the protein-RNA ligands ratio, by keeping constant the final concentration 
of biotinylated RNA-ligands i.e., 50 nM together with donor and acceptor beads 
concentration, i.e., 20 ng/µl, and varying rHuR protein levels from 10-100 nM. I obtained an 
optimal signal at 25 nM as hooking point (data not shown) because after this proportions of 
alpha-count obtained, started decreasing, due to excess of rHuR molecules oversaturated 
with donor or acceptor beads. So noting 25 nM protein concentration as optimal for the 
binding kinetics of rHuR- biotinylated RNA ligands, I further challenged this binding 
phenomenon with the addition of these novels DHTS analogs. After reading plate in alpha-
count reader we calculated Ki of these molecules using kd of 2.5 nM as reported by D’ Agostino 
et al., 2013. (Table 2). Although I saw the difference in obtained ki values, to abrogation 
behavior I observed in our in vitro, EMSA assays (Figure 26). This outcome may be explained 
by the different setup of two assays and especially the physical properties of the interfering 
these molecules. Nonetheless, some of these molecules reported with supposedly full 
abrogation of rHuR- RNA- complex formation (Figure 28 for Ki Graphs). 
MFM49 and DHTS do not influence substantial nucleocytoplasmic level of HuR in MCF-7 cells 
The p38 pathway is the main inducer of HuR nuclear or cytoplasmic localization or re-
localization. To check whether this HuR localization is affected by our compounds, I treated 
MCF-7 cells with MFM49, DHTS and Act D as control, for 3 hrs, after fixing, and following 
further immunofluorescence protocol; we saw that 1µM DHTS, 5 µM MFM49 did not affect 
subcellular localization of HuR (Figure 29A).  
     Ki (nM)  48,94                        ~ 2766,9 81 ~ 552077,4 289,7 130,6 
       Ki (µM)  0,048                      ~ 2,8 0,081 ~ 552,1 0,3 0,1 
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A. 
 
 
B.  
 
 
 
 
 
Figure 29 Nucleocytoplasmic levels of HuR upon MFM49 and DHTS treatment A) Immuno- fluorescence images 
showing HuR (Red) or nuclei (Blue) in MC7- cells. Actinomycin D was used as control, B) Ratio of N/C HuR level 
plotted after reading the plate under PerkinElmer image plate reader Operetta, Average of each biological 
replicates plotted and compared using Dunnett's Multiple Comparison Test showing ns outcome for Mock, 
MFM49, DHTS, and ActD. The test was only significant with P < 0.001 for ActD. (Experiment has been performed 
by me, Dr. Natthakan Thongon helped in following the protocol). 
After collection of values given by Operetta plate reader for nuclear-cytoplasmic ratio, I 
plotted them and compared, to ActD control which significantly impaired the 
nucleocytoplasmic HuR level to significant amount P < 0.001 (Figure 29B). In fact, both of the 
Merge 
HuR 
DAPI 
MOCK                                     MFM49                               DHTS                                    ActD 
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compounds have shown their beneficial pharmacological potential by confining the HuR level 
to the nucleus only. 
MFM49 and DHTS do not influence substantial nucleocytoplasmic level of NF-kB and HuR in 
RAW264.7 cells 
As mentioned in the introduction part, NF-kB has been shown to target HuR in Gastric 
carcinoma [58]. RAW264.7 cells were co-treated with LPS as LPS+DMSO, LPS+DHTS, 
LPS+MFM49, and LPS+ActD. Predominantly HuR stayed in the nucleus, which upon LPS 
stimulation localized to the cytoplasm with 10% increment. LPS co-treatment with DHTS (1 
µM) and MFM49 (5 µM) did not affect these substantial levels after 3 hrs of treatment. 
LPS+ActD treatment in RAW264.7 cells showed the low level of HuR, with impaired 
nucleocytoplasmic localization. I have also checked the nuclear translocation of NF-kB upon 
LPS stimulation. Notably, LPS caused a very strong shift of NF-Kb from the cytoplasm to 
nucleus. Accordingly, co-treatment of LPS and DHTS and MFM49 didn't affect LPS induced NF-
kB subcellular localization. Conversely, Actinomycin D treatment has indicated the significant 
localization of NF-kB to the nucleus after 3 hrs of LPS co-treatment. 
 
    A. 
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                  B.         
                               
 
Figure 30 Nucleocytoplasmic levels of HuR & NF-kB upon co-treatment with LPS and DMSO, MFM49, DHTS and 
ActD A) Ratio of N/C HuR and NF-kB levels plotted after reading the plate under PerkinElmer image plate reader 
Operetta, Average of each biological replicates plotted and compared using Dunnett's Multiple Comparison Test 
showing ns outcome for DMSO, LPS, LPS+MFM49, LPS+DHTS, LPS+ActD. The test was only significant with P < 
0.001 for ActD. B) Immuno- fluorescence images showing HuR (Red), NF-kB (Green) or nuclei (Blue) in RAW264.7 
cells. Actinomycin D was used as control.   (Experiment has been performed by me, Dr. Natthakan Thongon 
helped in following the protocol). 
DMSO 
               HuR                          HuR+DAPI                       NF-kB                               NF-kB+DAPI 
LPS
+ 
  LPS+ 
MFM49 
LPS+ 
DHTS 
LPS+ 
ActD 
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Considering the above observation, we can say that DHTS and MFM49 do not influence the 
nucleocytoplasmic level of HuR and NF-kB (Figure 30A and 30B). Moreover concerning the 
Min Ju et al., 2008, we didn't see HuR activation with increased nucleocytoplasmic shuttling 
upon NF-kB activation, in RAW 264.7 upon LPS challenge, which otherwise was observed in 
gastric cancer cell lines. This further confirms that, DHTS and MFM49 do not influence the p38 
and NF-kB axis while targeting HuR, in inflammation, where HuR act as key player. 
Anti-Inflammatory Properties of DHTS analogs 
RBPs are involved in the post-transcriptional control of genes encoding for cytokines [138]; 
[139]; [140]; [141]; [142]. AU-rich elements possessing genes are mainly involved in regulatory 
processes, e.g. cell communications, regulation of cellular physiological processes, 
nucleobase, nucleoside, nucleotide and nucleic acid metabolism, signal transduction, and 
transcription [143]. HuR and TTP play a role in stabilization and destabilization of the master 
cytokines, e.g., TNF, interleukins, etc. [43]. To check the anti-inflammatory properties of the 
compounds, I did two months internship period at MHH, Germany in prof. Matthias Gaestel 
lab. In Gaestel Lab, I tested some of these compounds (DHTS, MFM49, GD041, MB11V, VB062, 
and MB39). The cell lines used were RAW264.7 and TTP-KO RAW264.7.TTP-KO RAW264.7. 
were recently established and not yet available to the scientific community, the dose-
response curves for each compound were determined at 24 and 72 hrs, before starting all the 
experiments. The IC50 values obtained were in micromolar range for new analogs, based on 
IC50 values, I picked the relative sub-toxic doses lower than the IC50 values as DHTS = 1 µM, 
MFM49 = 5 µM, GD041 = 10 µM, MB11V = 5 µM, MB39 = 5 µM, and VB062= 10 µM 
Representative cell viabilities curve at 24 hrs and 72 hrs are shown in Figure 31. 
Cell Viability assays 
I treated RAW 264.7 cells with respective DHTS and DHTS analogs to up to 50 µM of each 
compound. We obtained higher IC-50 values and are listed in Table 3 in appendix. 
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A.                                                                                        B.                    
 
 
Figure 31 Dose Response curve for DHTS analogs and DHTS itself A) at 24 hrs, except DHTS, all showed very less 
cytotoxicity and the range of IC50 was in micromolar range  B) At 72 hrs, DHTS is most toxic than analogs, the 
IC50 conc. obtained were considered as reference for further experimental analysis. (Experiment has been 
performed by me). 
DHTS analogs down-regulates LPS Induced Cytokine Levels in RAW264.7 cells 
HuR and TTP are involved in regulation AU containing RNA elements upon activation of 
p38/MK-2 via LPS stimulation. I decided to check level mRNA of TNF, TTP, CXCL-2, and CXCL-
10, upon co-treatment of our compounds with LPS induction at 1, 4, 6 hrs. Also, these 
cytokines were found bound with HuR upon LPS stimulation in TTP/TTP-AA BMDMs via CLIP 
studies [144]. 
           A.                                                                             B.  
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C.                                                                                  D. 
Figure 32 DHTS analogs down-regulates cytokines produced after LPS stimulation mRNA level obtained by RT-
PCR analysis at 1 hr after treatment with LPS (1 µg/ml), DHTS (1 µM), MFM49, MB11V and GD041 (all 5 µM). The 
conditions were as indicated in the legends  A) TNFa levels obtained RT-PCR analysis at one hour after LPS co-
induction  B) TTP levels obtained RT-PCR analysis at one hour after LPS co-induction  C) CXCL2 levels obtained at 
6 hrs after LPS co-induction TTP D) CXCL10 levels obtained at 4 hrs after LPS co-induction TTP. Data expressed as 
mean±s.d. (n= 3), and analyzed using Dunnett's Multiple Comparison Test *P≤0.05, ** P≤0.01 and ** P≤0.001. 
(Experiment has been performed by me at MHH, Hannover). 
 
I saw almost 40-50% significant decrease in the levels of TNFα in RAW264.7 macrophages after 
1 hr LPS stimulation DHTS, MFM49, MB11V, and GD041, showing counteracting action of our 
DHTS analogs. Consistently at 4 hrs and 6 hrs not 40-50 % lowered level but the similar pattern 
of TNFa level were observed i.e., lower than LPS control (Figure 32A). For TTP mRNA, we found 
35-45% lowered level as compared to LPS control at one hour for MFM49, MB11V, and GD041. 
Conversely steady state TTP levels at 4 hrs and 6 hrs remained as they have reached the level 
of NTC control which was DMSO only (Figure 32B). For CXCL-2 mRNA at 1 and 4 hrs, our 
compounds didn’t show any counteraction behavior however at 6 hrs for MFM49, MB11V. 
GD041, MB11V has significantly lowered the CXCL-2 level as compared to MFM49 (Figure 
32C). 
The cxcl-10 level at 1, 4, 6 hrs differed as compared to TNF, TTP, and CXCL-2. The LPS induced 
CXCL-10 increased levels were 3 to 4 fold higher, and counteraction behavior of compounds 
were not seen at one hour, in spite of that DHTS altered the standard of CXCL-10 additively at 
one hour (not shown in the graph), although all of them lowered CXCL10 level at 4 hrs from 
10-30% (Figure 32D). At 6 hrs CXCL-10 level also reached steady state level and remained 
unchanged. HuR inhibitors has significantly decreased CXCL10 levels at 4 hrs, the intracellular 
mechanism of action of these compounds still needs to be explored, altogether considering 
the late counteraction pattern observed for CXCL-2 and CXCL10 at 6 hrs and 4 hrs respectively. 
The difference observed in levels for mRNA depends upon the differential specificity of these 
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compounds as they are structurally dissimilar. All the mRNA level normalized to 0 hr DMSO 
control after normalization with housekeeping gene i.e., Actin.   
             A.  
 
 
 
                   B. 
 
 
 
 
 
Figure 33 DHTS downregulate TNFa and TTP level A) TNFa levels obtained by qPCR analysis upon DHTS 
treatment at 1, 4 and 6 hrs (DMSO, LPS and LPS+DHTS) B) TTP levels obtained by qPCR analysis upon DHTS 
treatment at 1, 4 and 6 hrs. (DMSO, LPS and LPS+DHTS). Data expressed as mean ± s.d. (n= 3), and analyzed using 
Dunnett's Multiple Comparison Test ** P≤0.01, ** P≤0.001 and ns = not significant. (Experiment has been 
performed by me, at MHH, Hannover). 
DHTS downregulates TNFα and TTP levels  
DHTS fresh aliquot was used to check again level of TNFα and TTP. The level of CXCL-2 and 
CXCL-10 remained unchanged (data not shown) with the new fresh aliquot of DHTS. TNFα 
level as always were lowered to significant levels at 1, 4 and 6 hrs. Again consistent decrease 
of 60%, 50% and 60% were observed at 1, 4 and 6 hrs (Figure 33A). Then I checked the levels 
of TTP upon DHTS addition, this time 50%, 60% downregulation of TTP level were obtained at 
4 and 6 hrs. At one hour also slightly the level of TTP started decreasing which further resulted 
in significant reduction of TTP level at all time points checked (Figure 33B). 
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Downregulation of major cytokines by DHTS and MFM49 is HuR-dependent 
 
HuR is responsible for the increase in TNFα, CXCL2 and CXCL10 mRNA level induced by LPS 
stimulation. RAW 264.7 cells were transfected with siRNA oligos targeting HuR or the control 
via electroporation and allowed to grow for 72 hrs, and then challenged with LPS and LPS co-
treatment using DHTS (1 µM) and MFM49 (5 µM) for 3hrs (Figure 34A). TNFα, CXCL2 and 
CXCL10 mRNA levels were determined by real-time PCR. When HuR protein and mRNA 
expression was silenced (Figure 34B) the remaining TNFα, CXCL2 and CXCL10 mRNAs in LPS 
stimulated cells were further decreased to ~40%, ~80,  and ~60%, compared with that of 
control short interfering RNA (siRNA)-transfected cells.. Interestingly DHTS and MFM49 
significantly reduced TNFα, CXCL2 mRNAs stability compared with Si or SCR control (P ≤ 0.05). 
Conversely, CXCL10 mRNA levels were not affected (P =ns). MFM49 compound also 
significantly lowered TNFα, CXCL2, and CXCL10 mRNA compared with that of Si or SCR control 
(P ≤ 0.05) (Figure 34C, 34D and 34E). From these observations we can conclude that HuR 
absence has impacted on the stability of these cytokines, where upon addition of our 
compounds has caused a slight additive effect on their stability in siHuR cells, thus suggest the 
role of HuR in maintaining mRNA stability. 
             A.                                                                     B.  
           
 
 
          C.                                                                       D.  
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Figure 34 Downregulation of major cytokines by DHTS and MFM49 is HuR-dependent HuR is involved in the 
Increase in cytokine mRNA levels, when induced by LPS stimulation. A, B) Western blot and RT-PCR analysis 
showing siHuR protein and HuR mRNA expression for siHuR and scramble (Si control). C) TNFα mRNA levels in 
siRNA and scramble (SCR) control transfected cells at 3 hrs, the treatment conditions were as indicated in the 
legends but along with LPS 1 µg/ml. D) CXCL2 mRNA levels in siRNA and scramble (SCR) control transfected cells 
at 3 hrs, the treatment conditions were as indicated in the legends but along with LPS 1 µg/ml. E) CXCL10 mRNA 
levels in siRNA and scramble (SCR) control transfected cells at 3 hrs; the treatment conditions were as shown in 
the legends but along with LPS 1 µg/ml. Note: DHTS and MFM49 treatment conditions are with LPS (1µg/ml) co-
treatment.  Mean, and SD obtained are from 3 independent experiments and were analyzed by one-way ANOVA. 
*P ≤0.05, **P ≤0.01, ***P ≤0.001; ns, not significant. (All Experiment has been performed by me). 
 
TNFa downregulation by DHTS and DHTS analogs is independent of TTP in TTP-KO 
macrophages 
Qiu et al., 2015 confirmed the level of TNF in TTP-KO cells, were higher than the control in 
myeloid specific macrophages [145]. I wanted to check if our compound already has lowered 
the TNF levels were TTP dependent or independent, we induced TTP-KO macrophages with 
LPS (1 µg/ml) together with reference doses of DHTS and DHTS analogs.  
qPCR analysis revealed that at one hour, all analogs had lowered TNFa level significantly to 8-
10%.  At 2 hrs TNFa levels were consistently reduced to 60, 65, 65 and 35 % in case of DHTS, 
MFM49, MB11V, and GD041 (Figure 35A). Further at 4 hrs TNFa fold increase lowered and 
except the case of MFM49, where it is reducing consistently, for all other analogs including 
DHTS the level of TNFa repressed as compared to LPS control. Moreover at 6 hrs, the level of 
TNFα fold increase came to basal level to that of LPS but higher than the DMSO control (data 
not shown). Nonetheless at 1 and 2 hrs when the LPS stimulation were at its peak even in TTP-
KO macrophages and our compounds has counteracted TNFα, which shows that our 
compounds reduced TNFα level independent of TTP (Figure 35A). 
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A.  
 
 
 
 
 
Figure 35 TNFa levels counteracted by DHTS analogs independent of TTP in TTP KO cells TNFa levels obtained 
by qPCR analysis upon DHTS treatment at 1, 2, 4 and 6 hrs in TTP-KO RAW 264.7 cells. (DMSO, LPS, MFM49, 
MB11V, and GD041). Data expressed as mean ± s.d. (n= 3), and analyzed using Dunnett's Multiple Comparison 
Test ** P≤0.01, ** P≤0.001 and ns = not significant. (Experiment has been performed by me, at MHH, Hannover). 
 
Preliminary Results 
NF-kB activation is not influenced by DHTS analogs in RAW264.7 cells. 
NF-kB transcription factor is involved in the gene expressions of many immune-modulatory 
proteins, e.g., TNF, interleukins, iNOS and many others inflammatory proteins. Before the 
stimulation, a significant level of the Rel/NF-kB resides in the cytoplasm, along with IkBa. 
Multiple numbers of stimuli translocate Rel/NF-kB protein to the nucleus by induced 
phosphorylation of the IkBa, which further lead to proteasomal degradation of the IkBa [146]. 
To test the influence of our drugs on NF-kB activation upon LPS stimulation at 0, 15, 30 and 
60 minutes, I did differential fractionation of the RAW264.7 cells. 
After confirmation of the differential lysis by western blotting for nuclear and cytoplasmic 
markers (ATF-2, and GAPDH), we checked levels NF-kB (p65) and p-IkBa S32/36. Firstly, NF-kB 
translocation were not observed at 0 and 15 min for DMSO, DHTS and LPS. At 30 min the p65 
level increased in both DHTS and LPS, followed by a slight decrease in LPS while in DHTS p65 
levels remained unaffected at 60 min. Nonetheless, actual activation of p65 is shown by 
phosphorylation of p-IkBa S32/36 in the cytoplasm was observed in LPS treated cells. As 
expected DMSO didn't show any phosphorylation of p-IkBa S32/36,then I checked the p-IkBa 
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S32/36 level in DHTS (1 µM) presence at 15, 30 and 60 minutes, IkBa S32/36 level were 
marginally counteracted by DHTS especially at 15 and 30 minutes, which were increased in 
LPS control (Figure 36A).  
 
 
          A. 
 
 
 
 
           B. 
 
 
 
FIGURE 36 NF-kB activation is not influenced by DHTS analogs in RAW264.7 cells. A) NFkB activation and IkBα 
at 0, 15, 30, 60 min, for DMSO, DHTS (1 µM)+LPS, LPS (1 µg/ml). B) NFkB and IkBα activation at 0, 15, 30 and 60 
min, for LPS+MFM49 (5 µM), LPS+MB11V (5 µM) and LPS+GD041 (5 µM), ATF-2 and GAPDH are the nuclear and 
cytoplasmic marker for differential fractionation confirmation. (Experiment has been performed by me, at MHH 
Hannover) 
If we compare nuclear levels of p65 (NF-kB) translocation in case of MFM49, MB11V and 
GD041 treatment, except MFM49, which showed little increase at 15 minutes, was not shown 
by MB11V and GD041, while at 30 minutes all of them showed increased level. p65 
translocation at 60 minutes was same in case of MFM49 and MB11V, whereas GD041 has 
shown corresponding p65 translocation as to that of LPS control. p-IkBa S32/36 cytoplasmic 
activation level for  MFM49, MB11V and GD041 treatment were strongly induced in MFM49 
treated cells, while indistinguishable pattern was observed for MB11V and GD041 at 15 
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minutes. Phosphorylation of p-IkBa S32/36 at 30 min was similar in MFM49, MB11V and 
GD041, i.e., slightly lowered level than the LPS control. The levels of p-IkBa S32/36 low in 
MFM49 as compared to MB11V and GD041, where they showed increased phosphorylation 
of p-IkBa S32/36, similar to LPS control at 60 min (Figure 36B). Thus the p-IkBa S32/36 
activation were differentially regulated by DHTS, MFM49, MB11V, and GD041.  So taken all 
together DHTS, MB11V and GDO41 have shown similar behavior at 15 and 30 min, while in 
MFM49 as shown in opposite, i.e., fast activation at 15min and then lowered at 30 and 60 min 
consistently. This may explain that DHTS, MB11V, and GD041 has the activation at 15 and 30 
minutes, and later couldn't surpass the LPS induced action on p-IkBa S32/36. Hence our 
compounds do not influence the activation of NF-kB, as also evidenced by the 
immunofluorescence studies in Figure 30. 
  A. 
B.  
Figure 37: Activation of p-MK2 and α-TTP levels A) p-MK2(T222) levels obtained by western blot analysis upon 
co-treatment LPS and DHTS analogs, in legends only DHTS, MFM49, MB11V, and GD041 are without LPS 
treatment incubated for 6 hrs. B) α-TTP levels obtained by western blot analysis upon co-treatment LPS and 
DHTS analogs, only DHTS, MFM49, MB11V, and GD041 are without LPS treatment incubated for 6 hrs. 
(Experiment has been performed by me, at MHH Hannover) 
 
 84 
 
MAPK pathway activation upon co-treatment our with compounds 
As we know that p38 MAPK activated protein kinase (MAPK) pathway play an important role 
in the post-transcriptional regulation of inflammatory cytokines such as TNFα and other 
cytokines based on their cis-elements present in 3' or 5' UTRs. It was proved in MK-2 KO 
macrophages where no induction of the TNFα was observed, as compared to normal cells 
[147].  
I have seen strong down-regulation of TNFα upon co-treatment of our drugs with LPS. Further 
to confirm activation of MK-2 we performed western analysis upon co-treatment of our drugs 
with LPS, to see check activation pattern at different time points, i.e., at 0, 0.5, 1, 2, 4 and 6 
hrs. I observed activation of p-MK2 (T222) at 0.5, 1 and 2 hrs with LPS, where as in case of our 
compounds the MK-2 was activated strongly at  0.5, 1, 2 hrs followed by reactivation at 6 hrs 
in case of LPS, MB11V and GD041, similarly this activation was also observed in DMSO control. 
DHTS has already been shown in literature to strongly activate p38 at 0.5 hrs [148]. Therefore 
we also observed the strong activation of MK-2 at half an hour. Conversely treating cells with 
our compounds only has activated or phosphorylated MK-2 levels. Total MK-2 level were also 
checked by western blot analysis which showed differential expression pattern among the LPS 
and LPS co- treated macrophages. The MK-2 level started to accumulate at 4 and 6hrs for LPS 
and DHTS, whereas for the MFM49, MB11V and GD041 total MK-2 expression increased at 1, 
2, 4 and 6 hrs. At 2, 4, 6 hrs, MK-2 increased exceptionally (Figure 37A). 
If I report about TTP activation at 0, 0.5, 1, 2, 4 hrs accumulated after MK-2 diverse 
phosphorylation in LPS and co-LPS treated compounds. I saw abrupt increase TTP level in DHTS 
treated cells, besides this other 3 compounds (MFM49, MB11V and GD041) did not alter the 
substantial TTP level upon co-treatment with LPS, tiny differences in TTP could be seen in the 
TTP levels in but were not evident significantly. (Figure 37B). Huge alterered αTTP levels in 
DHTS treated cells were the stability issue of DHTS, which was later resolved with fresh aliquot 
of DHTS. (Data not shown).  
Taken all together these result shows that our compounds do not influence p38 MAPK 
pathway as we didn't see an alteration in TTP level upon LPS co-treatment with DHTS analogs.  
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Analysis of p38 MAPK pathway in TTP-KO cells 
p38 MAPK has been known to stabilize transcripts that contain AU-rich sequences [149]. LPS 
activates p38 MAPK pathway and as a model to check the level of TNFa decrease, if TTP 
dependent or not, our qPCR analysis showed that decrease was independent of TTP (Figure 
35), I further investigated by western blot the activation of p38 MAPK pathway, the pattern 
of and p-MK-2(T222) observed is similar to the normal RAW cells. LPS p-MK-2(T222) activation 
at 1 hour were same as in LPS co-treated cells with DHTS, MFM49, MB11V, and GD041. Also, 
pp38-T180/Y182 was strongly induced at 0.5 hrs in all treated RAW264.7 macrophages. The 
relative decline in the level of p38 MAPK were observed after 2 hrs i.e. at 4 hrs the partial level 
p38 were detected in case of compound co-treated cells. Total MK-2 levels remained 
unaltered in RAW264.7 TTP KO cells (Figure 38). 
 
Figure 38: Analysis of p38 MAPK pathway in TTP-KO cells. (Experiment has been performed by me, at MHH 
Hannover). 
Polysomal analysis in RAW264.7 upon LPS stimulation  
Polysome determine the fate of mRNAs by participating in mature mRNA translation. 
Polysomal profiling was done as described by [43]. We know that DHTS reduces the TNFa 
mRNA translational efficiency [129]. To evaluate if DHTS analogs arrests TNFα mRNA loading 
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A.                                                                               B.                
 
    C.                                                                                     D.   
 Figure 39 RT-qPCR analysis of actin and TNF mRNA levels in polysomal RNA fractions in RAW 264.7 cells. A) 
For DMSO only B) LPS+DMSO and C) LPS+MB11V D) LPS+MFM49 (Experiment has been performed by me, at 
MHH Hannover).                                                                                           
on the active translation machinery I treated RAW 264.7 with DHTS analogs at their reference 
doses with LPS co-induction (1 µg/ml) for 3hrs, followed by collection and sucrose gradient 
sub-polysomal fractionation of DMSO, DSMO+LPS, DHTS+LPS, MFM49+LPS, MB11V+LPS, 
GD041+LPS treated cells. For the moment we could analyze only 4 samples for their TNFα and 
actin distribution over the polysomes. Nonetheless I still have to analyze DHTS+LPS and 
GD041+LPS. From the graph obtained after qPCR analysis of fractionated samples, I could 
make some observation that relative cytoplasmic TNFα are very low in DMSO treated samples, 
whereas actin was distributed and its levels are unchanged (Figure 39A). In LPS treated cells, 
TNFa is greatly distributed over the translation machinery after 3 hrs of LPS induction, 
whereas actin qualitative or quantitative levels were found normally distributed over the 
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actively translating monosomes or polysomes (Figure 39B). However we observed qualitative 
and quantitative difference among the DMSO and LPS+DSMO treated samples. 
MB11V did not influence any polysomal distribution of TNFa, but apparent levels were 
reduced, if we compare with LPS control, TNFα sub-polysomal and polysomal distribution 
profile (Figure 39C). Conversely, MFM49 has influenced the TNFα level clearly from the active 
polysomes (Figure 39D). 
Besides this we have fractionated, samples of TTP-KO cells, treated with DHTS analogs DMSO, 
DSMO+LPS, DHTS+LPS, MFM49+LPS, MB11V+LPS, GD041+LPS, to investigate the influence of 
DHTS analogs on TTP-dependent translation of TNFα, after their RNA extraction and 
consequent steps to quantify the distribution profile of these DHTS analogs. 
 
Effect on mRNA Stability after transcriptional inhibition with Actinomycin D  
TNFα a key player in inflammation and Cxcl2 (homologue of human growth-regulated protein 
(Gro) is a potent attractant of neutrophils, and highly related to innate inflammatory 
responses [150], [151]. Also CXC10 (IP10) has been shown as an inflammatory mediator in the 
liver steatohepatitis, a type of fatty liver disease, characterized by inflammation of the liver 
[152]. We examined the kinetics of levels of remaining TNFa, CXCL2 and CXCL10 mRNAs in 
RAW264.7 macrophages. The half-life of TNFα mRNA in LPS withdrawn cells was lowered as 
compared LPS challenged and LPS co-treated cells with DHTS (1µM) and MFM49 (5µM). 
Showing slightly additive effect, our compound further decreased the mRNA stability of TNFα 
after ActD addition (Figure 40A). 
Conversely, the half-life of CXCL2 mRNA in LPS withdrawn cells was higher as compared LPS 
challenged and LPS co-treated cells. This could be due to the very low stability of CXCL-2. 
Following immediate transcriptional arrest with ActD (in co-treated cells) after LPS 
stimulation. CXCL2 mRNA levels were strongly reduced upon addition of ActD, where DHTS 
and MFM49 subsequently decreased CXCL2 stability to significant levels as shown in graph as 
t1/2 half-life (Figure 40B). 
Similarly CXCL10 stability was also affected upon ActD addition along with DHTS and MFM49 
after LPS stimulation, the half-life of CXCL10 mRNA in LPS withdrawn cells was higher as 
compared to LPS challenged and LPS co-treated cells with DHTS (1µM) and MFM49 (5µM) 
(Figure 40C).   
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Based on these observations, the half-life of all the transcripts has been affected to the 
significant level (P ≤ 0.001) by DHTS and MFM49. Mentioning HuR again as a target of DHTS 
and MFM49, influenced stability causing the behavior of HuR protein, within RAW 264.7 
macrophages. 
 
A.                                                                                 B.                                                                                 
                                                         C. 
 
                                                    
 
                                                      
 
 
 
Figure 40 Influence of DHTS and MFM49 on the stability of major cytokines in LPS-exposed RAW 264.7. 
RAW264.7 cells were co-treated with DMSO, LPS, LPS+ActD, DHTS+ActD and MFM49+ActD for 0, 15, 30, 60 and 
120 min. Real-time PCR was performed to assess the remaining A) TNFα, B) Cxcl12 and C) Cxcl-10 mRNA levels. 
The half-lives of different samples are indicated in the inset and was calculated using GraphPad Prism, using 
nonlinear regression analysis and then choosing one phase decay function to calculate the half-life of each 
mRNAs. Each replicate were plotted and compared using Dunnett's Multiple Comparison Test showing P values 
* P ≤ 0.05, *** P ≤ 0.001. (All Experiments has been performed by me). 
Other DHTS analogs 
Our team together, are involved further involved in screening other potent inhibitors named 
VB16, VB27, VB35, VB40, VB44, MFM48, VB49, VB062, MFM75, and DHTS again in 
biochemical and cell-based assays. We observed their low cytotoxic effect, when we 
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compared with DHTS in a panel of cell lines, e.g. MCF-7, MDA-MB231, PANC-1 and THP-1 cell 
lines (Figure 41). 
 
   
A. B.    
 
 
 
 
 
C.                                                                                          D.                                                                                                                     
 
Figure 41 Cell viability assays done on various cell line using HuR inhibitors (shown in legends) (IC50 values are 
not shown). Numbers on the right hand side indicate the name of each compound. (Dr. Natthakan Thongon, Dr. 
Chiara Zucal and Dr. Vito D’Agostino has contributed to these figures). 
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Discussion and Conclusion 
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Discussion 
To our knowledge, until now HuR inhibitors are yet not available in the market as anticancer 
therapy module. This may be due to HuR pleiotropic role in controlling gene expression is very 
complex, and consequent results of HuR inhibition are difficult to predict. We know that HuR 
inhibition is not compatible with life, but if we compare thousands of studies of multiple 
cancer types e.g. Breast cancer, colon cancer [153] oral cancer, Renal cell carcinoma (RCC), 
non-small lung cancer carcinoma (NSLC), non-muscle invasive bladder cancer (NMIBC), 
Pancreatic ductal adenocarcinoma (PDAC), and many others, where HuR has been associated 
with aberrant nucleus/cytoplasmic ratio relating to carcinogenesis and tumor progression 
[154]; [93]. With reference to these studies, HuR pharmacological modulation is possible and 
necessary [18]; [97]; [98] and [155]. Here in my dissertation, we used AlphaScreen technology, 
EMSA assays to target HuR-RNA interaction with small molecules in-vitro [156], [98], [139]. 
We show that DHTS and DHTS analogs are potent inhibitors of HuR-RNA complex formation, 
and can modulate HuR post-transcriptional control, by limiting association rate of HuR-RNA 
complex formation at low nanomolar/micromolar range, confirmed in vitro in biochemical 
assays (Figure 13).  
By using tandem RRM1/2, RRM2/3 biochemical experiments, we showed distinct binding 
preference of DHTS is within RRM1/2 domain, considering the individual RRMs EMSA, this 
finding also consistent with the EMSA of RRM1/2 (Figure 14 and Figure 15). 
Regarding DHTS selectivity, it does not interfere with RNA binding activity of RBPs Lin28b, 
TDP-43 and TTP (Figure 16). This further confirms that these type of molecules binds to site-
specific binding pocket of the HuR, was revealed by crystal structure of HuR, usually which 
possess dynamic conformational changes and selective affinity to its target RNA probe [20]. 
In last recent years, lot of HuR inhibitors have been screened, however interacting structural 
residual information between these molecules and HuR is lacking. We tried to dig-out this 
information based on the output of different biochemical approaches, used to find the basis 
of this interaction. Our collaboration with Prof. Marco Fragai, University of Florence has 
resulted in positive outcome, with residual amino acid information on HuR interaction with 
DHTS, suggesting a locus between first two tandem domains, is crucial for binding with target 
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RNA [20] or DHTS in our case by NMR studies (interacting residues are mentioned in result 
section).  
The linker region within HuR, between first two tandem domains, navigate the HuR function 
by altering the conformation of RRM2 at opposite orientation which represents the bound 
form of HuR. However, this binding is dynamic and affinity-dependent, toward the 
corresponding interacting RNAs. Titration of HuR with DHTS experienced some 
conformational changes. Therefore we suggest that linker region is involved in binding to 
DHTS as it was revealed by delta RRM1 studies, REMSA binding assays. C-terminal region 
removal within RRM1 resulted in reduced affinity binding of RRM1 domain to the target RNA, 
hence it also loses important kinetic binding interactions with DHTS, this proved that region 
next or within linker region are obligatory in order to establish the stable binding of respective 
proteins (RRM1/2 or FL-HuR) and ligand (DHTS) (Figure 17). We also proved binding of ΔRRM1 
to target FAM RNA probe in Fluorescence Polarization (FP) experiments, consistent with 
REMSA data we suggest that 14 amino acid region is critical for RNA binding as we observed 
K (obs), constant of ~8 min (Figure 17C and Table 1). 
Single point mutations in the interacting region at S94, N107, I133, and N134, to Alanine has 
shown us that these residues are crucial for preserving dynamic equilibrium state of free HuR 
protein in monomer/dimer form and the closed protein-RNA dimer. Interestingly muteins 
were fully resistant to DHTS, as DHTS has lost efficacy to interrupt the complexed binding of 
HuR muteins and target RNA (Figure 18B), this further supports that DHTS competes for the 
same protein regions, interacting with the target RNA probe. Stabilization of this ‘closed’ 
conformation alters the protein dynamics, reflecting the observed generalized decrease of 
signal intensity of the resonances in NMR, observed upon the addition of DHTS to the 
RRM1_M2 tandem domains. Unfortunately, the non-optimal solubility of DHTS hampered the 
quantitative assessment of its Kd with rHuR protein. Additionally CD and NMR measurements 
ruled out the putative interaction between DHTS and RNA Probe (Figure 19A and 19B). 
Moreover, the alpha signals at the hook point values for protein and RNA probes were 
significantly lowered in intensity compared to wild-type HuR, indicating a suboptimal 
environment, compatible with ligand self-aggregation [157]. Indeed, muteins showed 
significantly lower Kd values, i.e., an increased affinity in saturation binding experiments with 
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compared to wild-type HuR (Figure 20, 21), indicating again these residues are critical for self-
dimerization behavior of HuR, as imprudent aggregation was observed in muteins (Figure 22).  
Among well-known HuR inhibitors, naphthofuranone MS-444, which has been identified using 
fluorescence intensity distribution analysis (FIDA) screening on almost 50,000 natural plant 
extract, it was shown to inhibit the HuR-RNA binding by inhibiting HuR oligomerization at Kd 
of 40 nM respectively [18]. About ∼23,000 compounds were also tested by using FP-HTS 
based technique. Consequent validation by Alpha and SPR of ST-3 inhibitor and its analogs has 
decreased the HuR target mRNAs' half-life and accordingly encoded proteins (Bcl-2, XIAP, and 
Msi1/2. In this context using DHTS we measure strong nanomolar inhibition of complex 
formation rate among HuR and RNA in vitro, also lowered the level of pre-TNF and TNF half-
life followed by the decrease in TNF protein levels [129], [155]. MS-444 was examined for its 
direct HuR inhibition potential, preventing the association of HuR with miR116, and hence 
with TDP-43 and FUS mRNA, but at the high level than DHTS [158].  Furthermore, MS-444 has 
also been exploited for its potential to impact upon HuR inhibition in colorectal cancer 
tumorigenesis, where it resulted in growth inhibition of induced apoptotic gene expression 
[136]. We also noted this behavior of DHTS, activating Caspase at 24 hrs at its IC50 [99]. 
 Consequently this biological effects of DHTS were recapitulated in our cell models, where 
significant downregulation of TNFα, VEGF and other HuR targets were seen, nonetheless RNA 
Immunoprecipitation experiments also revealed the potential of DHTS to limit the association 
rate of HuR with target TNFa RNA. [99] (Figure 23). 
As mentioned already that several studies described in details regarding HuR inhibition. 
However a link between post-transcriptional control, phenotypic effects, and therapeutic 
exploitation is far from being elucidated. Here we show the repressive effect on cellular 
viability together with impact of DHTS at low doses, on cellular proliferation, based on HuR 
dependency, where DHTS efficacy was counteracted by HuR overexpression in breast cancer 
cell lines, (Figure 24).  
Moreover, DHTS belongs to tanshinone family and are known for their anti-inflammatory, 
anticancer, anti-atherosclerosis and cardio-protective properties. [122], [159]. 
Nevertheless, DHTS-dependent HuR dysregulation has a strong anti-cancer activity in vivo, as 
observed using a xenograft model of colon cancer (HCT116 cells). These results are consistent 
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with other findings in colon, leukemia, cervical, and breast cancer cells, and suggests that 
DHTS can enter tumors effectively [123], [160]–[162]. With no sign of systemic toxicity in 
treated animals supports the idea that inhibition of HuR by bioactive molecules can be a 
therapeutic route for future endeavor. Here the DHTS effects on the immune system have to 
be evaluated in a non-immuno-compromised mouse model. Interestingly, HCT116ΔHuR 
knockout cells in-vivo reflected limited ability to augment tumors, but the extent of DHTS 
inhibition on growth of those tumors did not match inhibition with that of WT tumors (Figure 
25). While we cannot dismiss the fact that loss of HuR may affect cancer cell drug uptake, all 
these results suggest in vivo specificity of DHTS and confirm the idea that DHTS requires HuR 
for its antitumor influence. We uncovered here previously unrecognized mechanism of action 
of DHTS, targeting post-transcriptional regulation of HuR. 
 Taken together, these results present DHTS as competitive inhibitor of RNA binding to HuR, 
and DHTS further has been exploited for its anticancer function in in vivo models based on 
HuR pathology (Figure 25).  
Another member of Tanshinones, Tan I is well known for its anti-adhesion properties in MDA-
MB231 by decreasing intracellular ICAM1 and V-CAM levels [163]. Moreover Tanshinones are 
also known for their repressive effect on certain mi-RNA (miR155) in colon carcinoma, they 
have been known for their repressive activity and on numerous other miRNAs [164]; [165]. In 
fact they have been known for their suppressive function on interleukins cox2, il-6, VEGF, and 
MMP [166]–[169]. 
Further, we provide evidence of improved efficacy of HuR inhibitors called DHTS analogs, in 
terms of loss of HuR and target RNA binding functions in vitro. The differences in inhibition 
quotient OR their activity depends upon the chemical structure they possessed (Figure 26) as 
mentioned in the result section we couldn't provide structural information, but nonetheless, 
we are describing the experimental outcome of these analogs, in context of HuR 
posttranscriptional control where they modulate anti-inflammatory and anti-cancer effects.  
 
The most potent MFM49 inhibitor was identified after cumbersome screening among other 
participant inhibitors (Figure 26, 27 and 28). MFM49 specificity with in cell based assays was 
also exploited using 5 µM of MFM49, This is a highest dose as compared to DHTS which may 
reflect the global functional potential of DHTS affecting numerous pathway. Indeed DHTS 
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showed lower IC50, conversely MFM49 being a specific HuR inhibitors its efficacy could be 
confined to HuR based influences within the cells. Moreover a noteworthy example of HuR 
inhibitor is MS-444, which has been shown to block HuR oligomerization, came up with its 
IC50 in  5-40 µM range, depending upon the cell type used and the pathologic substantial 
levels of HuR [136]. 
Cumulatively some of the outcomes, MFM49 has shown differential efficacy compared to 
DHTS. We did not observe DHTS, and DHTS analogs induced activation of p38 MAPK pathway 
hence HuR translocation to the cytoplasm, further supporting, the anticancer role of these 
inhibitors, specifically where cytoplasmic HuR is anticipating in the cause [16]. Additionally 
DHTS analog's influence on NF-kB translocation to the nucleus upon LPS stimulation could not 
reveal any difference concerning control (LPS) in RAW 264.7cells (Figure 29 and 30).  
Anti-inflammatory function of DHTS and DHTS analogs, was investigated in normal and TTP-
KO RAW264.7 cells macrophages, since HuR and TTP are involved in regulation of AU-rich 
sequences under the influence of p38 MAPK pathway [43]. Our compounds were efficient in 
lowering the cytokines TNFα, CXCL-2 and CXCL10 to significant levels depending on the target 
levels/affinity/preference to HuR (Figure 31, 32 and 33) [40] [43]. Nevertheless, initial pool of 
induced cytokines was lowered upon application of DHTS and MFM49, excluding some of the 
cytokines, which explains their tight affinity regulation by HuR within cell lines. [16], [170] 
(Supplementary Figure 1 and Figure 2). HuR silencing has confirmed that anti-inflammatory 
effects of DHTS and MFM49, is really due to inhibition of HuR, as further loss resulted in lower 
stability of important cytokines (Figure 34) [171]. 
TNFα decrease in TTP-KO upon application of DHTS and DHTS analog also showed that, this 
decrease was independent of TTP and further explain that p38 Activation stabilizes the AU-
rich elements, conversely this effect was counteracted to significant level by our compounds 
in a HuR dependent manner [171] [172] (Figure 35). 
Preliminary results 
NF-kB activation upon LPS stimulation in RAW264.7, and consequent blockade of 
translocation to the nucleus by DHTS and DHTS analogs was visible at the different extent, 
MFM49 has shown promising action, and nevertheless in immunofluorescence MFM49 didn’t 
show any strong evidence in this regard (Figure 36). Again in normal and TTP-KO 264.7 cells, 
we did not see a DHTS-analog’s induced activation of the p38 MAPK pathway, as we saw no 
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alteration in TTP protein levels, however substantial increase in the levels of p-MK2 (T222) , 
TTP in case of DHTS treatment was a stability issue, which was resolved  later (data not shown) 
[173] [174] (Figure 37 and Figure 38). 
Polysomal recruitment profile of DHTS analogs is being investigated analogs, in normal and 
TTP-KO RAW264.7, to check the influence of these analogs on TTP dependent translation. 
Interestingly, MFM49 has shown potential to displace TNFα from active polysomes, consistent 
with the finding in D’Agostino et al., 2015 (Figure 39). Moreover changes in major cytokines 
mRNA levels has been significantly reduced with the application of DHTS and MFM49, 
nonetheless, biological replicates of these findings need to be confirmed (Figure 40). Our lab 
is further involved in the screening of other HuR inhibitors, in various cell lines. (Figure 41).  
The mouse model with AOS/DSS induction was tested using the MS-444 HuR inhibitor. 
Although the general HuR deletion is difficult for cell survival, myeloid specific deletion of the 
HuR causes augmented tumor formation in size with increased invasiveness in AOS/DSS 
colitis-associated cancer mouse model when treated with reference doses of MS-444 and 
potential HuR oligomerization inhibitor. In return, they found reduced induction of apoptosis 
despite the decrease in proliferation rate in the absence of HuR and presence of MS-444 [176]. 
In preclinical cell model of pancreatic ductal adenocarcinoma, HuR silencing has impaired 
proliferation, decreased anchorage-independent growth as well as impaired invasion and 
migration [177]. HuR’s effect on the cancer phenotype is tissue and context type dependent. 
Typically, HuR as the determinant of cell pro-survival, in lethal stress conditions has been 
found promoter of cellular apoptosis in HeLa cells [178]. On the other hand HuR role in muscle 
cell differentiation cannot be avoided where it got cleaves at aspartate 226 to two parts HuR-
CP1 (24 kDa) and HuR-CP2 (8 kDa), however HuR-CP1 with the help of transportin-2 got 
accumulated in the cytoplasm and hence helps in muscle differentiation whereas HuR-CP2 (8 
kDa) associates with apoptosome activator PHAPI (putative HLA associated protein) to 
promote apoptosis [179]. Another advantage of HuR cleavage of HuR was demonstrated by 
HuRD226A, which further skipped cleavage by caspase and failed to recover apoptosis in cells 
devoid of endogenous HuR [178].  
HuR has been implicated in the regulation of mRNAs controlling the class switch antibody 
responses by B-cells. HuR absence has caused impaired mitochondrial metabolism with a 
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significant increase in the levels of ROS (Reactive oxygen species) and subsequent B-cells 
death [71]. HuR ablation has been reported to arrest the normal embryonic development in 
mice and where fetus failed to survive, even at halfway of gestation [180]. Myeloid-specific 
conditional knockout of HuR in mice resulted in aberrant cytokine expression followed by 
chemical-induced colitis progression and consequent colitis mediated cancer. This shows that 
HuR plays as coordinator of the mRNAs (Tnf, Tgfb, Il10, Ccr2, and Ccl2) which are further 
involved in controlling innate inflammatory effects. This further guide us to exploit the HuR 
related inflammation and cancer like anomalies. Loss of HuR is not compatible with life, or it 
may lead to systematic inflammation with increase in pro-inflammatory tnf, il-6, ccl2 thus 
leading to severe colitis [82]. On the other hand HuR role in intestinal homeostasis, cell growth 
and survival where loss of HuR intestinal tissue reduced the burden of small intestinal 
polyposis [83]. HuR dosage has been suggested as the important factor in cytokine production 
level, after confirmation in heterozygous and homozygous conditional HuR knockout mice 
model in Th2,  explaining the implication of HuR in asthma, allergies and autoimmune diseases 
when is ablated or dysregulated [81]. Considering these HuR based pathologies, it is now 
necessary to think about the pharmacological targeting of HuR. My thesis described some of 
the possible strategies to target HuR, when HuR is deregulated or has prognostic significance 
e.g. in as breast, colon or ovarian cancers or in inflammation-related disorders. 
There are many things to be noted for further DHTS usage in therapeutic based strategies, in 
our study it influenced TNFα level representing its post-transcriptional function to attenuate 
TNFa levels, instead of depletion induced by targeted antibody-based drugs. We exploited 
ability of DHTS to inhibit HuR-RNA complex formation and we showed efficacy of DHTS, 
relating to loss of function of HuR and impacting further on the phenotypic, in terms of 
proliferation and sensitivity in breast cancer cell models.  Overall our findings in context of 
DHTS a small natural molecule, possesses anti-inflammatory and anticancer properties, which 
could make the feasible measurement concerning “genome druggability” for anticancer 
therapy based on HuR pathology. 
 Summing up, to target HuR loss of function, is crucial and is evident from the numerous 
studies done in inflammation and cancer like conditions. HuR being an important factor at the 
posttranscriptional regulation channels, whose inhibition may result in ubiquitous, post-
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transcriptional alterations in the body nevertheless it depends absolutely on the cell and 
tissue type, and thus its pharmacological tuning is possible. 
 
CONCLUSIONS 
We have shown here previously unrecognized mechanism of DHTS and other analogs 
interfering with HuR-RNA binding complex in vitro, and in in vivo experiments. We provided 
information about residual participating amino acids, binding to DHTS. Mutational analysis 
has shown that inter-domain region is responsible for the RNA binding and DHTS binding. The 
most potent compound is MFM49 among other HuR inhibitors, revealed by EMSA or 
AlphaScreen technology. In cells based assays DHTS and analogs down-regulates the TNFa, 
and other cytokines. Additionally DHTS and MFM49 downregulates TNFα, CXCL2 and CXCL10 
in HuR dependent manner. Moreover DHTS and MFM49 do not influence activation of NF-kB 
in RAW 264.7 cells after LPS stimulation. At last DHTS analogs do not change LPS induced 
activation of p38 pathway, and hence consequently do not affect substantial TTP levels.  
 
 
 
 
 
 
 
 99 
 
References 
[1] T. Glisovic, J. L. Bachorik, J. Yong, and G. Dreyfuss, “RNA-binding proteins and post-
transcriptional gene regulation,” FEBS Lett., vol. 582, no. 14, pp. 1977–1986, 2008. 
[2] C. Burd and G. Dreyfuss, “Conserved structures and diversity of functions of RNA-
binding proteins,” Science (80-. )., vol. 265, no. 5172, pp. 615–621, 1994. 
[3] M.-H. Lee, “RNA-binding proteins,” WormBook, 2006. 
[4] M. J. Moore, “From birth to death: the complex lives of eukaryotic mRNAs.,” Science, 
vol. 309, no. 5740, pp. 1514–8, 2005. 
[5] S. Robinow and K. White, “Characterization and spatial distribution of the ELAV protein 
during Drosophila melanogaster development.,” J. Neurobiol., vol. 22, no. 5, pp. 443–
61, 1991. 
[6] A. R. Campos, D. Grossman, and K. White, “Mutant Alleles at the Locus elav in 
Drosophila melano- gaster lead to Nervous System Defects . A Develop- men t a1 - Gene 
tic An a1 y si s,” vol. 2, pp. 197–218, 1985. 
[7] A. Szabo et al., “HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-
binding domains and is homologous to Elav and Sex-lethal,” Cell, vol. 67, no. 2, pp. 325–
333, 1991. 
[8] P. J. Good, “A conserved family of elav-like genes in vertebrates.,” Proc. Natl. Acad. Sci. 
U. S. A., vol. 92, no. 10, pp. 4557–4561, 1995. 
[9] J. Dalmau, H. M. Furneaux, C. Cordon-Cardo, and J. B. Posner, “The expression of the 
Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human 
normal and tumor tissues.,” Am. J. Pathol., vol. 141, no. 4, pp. 881–886, 1992. 
[10] D. Antic and J. D. Keene, “Embryonic Lethal Abnormal Visual RNA-Binding Proteins 
Involved in Growth , Differentiation , and Posttranscriptional Gene Expression,” Am. J. 
Hum. Genet., vol. 61, pp. 273–278, 1997. 
[11] W. J. Ma and H. Furneaux, “Localization of the human HuR gene to chromosome 
19p13.2,” Hum. Genet., vol. 99, no. 1, pp. 32–33, 1997. 
[12] R. Treisman, “Transient accumulation of c-fos RNA following serum stimulation 
requires a conserved 5′ element and c-fos 3′ sequences,” Cell, vol. 42, no. 3, pp. 889–
902, 1985. 
[13] D. Caput, B. Beutler, K. Hartog, R. Thayer, S. Brown-Shimer, and A. Cerami, 
“Identification of a common nucleotide sequence in the 3’-untranslated region of 
mRNA molecules specifying inflammatory mediators.,” Proc. Natl. Acad. Sci. U. S. A., 
vol. 83, no. 6, pp. 1670–4, 1986. 
[14] D. Kontoyiannis, M. Pasparakis, T. T. Pizarro, F. Cominelli, and G. Kollias, “Impaired 
On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements,” 
Immunity, vol. 10, no. 3, pp. 387–398, 1999. 
 100 
 
[15] N. Mukherjee et al., “Integrative regulatory mapping indicates that the RNA-binding 
protein HuR couples pre-mRNA processing and mRNA stability,” Mol. Cell, vol. 43, no. 
3, pp. 327–339, Aug. 2011. 
[16] K. Abdelmohsen and M. Gorospe, “Posttranscriptional regulation of cancer traits by 
HuR,” Wiley Interdiscip. Rev. RNA, vol. 1, no. 2, pp. 214–229, 2010. 
[17] C. M. Brennan and J. a Steitz, “HuR and mRNA stability.,” Cell. Mol. Life Sci., vol. 58, no. 
2, pp. 266–277, 2001. 
[18] N.-C. Meisner et al., “Identification and mechanistic characterization of low-molecular-
weight inhibitors for HuR,” Nat. Chem. Biol., vol. 3, no. 8, pp. 508–515, Aug. 2007. 
[19] M. N. Hinman and H. Lou, “Diverse molecular functions of Hu proteins,” Cell. Mol. Life 
Sci., vol. 65, no. 20, pp. 3168–3181, 2008. 
[20] H. Wang et al., “The structure of the ARE-binding domains of Hu antigen R (HuR) 
undergoes conformational changes during RNA binding,” Acta Crystallogr. Sect. D Biol. 
Crystallogr., vol. 69, no. 3, pp. 373–380, 2013. 
[21] J. D. Keene, “Why is Hu where? Shuttling of early-response-gene messenger RNA 
subsets.,” Proc. Natl. Acad. Sci. U. S. A., vol. 96, no. 1, pp. 5–7, 1999. 
[22] W. Wang et al., “AMP-Activated Kinase Regulates Cytoplasmic HuR,” Mol. Cell. Biol., 
vol. 22, no. 10, pp. 3425–3436, 2002. 
[23] C. Tiedje, H. Holtmann, and M. Gaestel, “The role of mammalian MAPK signaling in 
regulation of cytokine mRNA stability and translation.,” J. Interferon Cytokine Res., vol. 
34, no. 4, pp. 220–32, 2014. 
[24] H. Tran, F. Maurer, and Y. Nagamine, “Stabilization of urokinase and urokinase receptor 
mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-
activated protein kinase-activated protein kinase 2.,” Mol. Cell. Biol., vol. 23, no. 20, pp. 
7177–88, 2003. 
[25] X. Yang et al., “Prostaglandin A2-mediated stabilization of p21 mRNA through an ERK-
dependent pathway requiring the RNA-binding protein HuR,” J. Biol. Chem., vol. 279, 
no. 47, pp. 49298–49306, 2004. 
[26] V. Lafarga, A. Cuadrado, I. Lopez de Silanes, R. Bengoechea, O. Fernandez-Capetillo, and 
A. R. Nebreda, “p38 Mitogen-Activated Protein Kinase- and HuR-Dependent 
Stabilization of p21Cip1 mRNA Mediates the G1/S Checkpoint,” Mol. Cell. Biol., vol. 29, 
no. 16, pp. 4341–4351, 2009. 
[27] R. M. Scheiba, Á. Aroca, and I. Díaz-Moreno, “HuR thermal stability is dependent on 
domain binding and upon phosphorylation,” Eur. Biophys. J., vol. 41, no. 7, pp. 597–
605, 2012. 
[28] H. K. Hyeon and M. Gorospe, “Phosphorylated HuR shuttles in cycles,” Cell Cycle, vol. 7, 
no. 20, pp. 3124–3126, 2008. 
 101 
 
[29] W. Wang, M. C. Caldwell, S. Lin, H. Furneaux, and M. Gorospe, “HuR regulates cyclin A 
and cyclin B1 mRNA stability during cell proliferation,” EMBO J., vol. 19, no. 10, pp. 
2340–2350, 2000. 
[30] K. Masuda et al., “Global dissociation of HuR-mRNA complexes promotes cell survival 
after ionizing radiation,” EMBO J., vol. 30, no. 6, pp. 1040–1053, 2011. 
[31] S. Schulz, A. Doller, N. R. Pendini, J. A. Wilce, J. Pfeilschifter, and W. Eberhardt, “Domain-
specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) 
isotype-triggered activities of the RNA binding protein HuR,” Cell. Signal., vol. 25, no. 
12, pp. 2485–2495, 2013. 
[32] L. Pang et al., “Loss of CARM1 is linked to reduced HuR function in replicative 
senescence,” BMC Mol. Biol., vol. 14, no. 1, p. 15, 2013. 
[33] H. Li et al., “Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing 
protein, by CARM1,” J. Biol. Chem., vol. 277, no. 47, pp. 44623–44630, 2002. 
[34] C. Lucchesi, M. S. Sheikh, and Y. Huang, “Negative regulation of RNA-binding protein 
HuR by tumor-suppressor ECRG2,” Oncogene, vol. 35, no. April, pp. 1–9, 2015. 
[35] A. Kotlyarov et al., “MAPKAP kinase 2 is essential for LPS-induced TNF-alpha 
biosynthesis.,” Nat. Cell Biol., vol. 1, no. 2, pp. 94–7, 1999. 
[36] A. Neininger et al., “MK2 targets AU-rich elements and regulates biosynthesis of tumor 
necrosis factor and interleukin-6 independently at different post-transcriptional 
levels,” J. Biol. Chem., vol. 277, no. 5, pp. 3065–3068, 2002. 
[37] C. A. Chrestensen et al., “MAPKAP Kinase 2 Phosphorylates Tristetraprolin on in Vivo 
Sites Including Ser178, a Site Required for 14-3-3 Binding,” J. Biol. Chem., vol. 279, no. 
11, pp. 10176–10184, 2004. 
[38] S. Rousseau, N. Morrice, M. Peggie, D. G. Campbell, M. Gaestel, and P. Cohen, 
“Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its 
interaction with cytokine mRNAs,” EMBO J., vol. 21, no. 23, pp. 6505–6514, 2002. 
[39] P. Briata et al., “p38-Dependent phosphorylation of the mRNA decay-promoting factor 
KSRP controls the stability of select myogenic transcripts,” Mol. Cell, vol. 20, no. 6, pp. 
891–903, 2005. 
[40] G. Stoecklin et al., “MK2-induced tristetraprolin:14-3-3 complexes prevent stress 
granule association and ARE-mRNA decay.,” EMBO J., vol. 23, no. 6, pp. 1313–24, 2004. 
[41] F. Bollig, R. Winzen, M. Gaestel, S. Kostka, K. Resch, and H. Holtmann, “Affinity 
purification of ARE-binding proteins identifies poly(A)-binding protein 1 as a potential 
substrate in MK2-induced mRNA stabilization,” Biochem. Biophys. Res. Commun., vol. 
301, no. 3, pp. 665–670, 2003. 
[42] V. Lafarga, A. Cuadrado, I. Lopez de Silanes, R. Bengoechea, O. Fernandez-Capetillo, and 
A. R. Nebreda, “p38 Mitogen-activated protein kinase- and HuR-dependent 
stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint.,” Mol. Cell. Biol., vol. 
 102 
 
29, no. 16, pp. 4341–51, 2009. 
[43] C. Tiedje et al., “The p38/MK2-Driven Exchange between Tristetraprolin and HuR 
Regulates AU-Rich Element-Dependent Translation,” PLoS Genet., vol. 8, no. 9, 2012. 
[44] P. Anderson, “Post-transcriptional control of cytokine production,” Nat Immunol, vol. 
9, no. 4, pp. 353–359, 2008. 
[45] S. Srikantan and M. Gorospe, “UneCLIPsing HuR Nuclear Function,” Mol. Cell, vol. 43, 
no. 3, pp. 319–321, 2011. 
[46] L. P. Ford, J. Watson, J. D. Keene, and J. Wilusz, “ELAV proteins stabilize deadenylated 
intermediates in a novel in vitro mRNA deadenylation/degradation system,” Genes 
Dev., vol. 13, no. 2, pp. 188–201, 1999. 
[47] T. Kawai, A. Lal, X. Yang, S. Galban, K. Mazan-Mamczarz, and M. Gorospe, “Translational 
control of cytochrome c by RNA-binding proteins TIA-1 and HuR,” Mol. Cell. Biol., vol. 
26, no. 8, p. 3295, 2006. 
[48] V. Katsanou et al., “HuR as a negative posttranscriptional modulator in inflammation,” 
Mol. Cell, vol. 19, no. 6, pp. 777–789, 2005. 
[49] E. Carballo, W. S. Lai, and P. J. Blackshear, “Feedback Inhibition of Macrophage Tumor 
Necrosis Factor-α Production by Tristetraprolin,” Science (80-. )., vol. 281, no. 5379, pp. 
1001–1005, 1998. 
[50] C. W. Muller, “DNA Recognition by NFKB and STAT Transcription Factors,” Ernst Scher. 
Res. Found. Work. 34, 2001. 
[51] A. R. Brasier, “The NF-κB Regulatory Network,” Cardiovasc. Toxicol., vol. 6, no. 2, pp. 
111–130, 2006. 
[52] A. Neri et al., “B cell lymphoma-associated chromosomal translocation involves 
candidate oncogene lyt-10, homologous to NF-κB p50.,” Cell, vol. 67, no. 6, pp. 1075–
1087, 1991. 
[53] R. Meyer et al., “Cloning of the DNA-binding subunit of human nuclear factor kappa B: 
the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor 
alpha.,” Proc. Natl. Acad. Sci. U. S. A., vol. 88, no. 3, pp. 966–70, 1991. 
[54] M. Kieran et al., “The DNA binding subunit of NF-κB is identical to factor KBF1 and 
homologous to the rel oncogene product,” Cell, vol. 62, no. 5, pp. 1007–1018, 1990. 
[55] G. P. Nolan, S. Ghosh, H. C. Liou, P. Tempst, and D. Baltimore, “DNA binding and I kappa 
B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide.,” Cell, 
vol. 64, no. 5, pp. 961–9, 1991. 
[56] D. W. Ballard et al., “The 65-kDa subunit of human NF-kappa B functions as a potent 
transcriptional activator and a target for v-Rel-mediated repression.,” Proc. Natl. Acad. 
Sci. U. S. A., vol. 89, no. 5, pp. 1875–9, 1992. 
[57] U. Sieben, G. Franzoso, and K. Brown, “STRUCTURE, REGULATION AND FUNCTION OF 
 103 
 
NF-1d3,” Annu. Rev. Cell Bioi, vol. 10, pp. 405–55, 1994. 
[58] M. J. Kang et al., “NF-κB Activates Transcription of the RNA-Binding Factor HuR, via 
PI3K-AKT Signaling, to Promote Gastric Tumorigenesis,” Gastroenterology, vol. 135, no. 
6, p. 2030–2042.e3, 2008. 
[59] T. D. Gilmore, “Introduction to NF-κB: players, pathways, perspectives,” Oncogene, vol. 
25, no. 51, pp. 6680–6684, 2006. 
[60] N. D. Perkins, “Integrating cell-signalling pathways with NF-kappaB and IKK function.,” 
Nat. Rev. Mol. Cell Biol., vol. 8, no. 1, pp. 49–62, 2007. 
[61] B. Samarasinghe, “The Hallmarks of Cancer 8: Tumor-Promoting Inflammation,” Sci. 
Am. Blog Netw., pp. 1–10, 2014. 
[62] B. Modrek, A. Resch, C. Grasso, and C. Lee, “Genome-wide detection of alternative 
splicing in expressed sequences of human genes,” Nucleic Acids Res., vol. 29, no. 13, 
pp. 2850–2859, 2001. 
[63] H. Zhu, M. N. Hinman, R. A. Hasman, P. Mehta, and H. Lou, “Regulation of neuron-
specific alternative splicing of neurofibromatosis type 1 pre-mRNA.,” Mol. Cell. Biol., 
vol. 28, no. 4, pp. 1240–51, 2008. 
[64] Y. I. G. Chen, R. E. Moore, H. Y. Ge, M. K. Young, T. D. Lee, and S. W. Stevens, “Proteomic 
analysis of in vivo-assembled pre-mRNA splicing complexes expands the catalog of 
participating factors,” Nucleic Acids Res., vol. 35, no. 12, pp. 3928–3944, 2007. 
[65] J. M. Izquierdo, “Hu antigen R (HuR) functions as an alternative pre-mRNA splicing 
regulator of Fas apoptosis-promoting receptor on exon definition,” J. Biol. Chem., vol. 
283, no. 27, pp. 19077–19084, 2008. 
[66] W. Zhao et al., “HuR and TIA1/TIAL1 are involved in regulation of alternative splicing of 
SIRT1 pre-mRNA,” Int. J. Mol. Sci., vol. 15, no. 2, pp. 2946–2958, 2014. 
[67] K. Abdelmohsen et al., “Phosphorylation of HuR by Chk2 Regulates SIRT1 Expression,” 
Mol. Cell, vol. 25, no. 4, pp. 543–557, 2007. 
[68] S. Lebedeva et al., “Transcriptome-wide Analysis of Regulatory Interactions of the RNA-
Binding Protein HuR,” Mol. Cell, vol. 43, no. 3, pp. 340–352, 2011. 
[69] M. Dutertre et al., “A recently evolved class of alternative 3’-terminal exons involved in 
cell cycle regulation by topoisomerase inhibitors.,” Nat. Commun., vol. 5, p. 3395, 2014. 
[70] J. Naipauer et al., “The use of alternative polyadenylation sites renders integrin β1 
(Itgb1) mRNA isoforms with differential stability during mammary gland 
development.,” Biochem. J., vol. 454, no. 2, pp. 345–57, 2013. 
[71] M. D. Diaz-Muñoz et al., “The RNA-binding protein HuR is essential for the B cell 
antibody response.,” Nat. Immunol., vol. 16, no. 4, pp. 415–25, 2015. 
[72] Y. Akaike et al., “HuR Regulates Alternative Splicing of the TRA2β Gene in Human Colon 
Cancer Cells under Oxidative Stress.,” Mol. Cell. Biol., vol. 34, no. 15, pp. 2857–73, 2014. 
 104 
 
[73] W. Al-Ahmadi, M. Al-Ghamdi, L. Al-Haj, M. Al-Saif, and K. S. A. Khabar, “Alternative 
polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich 
elements and auto-Regulation,” Nucleic Acids Res., vol. 37, no. 11, pp. 3612–3624, Jun. 
2009. 
[74] C. Denkert et al., “Expression of the ELAV-like protein HuR in human colon cancer: 
association with tumor stage and cyclooxygenase-2.,” Mod. Pathol., vol. 19, no. 9, pp. 
1261–9, 2006. 
[75] R. Calaluce et al., “The RNA binding protein HuR differentially regulates unique subsets 
of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.,” 
BMC Cancer, vol. 10, p. 126, 2010. 
[76] I. Kotta-Loizou, S. N. Vasilopoulos, R. H. A. Coutts, and S. Theocharis, “Current Evidence 
and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and 
Treatment,” Neoplasia, vol. 18, no. 11, pp. 674–688, 2016. 
[77] L. A. Licata, C. L. Hostetter, J. Crismale, A. Sheth, and J. C. Keen, “The RNA-binding 
protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines,” Breast 
Cancer Res. Treat., vol. 122, no. 1, pp. 55–63, 2010. 
[78] H. Janakiraman et al., “Repression of caspase-3 and RNA-binding protein HuR cleavage 
by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma,” 
Oncogene, no. October, pp. 1–12, 2016. 
[79] F. Baldan et al., “Identification of tumorigenesis-related mRNAs associated with RNA-
binding protein HuR in thyroid cancer cells,” Oncotarget, vol. 7, no. 39, pp. 63388–
63407, 2016. 
[80] P. Anderson, “Post-transcriptional regulons coordinate the initiation and resolution of 
inflammation.,” Nat. Rev. Immunol., vol. 10, no. 1, pp. 24–35, 2010. 
[81] M. M. Gubin et al., “Conditional knockout of the RNA-binding protein HuR in CD4+ T 
cells reveals a gene dosage effect on cytokine production,” Mol. Med., vol. 20, pp. 93–
108, Mar. 2014. 
[82] A. Yiakouvaki, M. Dimitriou, I. Karakasiliotis, C. Eftychi, S. Theocharis, and D. L. 
Kontoyiannis, “Myeloid cell expression of the RNA-binding protein HuR protects mice 
from pathologic inflammation and colorectal carcinogenesis,” J. Clin. Invest., vol. 122, 
no. 1, pp. 48–61, 2012. 
[83] A. Giammanco et al., “Intestinal epithelial HuR modulates distinct pathways of 
proliferation and apoptosis and attenuates small intestinal and colonic tumor 
development,” Cancer Res., vol. 74, no. 18, pp. 5322–5335, 2014. 
[84] T. Herjan et al., “HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 
mRNA stabilization.,” J. Immunol., vol. 191, no. 2, pp. 640–9, 2013. 
[85] J. Chen et al., “Posttranscriptional gene regulation of IL-17 by the RNA-binding protein 
HuR is required for initiation of experimental autoimmune encephalomyelitis.,” J. 
Immunol., vol. 191, no. 11, pp. 5441–5450, 2013. 
 105 
 
[86] C. Wheeler et al., “Sex hormone-dependent attenuation of EAE in a transgenic mouse 
with astrocytic expression of the RNA regulator HuR,” J. Neuroimmunol., vol. 246, no. 
1–2, pp. 34–37, 2012. 
[87] H. Park et al., “A distinct lineage of CD4 T cells regulates tissue inflammation by 
producing interleukin 17.,” Nat. Immunol., vol. 6, no. 11, pp. 1133–41, 2005. 
[88] L. A. Tesmer, S. K. Lundy, S. Sarkar, and D. A. Fox, “Th17 cells in human disease,” 
Immunol Rev, vol. 223, pp. 87–113, 2008. 
[89]  a Skliris et al., “Neuroprotection requires the functions of the RNA-binding protein 
HuR.,” Cell Death Differ., vol. 22, no. 5, pp. 1–16, 2014. 
[90] P. C. Chu, H. C. Chuang, S. K. Kulp, and C. S. Chen, “The mRNA-stabilizing factor HuR 
protein is targeted by β-TrCP protein for degradation in response to glycolysis 
inhibition,” J. Biol. Chem., vol. 287, no. 52, pp. 43639–43650, 2012. 
[91] W. Wang et al., “HuR regulates p21 mRNA stabilization by UV light,” Mol. Cell. Biol., vol. 
20, no. 3, pp. 760–769, Feb. 2000. 
[92] R. Upadhyay, S. Sanduja, V. Kaza, and D. A. Dixon, “Genetic polymorphisms in RNA 
binding proteins contribute to breast cancer survival,” Int. J. Cancer, vol. 132, no. 3, pp. 
128–138, 2013. 
[93] C. Zhang et al., “Cytoplasmic expression of the ELAV-like protein HuR as a potential 
prognostic marker in esophageal squamous cell carcinoma,” Tumor Biol., vol. 35, no. 1, 
pp. 73–80, 2014. 
[94] D. Jeong-Dan Cha, ShengJin Li, MD, PhD, In-Ho Cha, “Association between expression 
of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral 
squamous cell carcinoma,” Head Neck, vol. 36, no. 10, p. 1391, 2014. 
[95] D. P. Sun et al., “Clinicopathological significance of HuR expression in gallbladder 
carcinoma: With special emphasis on the implications of its nuclear and cytoplasmic 
expression,” Tumor Biol., vol. 34, no. 5, pp. 3059–3069, 2013. 
[96] Z. Zhu et al., “Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and 
poor outcome in breast cancer,” Tumor Biol., vol. 34, no. 4, pp. 2299–2308, 2013. 
[97] M.-J. Chae et al., “Chemical inhibitors destabilize HuR binding to the AU-rich element 
of TNF-α mRNA,” Exp. Mol. Med., vol. 41, no. 11, pp. 824–831, Nov. 2009. 
[98] V. G. D’Agostino, V. Adami, and A. Provenzani, “A Novel High Throughput Biochemical 
Assay to Evaluate the HuR Protein-RNA Complex Formation,” PLoS One, vol. 8, no. 8, 
pp. 1–9, 2013. 
[99] V. G. D’Agostino et al., “Dihydrotanshinone-I interferes with the RNA-binding activity 
of HuR affecting its post-transcriptional function.,” Sci. Rep., vol. 5, no. October, p. 
16478, 2015. 
[100] X. Wu et al., “Identification and Validation of Novel Small Molecule Disruptors of HuR-
 106 
 
mRNA Interaction,” ACS Chem. Biol., Mar. 2015. 
[101] Z. Wang, A. Bhattacharya, and D. N. Ivanov, “Identification of Small-Molecule Inhibitors 
of the HuR/RNA Interaction using a fluorescence polarization screening assay followed 
by NMR validation,” PLoS One, vol. 10, no. 9, pp. 1–13, 2015. 
[102] F. Bollmann et al., “Resveratrol post-transcriptionally regulates pro-inflammatory gene 
expression via regulation of KSRP RNA binding activity,” Nucleic Acids Res., vol. 42, no. 
20, pp. 12555–12569, 2014. 
[103] R. Muralidharan et al., “Folate receptor-targeted nanoparticle delivery of HuR-RNAi 
suppresses lung cancer cell proliferation and migration,” J. Nanobiotechnology, vol. 14, 
no. 1, p. 47, 2016. 
[104] R. Muralidharan, J. Panneerselvam, A. Chen, Y. D. Zhao, A. Munshi, and R. Ramesh, 
“HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 
expression, cell growth, migration and invasion in lung cancer,” Cancer Gene Ther, vol. 
22, no. 12, pp. 581–590, 2015. 
[105] J. Guo et al., “Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents 
in urothelial carcinoma of the bladder,” vol. 7, no. 29. 
[106] Y.-C. Cheng et al., “MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the 
Hypoxia-Inducible Factor-1  mRNA through Decreasing Nuclear-Cytoplasmic 
Translocation of RNA-Binding Protein HuR,” Mol. Cancer Ther., vol. 12, no. 7, pp. 1202–
1212, 2013. 
[107] S. Galban et al., “RNA-Binding Proteins HuR and PTB Promote the Translation of 
Hypoxia-Inducible Factor 1 ,” Mol. Cell. Biol., vol. 28, no. 1, pp. 93–107, 2008. 
[108] J. Y. Lee et al., “A novel cantharidin analog N-Benzylcantharidinamide reduces the 
expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic 
translocation of HuR,” Biochem. Biophys. Res. Commun., vol. 447, no. 2, pp. 371–377, 
2014. 
[109] L. Sun et al., “Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-
??-treated A549 cells,” Biochem. Biophys. Res. Commun., vol. 416, no. 1–2, pp. 99–105, 
2011. 
[110] Q. Liu et al., “Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 
expression through PI3-K/Akt and NF-??B pathways,” Mol. Immunol., vol. 44, no. 10, 
pp. 2686–2696, 2007. 
[111] Y. S. Hwang, K.-K. Park, and W.-Y. Chung, “Kalopanaxsaponin A inhibits the invasion of 
human oral squamous cell carcinoma by reducing metalloproteinase-9 mRNA stability 
and protein trafficking,” Biol. Pharm. Bull., vol. 35, no. 3, pp. 289–300, 2012. 
[112] B. Annabi, J. C. Currie, A. Moghrabi, and R. Béliveau, “Inhibition of HuR and MMP-9 
expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea 
polyphenol EGCg.,” Leuk. Res., vol. 31, no. 9, pp. 1277–1284, 2007. 
 107 
 
[113] H. Cao et al., “Green tea increases anti-inflammatory tristetraprolin and decreases pro-
inflammatory tumor necrosis factor mRNA levels in rats.,” J. Inflamm. (Lond)., vol. 4, p. 
1, 2007. 
[114] K. R. Houser, D. K. Johnson, and F. T. Ishmael, “Anti-inflammatory effects of 
methoxyphenolic compounds on human airway cells,” J. Inflamm., vol. 9, no. 1, p. 6, 
2012. 
[115] H. M. Chang et al., “Structure Elucidation and Total Synthesis of New Tanshinones 
Isolated from Salvia miltiorrhiza Bunge (Danshen),” J. Org. Chem., vol. 55, no. 11, pp. 
3537–3543, 1990. 
[116] H. J. Sung, S. M. Choi, Y. Yoon, and K. S. An, “Tanshinone IIA, an ingredient of Salvia 
miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the 
activation of caspase-3,” Exp. Mol. Med., vol. 31, no. 4, pp. 174–178, 1999. 
[117] W. W. L. C. and C. F.-C. Wu Lung, “Cytotoxic Activities of Tanshinones against Human 
Carcinoma Cell Lines,” Am. J. Chin. Med., vol. XIX, no. 8 August 1991, pp. 207–216, 1991. 
[118] S. I. Jang et al., “Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide 
synthase expression and production of TNF-alpha, IL-1 beta and IL-6 in activated RAW 
264.7 cells.,” Planta Med., no. 69, pp. 1057–1059, 2003. 
[119] J. Xie et al., “The antitumor effect of tanshinone IIA on anti-proliferation and decreasing 
VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line,” Acta 
Pharm. Sin. B, vol. 5, no. 6, pp. 554–563, 2015. 
[120] C.-Y. Lee et al., “Anticancer effects of tanshinone I in human non-small cell lung cancer,” 
Mol. Cancer Ther., vol. 7, no. 11, pp. 3527–3538, 2008. 
[121] J. W. Park et al., “15,16-Dihydrotanshinone I, a major component from Salvia 
miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing 
intracellular calcium mobilization,” Arch. Pharm. Res., vol. 31, no. 1, pp. 47–53, 2008. 
[122] X. Wang, S. L. Morris-Natschke, and K. H. Lee, “New developments in the chemistry and 
biology of the bioactive constituents of Tanshen,” Med. Res. Rev., vol. 27, no. 1, pp. 
133–148, 2007. 
[123] L. Wang et al., “Dihydrotanshinone i induced apoptosis and autophagy through caspase 
dependent pathway in colon cancer,” Phytomedicine, vol. 22, no. 12, pp. 1079–1087, 
2015. 
[124] L. Wang et al., “Dihydrotanshinone induces p53-independent but ROS-dependent 
apoptosis in colon cancer cells,” Life Sci., vol. 93, no. 8, pp. 344–351, 2013. 
[125] J. Li, C. Mi, J. Ma, K. S. Wang, J. J. Lee, and X. Jin, “Dihydrotanshinone I inhibits the 
translational expression of hypoxia-inducible factor-1??,” Chem. Biol. Interact., vol. 
240, pp. 48–58, 2015. 
[126] F. Wang, J. Ma, K. S. Wang, C. Mi, J. J. Lee, and X. Jin, “Blockade of TNF-??-induced NF-
??B signaling pathway and anti-cancer therapeutic response of dihydrotanshinone I,” 
 108 
 
Int. Immunopharmacol., vol. 28, no. 1, pp. 764–772, 2015. 
[127] C. Zucal et al., “Targeting the multifaceted HuR protein, benefits and caveats,” Curr. 
Drug Targets, vol. 16, no. 5, pp. 499–515, 2015. 
[128] X. Ouyang et al., “Protective effect of Salvia miltiorrhiza on angiotensin II-induced 
hypertrophic responses in neonatal rat cardiac cells.,” Jpn. J. Pharmacol., vol. 87, no. 4, 
pp. 289–96, 2001. 
[129] V. G. D’Agostino et al., “Dihydrotanshinone-I interferes with the RNA-binding activity 
of HuR affecting its post-transcriptional function,” Sci. Rep., vol. 5, 2015. 
[130] P. Lal et al., “Regulation of HuR structure and function by dihydrotanshinone-I,” Nucleic 
Acids Res., 2017. 
[131] T. Peritz et al., “Immunoprecipitation of mRNA-protein complexes,” Nat. Protoc., vol. 
1, no. 2, pp. 577–580, 2006. 
[132] X. Guo and R. S. Hartley, “HuR contributes to cyclin E1 deregulation in MCF-7 breast 
cancer cells,” Cancer Res., vol. 66, no. 16, pp. 7948–7956, Aug. 2006. 
[133] C. K. Chang and T. H. Huang, “Untangling the structure of the TDP-43 N-terminal 
domain,” FEBS J., vol. 283, no. 7, pp. 1239–1241, 2016. 
[134] H. Wang, F. Zeng, H. Liu, M. Teng, and X. Li, “Crystal structure of two tandem RNA 
recognition motifs of Human antigen R,” To be Publ., p. null-null, Mar. 2012. 
[135] K. L. Morrison and G. A. Weiss, “Combinatorial alanine-scanning,” Curr. Opin. Chem. 
Biol., vol. 5, no. 3, pp. 302–307, Jun. 2001. 
[136] F. F. Blanco et al., “Impact of HuR inhibition by the small molecule MS-444 on colorectal 
cancer cell tumorigenesis,” Oncotarget, vol. 7, no. 45, 2016. 
[137] S. Lal, Cheung, E.C., Zarei, M., Preet, L. et al. (2017) C. knockout of the H. gene Causes,  
lethal phenotype. M. C. Res., and Doi:10.1158/1541-7786.MCR-16-0361., “CRISPR 
knockout of the HuR gene causes a xenograft lethal phenotype.” 
[138] X. C. Fan and J. A. Steitz, “HNS, a nuclear-cytoplasmic shuttling sequence in HuR,” Proc. 
Natl. Acad. Sci. U. S. A., vol. 95, no. 26, pp. 15293–15298, Dec. 1998. 
[139] J. L. Dean, R. Wait, K. R. Mahtani, G. Sully, A. R. Clark, and J. Saklatvala, “The 3’ 
untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-
stabilizing factor HuR,” Mol. Cell. Biol., vol. 21, no. 3, pp. 721–730, Feb. 2001. 
[140] C. Y. Chen et al., “AU binding proteins recruit the exosome to degrade ARE-containing 
mRNAs,” Cell, vol. 107, no. 4, pp. 451–464, 2001. 
[141] C. Barreau, L. Paillard, and H. B. Osborne, “AU-rich elements and associated factors: Are 
there unifying principles?,” Nucleic Acids Res., vol. 33, no. 22, pp. 7138–7150, 2005. 
[142] G. Stoecklin, T. Mayo, and P. Anderson, “ARE-mRNA degradation requires the 5’-3’ 
decay pathway.,” EMBO Rep., vol. 7, no. 1, pp. 72–7, 2006. 
 109 
 
[143] T. Bakheet, M. Frevel, B. R. Williams, W. Greer, and K. S. Khabar, “ARED: human AU-rich 
element-containing mRNA database reveals an unexpectedly diverse functional 
repertoire of encoded proteins.,” Nucleic Acids Res., vol. 29, no. 1, pp. 246–54, 2001. 
[144] C. Tiedje et al., “The RNA-binding protein TTP is a global post-transcriptional regulator 
of feedback control in inflammation,” Nucleic Acids Res., vol. 44, no. 15, pp. 7418–7440, 
2016. 
[145] L.-Q. Qiu, W. S. Lai, A. Bradbury, D. C. Zeldin, and P. J. Blackshear, “Tristetraprolin (TTP) 
coordinately regulates primary and secondary cellular responses to proinflammatory 
stimuli,” J. Leukoc. Biol., vol. 97, no. 4, pp. 723–736, 2015. 
[146] G. Grigoriadis et al., “The Rel subunit of NF-kappaB-like transcription factors is a 
positive and negative regulator of macrophage gene expression: distinct roles for Rel in 
different macrophage populations.,” EMBO J., vol. 15, no. 24, pp. 7099–107, 1996. 
[147] E. Hitti et al., “Mitogen-activated protein kinase-activated protein kinase 2 regulates 
tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin 
expression, stability, and binding to adenine/uridine-rich element.,” Mol. Cell. Biol., vol. 
26, no. 6, pp. 2399–2407, 2006. 
[148] R. Cheng, J. Chen, Y. Wang, Y. Ge, Z. Huang, and G. Zhang, “Dihydrotanshinone induces 
apoptosis of SGC7901 and MGC803 cells via activation of JNK and p38 signalling 
pathways,” Pharm. Biol., vol. 54, no. 12, pp. 3019–3025, 2016. 
[149] J. L. E. Dean, R. Wait, K. R. Mahtani, A. R. Clark, J. Saklatvala, and G. Sully, “The 3 ′ 
Untranslated Region of Tumor Necrosis Factor Alpha mRNA Is a Target of the mRNA-
Stabilizing Factor HuR The 3Ј Untranslated Region of Tumor Necrosis Factor Alpha 
mRNA Is a Target of the mRNA-Stabilizing Factor HuR Downloaded from 
http://mcb.asm.org,” vol. 21, no. 3, pp. 721–730, 2001. 
[150] K. De Filippo et al., “Mast cell and macrophage chemokines CXCL1 / CXCL2 control the 
early stage of neutrophil recruitment during tissue inflammation,” Blood, vol. 121, no. 
24, pp. 4930–4937, 2013. 
[151] A. Zlotnik and O. Yoshie, “The Chemokine Superfamily Revisited,” Immunity, vol. 36, no. 
5, pp. 705–712, 2012. 
[152] X. Zhang et al., “CXCL10 plays a key role as an inflammatory mediator and a non-
invasive biomarker of non-alcoholic steatohepatitis,” J. Hepatol., vol. 61, no. 6, pp. 
1365–1375, 2014. 
[153] I. Loez De Silanes et al., “Role of the RNA-binding protein HuR in colon carcinogenesis,” 
Oncogene, vol. 22, pp. 7146–7154, 2003. 
[154] H. Ronkainen, M. H. Vaarala, P. Hirvikoski, and A. Ristimäki, “HuR expression is a marker 
of poor prognosis in renal cell carcinoma,” Tumor Biol., vol. 32, no. 3, pp. 481–487, 
2011. 
[155] X. Wu et al., “Abstract 2449: Targeting an ‘undruggable’ RNA-binding protein: Discovery 
of small molecule inhibitors of HuR for novel breast cancer therapy,” Cancer Res., vol. 
 110 
 
75, no. 15 Supplement, pp. 2449–2449, Aug. 2015. 
[156] J. Viiri et al., “Autophagy Activation Clears ELAVL1/HuR-Mediated Accumulation of 
SQSTM1/p62 during Proteasomal Inhibition in Human Retinal Pigment Epithelial Cells,” 
PLoS One, vol. 8, no. 7, pp. 1–16, 2013. 
[157] M. R. Arkin, M. A. Glicksman, H. Fu, J. J. Havel, and Y. Du, “Inhibition of Protein-Protein 
Interactions: Non-Cellular Assay Formats,” in Assay Guidance Manual, G. S. 
Sittampalam, N. P. Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, B. Bejcek, M. 
Glicksman, J. Inglese, P. W. Iversen, Z. Li, J. McGee, O. McManus, L. Minor, A. Napper, 
J. M. Peltier, T. Riss, O. J. Trask, and J. Weidner, Eds. Bethesda (MD): Eli Lilly & Company 
and the National Center for Advancing Translational Sciences, 2004. 
[158] L. Lu et al., “Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-
43 and FUS/TLS: Implications for amyotrophic lateral sclerosis,” J. Biol. Chem., vol. 289, 
no. 46, pp. 31792–31804, 2014. 
[159] X. H. Tian and J. H. Wu, “Tanshinone derivatives: A patent review (January 2006 - 
September 2012),” Expert Opin. Ther. Pat., vol. 23, no. 1, pp. 19–29, 2013. 
[160] S. L. Tsai et al., “Anti-tumor potential of 15,16-dihydrotanshinone I against breast 
adenocarcinoma through inducing G1 arrest and apoptosis,” Biochem. Pharmacol., vol. 
74, no. 11, pp. 1575–1586, 2007. 
[161] Y. Ye, W. Xu, W. Zhong, Y. Li, and C. Wang, “Combination treatment with 
dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical 
cancer by HPV E6 down-regulation and caspases activation,” Mol. Cell. Biochem., vol. 
363, no. 1–2, pp. 191–202, 2012. 
[162] J.-J. Liu, H.-H. Wu, T.-H. Chen, W. Leung, and Y.-C. Liang, “15,16-Dihydrotanshinone I 
from the Functional Food Salvia miltiorrhiza Exhibits Anticancer Activity in Human HL-
60 Leukemia Cells: in Vitro and in Vivo Studies,” Int. J. Mol. Sci., vol. 16, no. 8, pp. 
19387–19400, 2015. 
[163] I. T. Nizamutdinova et al., “Tanshinone I suppresses growth and invasion of human 
breast cancer cells, MDA-MB-231, through regulation of adhesion molecules,” 
Carcinogenesis, vol. 29, no. 10, pp. 1885–1892, 2008. 
[164] N. S. Levy, S. Chung, H. Furneaux, and A. P. Levy, “Hypoxic stabilization of vascular 
endothelial growth factor mRNA by the RNA-binding protein HuR,” J. Biol. Chem., vol. 
273, no. 11, pp. 6417–6423, Mar. 1998. 
[165] D. a Dixon et al., “Altered expression of the mRNA stability factor HuR promotes 
cyclooxygenase-2 expression in colon cancer cells,” Cell, vol. 108, no. 11, pp. 1657–
1665, 2001. 
[166] L. Cerofolini et al., “Examination of matrix metalloproteinase-1 in solution: a preference 
for the pre-collagenolysis state,” J. Biol. Chem., vol. 288, no. 42, pp. 30659–30671, Oct. 
2013. 
[167] U. H. Jin et al., “Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic 
 111 
 
smooth muscle cell migration and MMP-9 activity through AKT signaling pathway,” J 
Cell Biochem, vol. 104, no. 1, pp. 15–26, 2008. 
[168] Y. Xing, J. Tu, L. Zheng, L. Guo, and T. Xi, “Anti-angiogenic effect of tanshinone IIA 
involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells,” Oncol. 
Rep., vol. 33, no. 1, pp. 163–170, 2015. 
[169] D. Cox- et al., “Cryptotanshinone Attenuates Cardiac Fibrosis via,” vol. 64, no. 1, pp. 28–
37, 2014. 
[170] J. Fan et al., “Chemokine transcripts as targets of the RNA-binding protein HuR in 
human airway epithelium.,” J. Immunol., vol. 186, no. 4, pp. 2482–94, 2011. 
[171] Y. Ke et al., “Erratum: PARP1 promotes gene expression at the post-transcriptional level 
by modulating the RNA-binding protein HuR,” Nat. Commun., vol. 8, p. 15191, 2017. 
[172] J. L. E. Dean, G. Sully, A. R. Clark, and J. Saklatvala, “The involvement of AU-rich element-
binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA 
stabilisation,” Cell. Signal., vol. 16, no. 10, pp. 1113–1121, 2004. 
[173] S. A. Brooks, J. E. Connolly, and W. F. C. Rigby, “The role of mRNA turnover in the 
regulation of tristetraprolin expression: evidence for an extracellular signal-regulated 
kinase-specific, AU-rich element-dependent, autoregulatory pathway.,” J. Immunol., 
vol. 172, no. 12, pp. 7263–7271, 2004. 
[174] C. R. Tchen, M. Brook, J. Saklatvala, and A. R. Clark, “The stability of tristetraprolin 
mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin 
itself,” J. Biol. Chem., vol. 279, no. 31, pp. 32393–32400, 2004. 
[175] K. R. Mahtani, M. Brook, J. L. Dean, G. Sully, J. Saklatvala, and A. R. Clark, “Mitogen-
activated protein kinase p38 controls the expression and posttranslational modification 
of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability.,” Mol. Cell. 
Biol., vol. 21, no. 19, pp. 6461–9, 2001. 
[176] M. Lang et al., “Mo1670 Systemic HuR Inhibition Augments Tumorigenesis in the 
AOM/DSS Mouse,” Gastroenterology, vol. 146, no. 5, p. S-632, 2014. 
[177] M. Jimbo et al., “Targeting the mRNA-binding protein HuR impairs malignant 
characteristics of pancreatic ductal adenocarcinoma cells,” Oncotarget, vol. 6, no. 29, 
pp. 27312–27331, 2015. 
[178] C. von Roretz et al., “Apoptotic-induced cleavage shifts HuR from being a promoter of 
survival to an activator of caspase-mediated apoptosis,” Cell Death Differ., pp. 154–
168, 2012. 
[179] P. Beauchamp et al., “The cleavage of HuR interferes with its transportin-2-mediated 
nuclear import and promotes muscle fiber formation.,” Cell Death Differ., vol. 17, no. 
10, pp. 1588–1599, 2010. 
[180] V. Katsanou et al., “The RNA-binding protein Elavl1/HuR is essential for placental 
branching morphogenesis and embryonic development.,” Mol. Cell. Biol., vol. 29, no. 
 112 
 
10, pp. 2762–2776, 2009. 
 
 APPENDIX 
TABLE 3 IC-50 values for DHTS and its analogs at 24 & 72 hrs. 
 
GD041 MB11V VB062 MFM49 MB39 DHTS 
IC50 (µM) 24  hrs ∼24.17 9.938 21.079 ∼9.813 8.813 ∼3.687 
             R2 0.9693 0.9927 0.9734 0.9772 0.9428 0.9972 
IC50 (µM) 72 hrs ∼29.68 16.12 ∼32.98 14.22 ∼11.36 2.564 
             R2 0.991 0.99 0.96 0.9945 0.997 0.967 
 
TABLE 4 qPCR Primer sequences  
NAME SEQUENCE 5’ to 3’ (F and R) 
TNFa 
Human 
5’-GGGACCTCTCTCTAATCAGC 
5’ TCAGCTTGAGGGTTTGCTAC 
VEGF 
Human 
5'-CCGCAGACGTGTAAATGTTCCT 
5'-CGGCTTGTCACATCTGCAAGTA'   
GAPDH 
Human 
5’-CAAGGTCATCCATGACAACTT 
5′-GTCCACCACCCTGTTGCTGTA 
Zfp36 
Mouse 
5’-GGACTTTGGAACATAAACTCGGACT 
5’-GAAGTAGGTGAGGGTGACAGCTCA 
CXCL-2 
Mouse  
5’-CCACCAACCACCAGGCTACA 
5’-GCTTCAGGGTCAAGGCAAACT 
CXCL-10 
Mouse 
5’-TCAGCACCATGAACCCAAG 
5’-CTATGGCCCTCATTCTCACTG 
18S 
mouse 
5’-GTA ACCCGTTGAACCCCATT 
5’-CCATCCAATCGGTAGTAGCG 
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TNFa 
Taqman 
5’- CATCTTCTCAAAATTCGAGTGACA 
5’-TGGGAGTAGACAAGGTACAACCC 
Actin  
Taqman 
Mouse 
Actin Probe Mix: Mouse ACTB, Applied 
Biosystems/Thermo Fisher, VIC-labelled 
#4352341E 
 
TABLE 5 HuR RRMs Primer and Muteins Primers 
NAME SEQUENCE 5’ to 3’ (F and R) 
RRM1/2 
 
5’-CCCGCATATGATGTCTAATGGTTATG  
5’-TATACTCGAGGCGAGAGGAGTGCC 
RRM2/3 
 
5’- CCGCATATGATGACCCAGAAGGACGTA  
5’- GGCCTCGAGTTTGTGGGACTTGT 
RRM1 5’-CCCGCATATGATGTCTAATGGTTATG 
5’-CCGCTCGAGTACGTCCTTCTGGG 
ΔRRM1 5’-CCCGCATATGATGTCTAATGGTTATG 
5’-GGCCTCGAGCACCTTAATGGTTTTTGAC 
RRM2  5’-CCGCATATGATGACCCAGAAGGACGTA 
5’-GGCTCGAGTCGCGCTGGCGAGT 
RRM3 5’-GGCATATGTCCTCCGGCTGGTGCAT 
5’-GGCCTCGAGTTTGTGGGACTTGT 
HuR 
S94A 
5’-AACCATTAAGGTGGCGTATGCTCGCCC 
5’-GGGCGAGCATACGCCACCTTAATGGTT 
HuR 
N107A 
5’-ATCAAAGACGCCGCCTTGTACATCAGC 
5’-GCTGATGTACAAGGCGGCGTCTTTGAT 
HuR 
I133A 
5’-TTGGGCGGATCGCCAACTCGCGGGTCC 
5’- GGACCCGCGAGTTGGCGATCCGCCCAA 
HuR 
N134A 
5’-GGGCGGATCATCGCCTCGCGGGTCCTC 
5’-GAGGACCCGCGAGGCGATGATCCGCCC 
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Supplementary Figures 
1. 
 
 
 
 
 
2. 
 
 
 
 
 
 Figure 42 (1 & 2) Evaluation of anti-inflammatory effect of DHTS and MFM49, by checking number of fold 
reduced target gene, upon LPS co treatment with DHTS and MFM49 application in THP-1 cells (3hrs). The relative 
expression was normalized with Gapdh. (qPCR Primer used for these targets are not listed). (Dr. Vito D’Agostino 
has contributed to these figures). 
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ABSTRACT
The Human antigen R protein (HuR) is an RNA-
binding protein that recognizes U/AU-rich elements
in diverse RNAs through two RNA-recognition mo-
tifs, RRM1 and RRM2, and post-transcriptionally reg-
ulates the fate of target RNAs. The natural prod-
uct dihydrotanshinone-I (DHTS) prevents the asso-
ciation of HuR and target RNAs in vitro and in cul-
tured cells by interfering with the binding of HuR
to RNA. Here, we report the structural determinants
of the interaction between DHTS and HuR and the
impact of DHTS on HuR binding to target mRNAs
transcriptome-wide. NMR titration and Molecular Dy-
namics simulation identified the residues within
RRM1 and RRM2 responsible for the interaction be-
tween DHTS and HuR. RNA Electromobility Shifts
and Alpha Screen Assays showed that DHTS inter-
acts with HuR through the same binding regions as
target RNAs, stabilizing HuR in a locked conforma-
tion that hampers RNA binding competitively. HuR
ribonucleoprotein immunoprecipitation followed by
microarray (RIP-chip) analysis showed that DHTS
treatment of HeLa cells paradoxically enriched HuR
binding to mRNAs with longer 3′UTR and with higher
density of U/AU-rich elements, suggesting that DHTS
inhibits the association of HuR to weaker target mR-
NAs. In vivo, DHTS potently inhibited xenograft tu-
mor growth in a HuR-dependent model without sys-
temic toxicity.
INTRODUCTION
The Human antigen R (ELAVL1, HuR) is an ubiquitously
expressed RNA-binding protein, belonging to the ELAVL
(Embryonic Lethal Abnormal Vision)-like family, that pref-
erentially binds U- andAU-rich elements (AREs) abundant
in the 3′ untranslated regions (3′UTRs) of certain mRNAs.
It is mainly localized within the nucleus (90%), where it
exerts post-transcriptional functions such as splicing (1–4)
and alternative polyadenylation (5–7), and is able to shut-
tle to the cytoplasm, where it mainly regulates the fate of
target RNAs (8). HuR regulates cellular responses to dif-
ferentiation, senescence, inflammatory factors, and immune
stimuli by tightly controlling the post-transcriptional fate of
specific mRNAs (9–12). Notably, HuR binds to and reg-
ulates the half-life of mRNAs and/or the translation of
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mRNAs encoding key inflammatory cytokines and inter-
leukins, such as tumor necrosis factor- (TNF) (13) and
interleukin IL-1, IL-3 (14), IL-6 (15), IL-8, IL-10, IL-4,
CXCL1 (16–18), in turn governing the development and
maturation of B and T lymphocytes (19,20). HuR is highly
expressed in many cancer types, and is believed to promote
tumorigenesis by interacting with mRNAs encoding pro-
teins implicated in cell proliferation and survival, angiogen-
esis, invasion, pharmacoresistance and metastasis (21–27).
The role of HuR in inflammation and cancer has prompted
the search for inhibitors/modulators to interfere with its bi-
ological activity (28–32).
A number of natural and synthetic molecules have been
found to interfere with the formation of HuR/mRNA com-
plexes in vitro (29,32–35). The structural basis of the inter-
action of such molecules with HuR is still poorly character-
ized. HuR contains three highly conserved RNA recogni-
tion motifs (RRMs) among which the first two, RRM1 and
RRM2, bind with high affinity toU/AU-rich RNA (36). By
contrast, the third domain, RRM3, contributes to the inter-
action of HuR with poly(A) tails of target mRNA, and is
believed to be involved in mRNA-induced cooperative as-
sembly of HuR oligomers (37) (Figure 1A). Each RRMdo-
main adopts a 1–1–2–3–2–4 topology with the two
-helices packed in an antiparallel four-stranded -sheet.
Residues at conserved positions located on -strands 1 and
3 are essential for mRNA binding, and are either involved
in stacking interactions with mRNA bases or inserted be-
tween two sugar rings (38). At present, two crystal struc-
tures of the isolated RRM1 domain (PDB codes 3HI9 and
4FXV (39)) and two of the RRM1–RRM2 domains (PDB
codes 4ED5 (40) and 4EGL) are available in the Protein
Data Bank (PDB). Conformational changes occurring on
the tandem RRM1–RRM2 domains are crucial for mRNA
binding (40). As suggested by the crystal structures, the tan-
dem construct adopts an ‘open’ conformation in the free
form and a ‘closed’ conformation when the RRM1 and
RRM2 domains bind mRNA (Figure 1B and C). This hy-
pothesis is supported by SAXS data that show an equilib-
rium among ‘closed’ and ‘open’ conformations for HuR in
solution, in the absence of mRNA. When a target mRNA
sequence is present, the two domains form a stable com-
plex with mRNA and adopt a ‘closed’ globular conforma-
tion around the mRNA strand (41).
Dihydrotanshinone-I (DHTS) is a natural compound
present in Salvia miltiorrhiza that interferes with the forma-
tion of HuR/RNA complexes (31). However, there is cur-
rently no detailed information about the specific interac-
tion of DHTS with HuR or about the perturbations of the
RNA-binding abilities of HuR transcriptome-wide. Here,
we report the analysis of the interaction betweenDHTS and
HuR by NMR, Molecular Dynamics simulation, and mu-
tagenesis experiments. We have characterized the internal
dynamics of the HuR RRM1–RRM2 domains, and have
used this information to analyze the role of the two domains
in ligand binding. In this respect, the identification of the
flexibility of the two domains, RRM1 and RRM2, was par-
ticularly interesting.Moreover, ribonucleoprotein immuno-
precipitation followed by microarray analysis revealed that
DHTS dysregulates HuR by enriching HuR binding to-
wards longer mRNAs highly rich in U/AU-rich 3′UTRs,
including the mRNAs that encode apoptotic and cell-cycle
regulatory proteins in cells, and inhibits cancer cell growth
in vivo.
MATERIALS AND METHODS
Cell lines and reagents
Human cervical adenocarcinoma HeLa cells (ATCC®
CCL2™), colon carcinoma cells HCT116 (ATCC; Man-
assas, VA) were cultured in standard Dulbecco’s Mod-
ified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum (Gibco/Invitrogen), 1% L-glutamine
(Gibco/Invitrogen), 1% penicillin–streptomycin (Invitro-
gen), and growth conditions at 37◦C in 5% humidi-
fied CO2 incubators. Creation and characterization of
CRISPR/Cas9-mediated knockout of the ELAVL1 gene in
HCT116 cells was accomplished as described (42). Dihy-
drotanshinone I (D0947) was purchased from Sigma and
dissolved in ultrapure dimethylsulfoxide (DMSO, Amresco,
N182) to 10 mM final concentration. Antibodies used rec-
ognized HuR (sc-71290; from Santa Cruz Biotechnology),
His tag (anti-6x His (ab1187; from Abcam)) and -actin
(Clone C4; MP Biomedicals).
Cell and tumor growth assays
Transient transfection of cells with a HuR expres-
sion construct (pcDNA3.1/Zeo/HuR-Flag) or empty
vector was accomplished using Lipofectamine Plus
(Gibco/Invitrogen) as described (43) for 48 h, following
addition of 10 M DHTS or vehicle. Cell survival was
assayed using the MTT-based cell growth determination
kit (Sigma-Aldrich) as previously described (30).
Anchorage- and serum-independent growth assays were
accomplished by plating cells (20 cells per well) on 96-well
ultra-low attachment plates (Corning) in in spheroid growth
medium (DMEM supplemented with 10 mM HEPES, N2
supplement (1×; Gibco), B-27 supplement (1×; Gibco), In-
sulin Transferrin Selenium (1×; Gibco), FGF (10 ng/ml;
Gibco) and EGF (20 ng/ml; Gibco)). After 3 days of
growth, spheroids were treated with 10 M DHTS or ve-
hicle for 15 days changing medium every 3 days. Individual
spheroids (n = 5–10/time point) were imaged every 3 days
and area was measured using ImageJ software.
Six week-old athymic nude (Nu/Nu) mice were pur-
chased from Jackson Laboratories and maintained under
sterile conditions in cage micro-isolators according to ap-
proved IACUC guidelines. Parental HCT116 and a repre-
sentative HuR knockout clone (2 × 106 cells) used between
passages 14 and 23 were resuspended in PBS containing
50%Matrigel (Corning) and injected into the dorsal subcu-
taneous tissue (three mice/group with two tumors/mouse).
Mice (three per group) received intraperitoneal (IP) injec-
tions of DHTS (10 mg/kg) dissolved in PBS/5% N-methyl
pyrrolidine (NMP) (Sigma-Aldrich) or vehicle control every
48 h. Tumor volumes and body weight were measured three
times per week using a caliper, and tumor volumes were cal-
culated using the formula: volume = length × width2/2.
Upon termination of the experiment, mice were euthanized
and tumors were harvested.
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Figure 1. Multidomain organization of HuR (A). The RRM1–RRM2 tandem domains (RRM1 aminoacids (aa) Thr20-Pro98 and RRM2 aa Ala106-
Asn186) are separated by a short linker of 7 residues (aa Ser99-Asp105), while RRM3 (aa Trp244-Asn322) is connected to the other two domains by
a long hinge region of about 60 residues (aa Pro187-Gly243), which includes the HuR Nucleocytoplasmic Shuttling (HNS) sequence, responsible for
nuclear/cytoplasmic shuttling of HuR. RRM1 is represented in green, RRM2 in blue and RRM3 in red. The HuRNucleocytoplasmic Shuttling Sequence
(HNS) is indicated in orange. Cartoon representation of the ‘open’ structure of the tandem RRM1–RRM2 domains crystallized in the absence of RNA
(pdb code 4ED5) (B), and of the ‘closed’ structure of the tandem RRM1–RRM2 domains in complex with RNA (pdb code 4EGL) (C). The two domains
and the linker are highlighted with different colors (RRM1 in green, linker in yellow and RRM2 in blue). (D) Comparison of experimental backbone 15NH
R1 values for RRM1–RRM2 (data collected at 298 K, black filled circles) with the calculated values (grey bars) for isolated RRM1 and RRM2 domains
(1), for monomeric RRM1–RRM2 construct (3) and for rigid dimeric adduct (5). Comparison of experimental backbone 15NH R2 values for RRM1–
RRM2 (data collected at 298 K, black filled circles) with the calculated values (grey bars) for isolated RRM1 and RRM2 domains (2), for monomeric
RRM1–RRM2 construct (4) and for rigid dimeric adduct (6). Experimental NOE values for RRM1–RRM2 (data collected at 298 K) (7) and S2 order
parameter calculated with the program TENSOR2 (8).
AlphaScreen and RNA electromobility shift (REMSA) as-
says
Amplified Luminescent Proximity Homogenous Assay (Al-
pha) with a 5′-Biotinylated RNA probe (Bi-TNF, 5′-
AUUAUUUAUUAUUUAUUUAUUAUUUA) was used
with FL-HuR and four studiedmutants. 384-well optiplates
(PerkinElmer; 6007299) were usedwith 20l final volume in
each well. Hooking points of all the respective proteins were
determined. Reagents were used in the nanomolar range us-
ing the AlphaScreen His detection kit (PerkinElmer) in al-
pha buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 0.1%
BSA). Donor and acceptor beads were used at 10 g/ml as
their final concentration, proteins and constructs were ac-
cording to their hooking points and incubated for 1 hour at
room temperature. Plates were read for fluorescence signals
in an Enspire plate reader instrument (PerkinElmer; 2300-
001A), and specific binding was calculated by subtracting
the background, obtained in the absence of the protein.
For REMSA experiments, equimolar concentrations of pu-
rified RRMs and FAM-TNFRNAprobes were used (32) in
REMSA buffer (20 mM HEPES pH 7.5, 50 mM KCl, 0.5
g BSA, 0.25% glycerol) together with reference doses of
DHTS were run on the native Polyacrylamide (6%) gel, in
0.5× TBE buffer at 55 V for 90 min. The gel was analysed
by a Typhoon instrument (GEHealthcare; 00-4277-85 AC).
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R 1, R2 and NOE measurements
The experiments for the determination of 15N longitudi-
nal and transverse relaxation rates and 15N–1H NOE (44)
were recorded at 298 K and 700MHz on 15N-enriched sam-
ples of the RRM1–RRM2 tandem domains of HuR. 15N
Longitudinal relaxation rates (R1) were measured using a
sequence modified to remove cross-correlation effects dur-
ing the relaxation delay (45). Inversion recovery times rang-
ing between 2.0 and 2500 ms, with a recycle delay of 3.5
s, were used for the experiments. 15N transverse relaxation
rates (R2) were measured using a Carr-Purcell-Meiboom-
Gill (CPMG) sequence (45,46), with delays ranging between
8.5 and 237.4 ms and a refocusing delay of 450 s. Longi-
tudinal and transverse relaxation rates were determined by
fitting the cross-peak intensities as a function of the delay to
a single-exponential decay using the Origin software. Het-
eronuclear NOE values were obtained from the ratio of the
peak height for 1H-saturated and unsaturated spectra. The-
oretical predictions of NH R1 and R2 values for RRM1–
RRM2 tandem domains were made using HYDRONMR
(47) and the pdb structure 4ED5 (40), considering (i) the
isolated domains, (ii) the monomeric and (iii) the dimeric
constructs.
Molecular dynamics simulation and analysis
TheHuR-DHTS complex, as issuing from docking calcula-
tions (see SI for details), was submitted to MD simulation
with NAMD (48) using the ff99SBildn Amber force field
parameters (49,50) for proteins and the parameters recently
developed by Allne´r and co-workers for ions (51). Parame-
ters for DHTSwere generated in two steps. Initially, charges
were computed using the restrained electrostatic potential
(RESP) fitting procedure (52). The ESP was first calculated
by means of the Gaussian09 package (53) using a 6–31G*
basis set at Hartree-Fock level of theory, and then the RESP
charges were obtained by a two-stages fitting procedure us-
ing the program RED (54,55). Missing bond, angle, torsion
and improper torsion angle parameters were then generated
using Antechamber (56). The complex was then solvated in
a 15 A˚ layer cubic water box using the TIP3P water model
parameters. Neutrality was ensured by adding five further
Cl− ions. The final system size was∼74 A˚× 93 A˚× 74 A˚ for
a total number of atoms of∼48 000. A 10 A˚ cutoff (switched
at 8.0 A˚) was used for atom pair interactions. The long-
range electrostatic interactions were computed by means of
the particle mesh Ewald (PME) method using a 1.0 A˚ grid
spacing in periodic boundary conditions. The RATTLE al-
gorithm was applied to constrain bonds involving hydrogen
atoms, and thus a 2 fs integration time step could be used.
More details in the Supplementary Methods
RIP-chip protocol
To analyze the influence of DHTS on the interaction of
HuR with endogenous mRNAs, immunoprecipitation (IP)
of endogenous ribonucleoprotein complexes was performed
as described previously (57). Briefly, HeLa cells were lysed
in 20 mM Tris–HCl at pH 7.5, 100 mMKCl, 5 mMMgCl2,
and 0.5%NP-40 for 10 min on ice and centrifuged at 15 000
× g for 10 min at 4◦C. The supernatants were incubated for
2 h at 4◦Cwith protein G Sepharose beads (GEHealthcare)
coated either with anti-HuR or with control IgG antibod-
ies (both from Santa Cruz Biotechnology). The beads were
washed with NT2 buffer (50 mM Tris–HCl [pH 7.5], 150
mMNaCl, 1 mMMgCl2, 0.05% NP-40), followed by incu-
bation with 20 units of RNase-free DNase I for 15 min at
37◦C to remove the DNA. The samples were then incubated
for 15 min at 55◦C with 0.1% SDS–0.5 mg/ml proteinase
K to digest proteins. Microarray analysis was performed in
duplicate (GEO number GSE94360). The RNA from the
IP samples was extracted using phenol–chloroform, precipi-
tated, and used for cDNAmicroarray analysis or RT-qPCR
validation.
Analysis of enriched mRNAs
GC content, length and secondary structure density (com-
puted as the fraction of unpaired nucleotides) for the UTRs
of DEC and INC genes were obtained from the AURA 2
database (58), and plotted with the R software. The enrich-
ment of post-transcriptional regulatory elements was per-
formed with the Regulatory element enrichment feature of
AURA 2. Gene ontology and pathway enrichment analyses
were performed with the Enrichr tool (59) on GO (Biolog-
ical process, Molecular function and Cellular Component)
and pathways (KEGG and Reactome) libraries, using a five
genes overlap and minimum combined score of 2 as signifi-
cance threshold. GO terms were clustered by semantic sim-
ilarity with the GoSemSim R package (60), and the cluster
score computed as the average combined score of compos-
ing terms.
RESULTS
NMR resonance assignment
The 2D 1H–15N HSQC spectrum of tandem RRM1–
RRM2 domains shows well-dispersed signals in agreement
with a uniform and folded protein structure (Supplemen-
tary Figure S1). All the residues (but Pro172), including
those forming the linker region that is crucial for the pro-
tein function, have been assigned (Supplementary Table
S1, BMRB code: 27002). Our assignment of the tandem
RRM1–RRM2 domains was also compared with the ones
reported for the isolated RRM1 domain (61) as in the
RRM1–RRM2 tandem domains (35). The resonances of
residues forming the RRM1 domain are almost the same
in the isolated domain (61), and in the RRM1–RRM2 con-
struct. As reported by Wang and coworkers (35), this ob-
servation suggests that the RRM1 and RRM2 domains do
not interact with each other when they form the tandem
construct. Based on TALOS+ predictions, each domain in
theRRM1–RRM2 construct is constituted by two-helices
and four -strands, in agreement with the previously re-
ported crystal structures of the RRM1 and RRM1–RRM2
domains of HuR (39,40,62) (Supplementary Figure S2).
Internal dynamics of RRM1–RRM2 tandem domains
To characterize protein dynamics, measurements of longi-
tudinal (R1) and transverse (R2) relaxation rates of back-
bone amide nitrogens at 700 MHz, 1H Larmor frequency,
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and 298 K were performed on 15N-enriched samples of the
RRM1–RRM2 construct. Theoretical estimates of R1 and
R2 values were calculated for the following model struc-
tures: (i) the isolated RRM1 (T20-P98) and RRM2 (A106-
N186) domains (Figure 1D, panels 1, 2), (ii) the monomeric
RRM1–RRM2 construct (Figure 1D, panels 3, 4) and, (iii)
the dimeric adduct (Figure 1D, panels 5, 6) (PDB 4ED5).
Figure 1D shows the experimental R1 and R2 values (black
circles) as well as the theoretical ones (grey bars). The com-
parison of experimental R1 and R2 data with theoretical
values calculated for the isolated RRM1 and RRM2 do-
mains shows that experimental R1 values were smaller and
R2 values are larger than their theoretical counterparts (Fig-
ure 1D, panels 1, 2). At the same time, experimental R1 val-
ues were higher than theoretical estimates calculated for the
monomeric construct in solution (Figure 1D, panel 3), in-
dicating that the RRM1–RRM2 construct did not behave
as a rigid body but instead displayed inter-domain flexi-
bility, simulating a protein of lower molecular weight (63–
65). Experimental R2 values were instead slightly higher
than their theoretical counterparts, indicating the occur-
rence of possible aggregation phenomena (Figure 1D, panel
4). On the other hand, experimental R1 values were dra-
matically higher, and R2 dramatically lower than theoret-
ical values calculated for the rigid dimer (Figure 1D, panel
5, 6), suggesting that the RRM1–RRM2 dimer was not
present in solution as a stable complex. Further indication
of the presence of inter-domain flexibility was provided by
the 15N–1HNOE values for the linker residues Ser99 (0.46),
Ser100 (0.34), Glu101 (0.31), Val102 (0.30), Ile103 (0.32)
and Lys104 (0.40) (Figure 1D, panel 7). The small NOE val-
ues of the residues in the linker between the two domains
are evidence of fast motions on ps-ns timescale (faster than
the overall protein-tumbling rate). Very small NOE values
are found also for the N- and C-terminal tails, and for some
residues in the loops of RRM1 (Val56, Ala57, Gly58) and
RRM2 (Gln141, Thr142, Leu145) domains. The order pa-
rameter S2 calculated with the program TENSOR2 (66)
starting from experimental R1, R2 and NOE values is also
reported in Figure 1D, panel 8. The S2 values confirm the
presence of high flexibility between the two domains, and
for some loops within each domain.
DHTS stabilizes HuR in a closed conformation and competes
with mRNA for binding
The interaction of HuR with DHTS was investigated
through solution NMR. The significant precipitation of
the ligand in the solution, occurring at the high concen-
trations required by the NMR analysis, prevented the es-
timation of the affinity constant. Nevertheless, after the ad-
dition of increasing amounts of DHTS to the protein, we
observed a generalized decrease in signal intensity, with
few residues (Thr20, Asn21, Ile52, Ser94, Tyr95, Ala106,
Asn107, Leu108, Ile133, Asn134, Val137, Leu138, Arg147,
Ile152, Phe154, Asp155, Lys182) experiencing a larger ef-
fect. These residues were located in the -platform of both
RRMdomains (Figure 2A andB). The generalized decrease
of signal intensity, and the distribution of affected residues
over the large surfaces of the -platform in each domain
suggested an alteration of the equilibrium among ‘closed’
and ‘open’ conformations upon ligand binding. Specifically,
the decrease of signal intensity was consistent with a mech-
anism where the small molecule stabilizes a ‘closed’ confor-
mation of HuR. After the addition of DHTS to the protein,
only negligible chemical shift changes occur. The residues
experiencing the largest chemical shift perturbations are lo-
cated close to the -platforms (Supplementary Figure S3).
With the dual aim of bringing some insights into
DHTS binding mode and mechanism of action, we car-
ried out a molecular modeling study. We employed a ‘tan-
dem’ approach of docking calculations and molecular dy-
namics (MD) simulations in the attempt to follow the
protein/ligand reciprocal conformational mutations. We
first performed a docking calculation to the whole mRNA
binding surface of HuR by means of AutoDock 4.2, which
converged to a single binding pose. As a result, DHTS was
found at the center of the mRNA binding cleft, which is
shaped by the RRM1 and RRM2 domains (residues 18–95
and 107–185, respectively), and in proximity of the inter-
domain linker. To allow both the ligand and the protein
to fully adapt to each other, we performed an extended
(0.5-s) MD simulation. During the first 100 ns of simu-
lation, DHTS was displaced from its starting position later-
ally along the surface of the RRMdomain -sheets, though
always remaining bound to the HuR surface (Supplemen-
tary Figure S4A and B). This displacement was accompa-
nied by aHuR conformational shift towards a ‘closed’ form
featuring the two RRM domains even closer to each other
(SupplementaryFigure S4C), and establishing further inter-
residues contacts (Supplementary Figure S4D) lacking in
the mRNA-bound conformation, e.g. a salt bridge between
Asp-105 and Arg-153, a backbone hydrogen bond between
Ile-133 and Asn-25 or a hydrophobic contact between Ile-
133 and Ile-23. For the sake of comparison, a further 500
ns MD was performed, starting from the X-ray HuR-RNA
complex. The simulation resulted in an overall greater struc-
tural stability as compared to the HuR–DHTS complex
(Supplementary Figure S5A and B). Furthermore, we ob-
served neither a decrease in the distance between the two
RRM domains nor a significant increase in the number of
inter-domain residue contacts (Supplementary Figure S5C
and D).
In the final HuR–DHTS complex, which remained stable
for the rest of the simulation, DHTS is accommodated in
a narrow, elongated and mostly hydrophobic pocket (Fig-
ure 2C) shaped by residues of the two RRM domain -
sheets (RRM1:Ile-23, Asn-25, Tyr-26, Leu-61, Tyr-63, Phe-
65; RRM2: Asp-105, Ile-133, Asn-134, Arg-153) and of
inter-domain linker (Ile-103 side chain and Lys-104, Arg-97
and Ala-96). The aromatic rings of DHTS establish several
-interactions, among which a cation- interaction with
Arg-153 and a NH– interaction with the Asn-134 side
chain. However, although DHTS is gripped between the
two domains, it does not bind HuR rigidly, but rather gen-
tly sways along the binding surface (Figure 2D). Taken to-
gether, our structural data indicate that DHTS competes
with RNA for the binding to HuR, interacting with the -
platform of both RRM domains in the proximity of the in-
terdomain linker, and thus stabilizing HuR in a closed con-
formation.
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Figure 2. Graphical representation of the intensity changes per residues of RRM1–RRM2 HuR protein (50 M in solution) in the presence of DHTS
(200 M) (A) and surface representation of the closed conformation of HuR (pdb: 4ED5) (B) with the residues exhibiting the highest decreases in signal
intensities highlighted in red. (C) Global view of the HuR (green cartoons)-DHTS (orange spheres) complex. Note how the insertion of DHTS into the
mRNA binding cleft and the further closure of the latter, as compared to the mRNA-bound conformation (yellow), prevents the accommodation of the
mRNA strand (blue ribbons). (D) Theoretical DHTS binding mode, as suggested by our MD simulation. DHTS and HuR residues involved in binding
interactions are displayed as sticks.
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The -platforms of RRM domains are involved in DHTS in-
hibitory activity
To support NMR and molecular modeling that addressed
a specific interacting region on HuR, we produced HuR
protein domains made of the first RRM domain (RRM1),
of the second RRM domain (RRM2), of the RRM1–
RRM2 wild-type RRM domains, and of RRM1 lack-
ing 14 aminoacids at the C-terminus (RRM1, missing
residues from Ser94 to Asn107) and performed in vitro
RNA binding experiments. Some of these residues belong
to the inter-domain linker (Ser99–Asp105) and the others
to the -platform regions of the two domains, where some
aminoacids experienced decreased intensity in the presence
of DHTS (Ser94–Tyr95 in RRM1 and Ala106–Asn107 in
RRM2). HuR domains were produced in Escherichia coli
using the pET42 plasmid (31). We obtained the same purity
for all the protein isoforms (Supplementary Figure S6). As
single domains lose RNA-binding activity very quickly, the
in vitro activity of the single protein domains and of their
combination was evaluated by REMSA, mixing equimo-
lar concentration of each, freshly prepared, with 0.2 M
of the FAM-ARE ssRNA probe (Figure 3A). The RRM1–
RRM2 isoform was used as positive control because it dis-
played a similar Kd (2.62 ± 0.6 nM (31)) to the FL HuR
protein, and because it was used in the NMR experiments
(35). RRM1 retained the capability to recognize mRNA
substrates (40), however with a lower affinity compared to
the RRM1–RRM2 construct, probably indicating a change
in the stoichiometry of cooperative protein binding (Figure
3A, Supplementary Figure S7) (40,62).
Importantly, the RRM1–RNA complex was still sensi-
tive to DHTS. After removing 14 aminoacids, the binding
capacity of RRM1 to RNA was slightly reduced (∼20%)
in comparison with the RRM1 domain (Figure 3A). Con-
versely, RRM1 became resistant to DHTS, suggesting
that this region is important for DHTS inhibitory activ-
ity (Figure 3A). REMSA performed with RRM2 and in
vitro complementation of the two domains (RRM1 + M2
and RRM1 +M2) did not provide information about the
contact region of DHTS (Supplementary Figure S7B–D).
By using fluorescence polarization, we analyzed the bind-
ing kinetics of proteins (200 nM) toward the FAM–ARE
RNA probe (100 nM). We confirmed that full-length HuR
and RRM1–RRM2 tandem domains behave almost simi-
larly (average Kobs ∼4 min), reaching equilibrium after 10
min. On the other hand, the RRM1 domain rapidly rec-
ognized the substrate (Kobs ∼1 min), but this affinity was
significantly impaired in the RRM1 construct (Kobs of
∼8 min) (Figure 3B). Circular dichroism (CD) experiments
performed at 10 M concentration of both reagents, and
NMR measurements ruled out a putative interaction be-
tween DHTS and RNA (Supplementary Figure S8A and
B). Collectively, these findings show that the residues form-
ing the -platform and placed at the C-terminal in RRM1
domain are critical for RNA binding and the inhibitory ac-
tivity of DHTS.
Single point mutations in the HuR–DHTS interacting region
abolishes DHTS efficacy
Based on NMR data and an initial raw model of DHTS
binding as derived by docking calculations, residues Ser94,
Asn107, Ile133 and Asn134 of the RRM1–RRM2 inter-
domain region were mutated to probe their relevance for
DHTS binding.We produced residue-to-Alaninemutations
in the full-length HuR sequence by site-directed mutagen-
esis (67) (Supplementary Figure S9). The preservation of
the folding of the mutants was assessed by 1H 1D NMR
spectra (Supplementary Figure S10). By reacting equimolar
amount of wild-type HuR or muteins with 0.2 M FAM–
ssRNA, we observed an inhibitory effect of DHTS only
with wild-type HuR, while any functional single point mu-
tation led to resistance to DHTS (Figure 3C). Interestingly,
we observed a qualitatively distinct binding profile among
muteins: at least three discrete supershifts, numbered ac-
cording to the molecular weight (1 being the lightest, 2,
and 3), were detectable for wild-type HuR. Supershift 3 was
markedly enriched in N134A and N107A, and to a lesser
extent in I133A muteins (Figure 3C). This behavior could
result from a higher efficiency in recognition and dimeriza-
tion along the mRNA substrate, or alternatively from an
aggregation-prone tendency of muteins that therefore ag-
gregate on the same molecule of RNA probe. Indeed, mu-
tants showed significantly lower Kd values, i.e. an increased
affinity in saturation binding experiments with respect to
wild-typeHuR (Figure 3D, Supplementary Figures S11 and
S12). Additionally, the raw signals at the hook point val-
ues for protein and RNA probes were significantly reduced
in intensity compared to wild-type HuR, indicating a sub-
optimal assay environment, compatible with ligand self-
aggregation (68).
According to these data, when Ser94, Asn107, Ile133 and
Asn134 are mutated into Alanine, DHTS does not bind to
any mutein. The four residues are thus crucial in providing
the required flexibility to HuR for its mRNA binding func-
tion.
DHTS prevents HuR binding to low AU-rich density mRNA,
but enriches it to high AU-rich density species
We evaluated the ability of DHTS to disrupt the inter-
action of HuR with its target mRNAs by employing a
transcriptome-wide approach. We performed a RIP-chip
(ribonucleoprotein immunoprecipitation followed by mi-
croarray) experiment in HeLa cells, and observed that, out
of the 2306 mRNAs bound to HuR, DHTS only reduced
binding of 79 transcripts. Conversely, 558 mRNAs were en-
riched after treatment with DHTS. Therefore, contrary to
our expectations, we observed an overall enrichment ofmR-
NAs bound to HuR after treatment with DHTS. We rea-
soned that DHTS could displace mRNAs that had lower
affinity to HuR than DHTS itself had, and, paradoxically,
provide the opportunity for mRNAs with higher affinity
for HuR than DHTS to bind in higher copy numbers to
HuR.We observed that HuR-boundmRNAs had relatively
higher frequency of U/AU-rich segments compared to the
frequency transcriptome-wide, as expected (69). However,
the U/AU density in UTRs in enriched mRNAs was sig-
nificantly higher than that in downregulated mRNAs (Sup-
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Figure 3. The inter-domain region between RRM1 and RRM2 is crucial for RNA and DHTS binding. (A) On left, representative REMSAs of at least
three independent protein preparations of recombinant RRM1 + RRM2 (M1 +M2) domains, RRM1 (M1), RRM2 (M2), RRM1–RRM2 (M1M2) HuR
proteins. REMSAs were performed with 0.2 Mof protein, 0.2 Mof Cy-3 RNA probe and DMSO or DHTS at indicated doses. On right, representative
REMSA performed with 2.5 M of RRM1 and 75 fM of probe RNA titrated with DHTS (concentration as shown in the legend). Densitometric
quantification plotted below represents specific HuR–RNA binding challenged by DHTS. Mean ± SD refers to three independent experiments (n = 3,
* indicates t-test P-value < 0.05). (B) Kinetic saturation binding experiment by fluorescence polarization. 200 nM wild-type protein or mutants were
incubated with FAM-ARE RNA probe (100 nM). Full-length HuR and RRM1–RRM2 tandem domains (M1M2) have similar Kobs. RRM1 (M1) is
binding faster (Kobs of ∼1 min), ) but deletion of the inter-domain region abolishes the binding properties of RRM1 (M1) (Kobs of ∼8 min). (C) RNA-
and DHTS-interacting amino acids are crucial for DHTS and RNA binding, and for protein dimerization. Representative REMSAs of at least three
independent protein preparations of recombinant full-length HuR and indicated muteins. REMSAs were performed with 0.2 M of protein, 0.2 M of
Cy-3 RNA probe, and DMSO or 5 MDHTS.Muteins are insentive to DHTS and show different binding patterns to the RNA probe. (D) Representative
REMSAs of at least three independent protein purification performed with increasing concentration of WT and HuR single point mutant N134A with 75
fM of probe RNA.
plementary Table S2, median of 1.37 ARE nts/100 nts for
enriched genes, 0.97 for depleted genes; mean of 2.24 ARE
nts/100 nts for enriched genes, 1.49 for depleted genes; max-
imum of 81.97 ARE nts/100 nts for enriched genes, 7.92 for
depleted ones). Moreover, the highest differences were ob-
served in the 3′UTR (Figure 4A), where the percentage of
AU bases increased from 58% (depleted) to 65% (enriched).
Additionally, 3′UTRs, but not 5′UTRs, were significantly
longer for the enriched mRNAs (Figure 4B), while no dif-
ferences in the density of secondary structure elements were
observed (Figure 4C).
Functional analyses of depleted genes provided no con-
siderable enrichment, due to the small size of the set and
because it was partially composed of unannotated mRNAs.
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Figure 4. Enriched and depleted mRNAs and their UTRs have distinct properties. (A) Distribution of GC content for depleted (dec) and enriched (inc)
UTRs, with Wilcoxon test-P-values of the differences. (B) Length distribution for depleted (dec) and enriched (inc) UTRs, with Wilcoxon test-P-values
of the differences. (C) Secondary structure density (computed as the fraction of unpaired nucleotides) of depleted (dec) and enriched (inc) UTRs, with
Wilcoxon test-P-values of the differences. (D) Gene Ontology enrichment analysis for the enriched gene set. Number of genes belonging to each terms
cluster is shown at the end of the corresponding bar. Mean score represents the mean of the Enrichr combined score for all belonging terms. GO classes
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Enriched mRNAs (Figure 4D and E, Supplementary Ta-
ble S3) showed that, during DHTS treatment, HuR bound
preferentially to mRNAs encoding proteins with functions
in the regulation of gene expression, cell cycle progres-
sion, and apoptosis. Data validation also suggested that
the changes in HuR binding were independent of changes
in total mRNA levels, as mRNA abundance was generally
unchanged (Figure 4F and G). In summary, the ability of
DHTS to displace HuR-bound RNAs was specifically lim-
ited tomRNAswith a low affinity for HuR, which generally
displayed lower AU content in their 3′UTRs.
DHTS is effective on HuR-positive models in vitro and in vivo
To evaluate this mechanism of action, in which a lim-
ited displacement of RNAs from HuR may be effec-
tive in HuR-dependent tumor growth, we studied tumor
growth in vitro and in vivo. HCT116 colon cancer cells
were used as a model, based on high endogenous lev-
els of HuR and their sensitivity to HuR inhibition (30).
Creation and characterization of CRISPR/Cas9-mediated
knockout of the ELAVL1 gene in HCT116 cells was ac-
complished as described (42). HCT116 and HuR-knockout
cells (HCT116HuR) were grown under anchorage- and
serum-independent conditions to facilitate tumorspheroid
growth, and HuR was observed to be needed for tumor-
sphere growth (Figure 5A and B). In the presence of
DHTS, growth of HCT116 spheroids was attenuated 2-
fold, whereas DHTS did not impact HCT116HuR sphere
growth (Figure 5A and B). To test the effects of DHTS on
tumor growth in vivo, mice bearing HCT116 cell xenografts
received IP injections of DHTS (10 mg/kg body weight)
or vehicle every 48 h. Over the course of the experiment,
DHTSwas well tolerated andmice did not display any signs
of acute toxicity and maintained similar weights. Signifi-
cant anti-tumor effects of DHTS were observed, with ap-
proximately a 4-fold reduction in tumor size (Figure 5C
and D). Additionally, the efficacy of DHTS was strictly
dependent on the presence of HuR. HCT116HuR cells
grew significantly more slowly and formed smaller tu-
mors, but were completely insensitive to DHTS. Further-
more, this decreased growth sensitivity of DHTS in HuR-
deficient cells could be restored with expression of HuR
in HCT116HuR cells (Figure 5E and F). These results
indicate that DHTS has significant antitumor activity in
vitro and in vivowithout major systemic toxicity, along with
demonstrating specificity of HuR inhibition.
DISCUSSION
Previous efforts targeted towards HuR disruptors (28–
30,32,70) identified small molecules that can inhibit the
HuR–RNA interaction in the nanomolar range. Here, we
have characterized from a structural and functional per-
spective the mechanism of action of DHTS, a disruptor of
the HuR–RNA interaction, identifying the protein regions
that promote the interaction, and providing hints for the
rational design of more potent HuR inhibitors. Addition-
ally, we showed the cellular effects of DHTS treatment on
HuR ability to bind mRNAs, and we described a paradox-
ical enrichment of mRNAs containing longer 3′UTRs with
increased AU content. Such effects result in dysregulation
of HuR function, specific to cells that are strictly depen-
dent on HuR function. Starting from the relaxation mea-
surements of RNA-free protein in solution, we described
the events preceding RNA binding. The analysis of NMR
relaxation data indicates that the free RRM1–RRM2 con-
struct is largely monomeric in solution. However, the ob-
served R2 values are slightly higher than those expected for
a monomeric protein, suggesting the presence of an equi-
librium with a fraction of protein experiencing a larger ro-
tational correlation time. On the other hand, the discrep-
ancy of observedR1 data with respect to the theoretical val-
ues calculated for a rigid RRM1–RRM2 monomer are ex-
plained by the presence of inter-domain flexibility. The low
NOE values suggest a significant conformational plasticity
of the protein that is needed for mRNA binding. Therefore,
even if it is reported that the RRM1–RRM2 tandem con-
struct forms a separated functional unit from the RRM3
domain (71), RRM1 and RRM2 domains are not rigidly
held together but undergo independent motions that can fa-
cilitate the recognition of the RNA partner. This confirms
observations from the crystal structure of non-complexed
HuR, where no contacts between the two domains were de-
tected (40,62) and supports earlier results that phosphory-
lation at the linker (e.g. Ser100) had a profound impact on
HuR binding to target mRNAs (72). Moreover, the large
R1 values and small NOE values seen for the linker indicate
that this region highly influences the conformational change
of the protein from an open/flexible free conformation to-
wards a closed one bound to mRNA.
As previously reported (40), binding of mRNA to HuR
can occur starting from the open/flexible state of the pro-
tein, whereHuRfirst binds themRNA strand via its RRM1
domain. As a result of the subsequent conformational
change, the linker and the RRM2 domain bind the mRNA
filament to form a stable complex (40). Therefore, the linker
takes part in the binding allowing the reciprocal reorienta-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
found in each cluster are represented by the bars color. (E) KEGG and REACTOME pathway enrichment analysis for the enriched gene set. Number of
genes belonging to each pathway is shown at the end of the corresponding bar. The score is the Enrichr combined score for the pathway. Pathway database
of each entry is represented by the bars color. RIP of HuR in DHTS-treated HeLa cells. (F) Microarray data for selected targets. Fold enrichment of each
mRNA during DHTS treatment is reported, black bars represent microarray values obtained. (G) Validation of microarray data by RT-qPCR. Gray bars
represent fold enrichment of each mRNA during DHTS treatment compared with the control condition (DMSO). Comparison between microarray (F)
and RT-qPCR data (G) shows similar results for enriched transcripts (PABPC1, YTHDF1 and UPF2 mRNAs), unchanged transcripts (CASC3 mRNA)
and depleted transcripts (BRIP1 and TBCCD1mRNAs). In RT-qPCR validation experiments,RPLP0mRNAwas used as an endogenous control mRNA
that did not bind to HuR. Error bars represent SD. P-value is *<0.05. **<0.001. Mirocrarray experiments were done in duplicate (n = 2), qRT-PCR in
triplicate (n= 3). (H) RT-qPCR analysis of mRNAs bound to of HuR showing no changes in total expression levels after DHTS treatment.RPLP0mRNA
was used as an endogenous control. Error bars represent SD. Experiments were done in triplicate (n = 3).
Downloaded from https://academic.oup.com/nar/article-abstract/45/16/9514/3978036/Regulation-of-HuR-structure-and-function-by
by Universita di Trento - Biblioteca user
on 28 September 2017
9524 Nucleic Acids Research, 2017, Vol. 45, No. 16
Figure 5. DHTS efficacy relies on HuR presence in vivo. (A) Spheroid growth of parental HCT116 (HCT116) and HuR-knockout cells (HCT116HuR)
treated with DHTS (10 M) or vehicle. DHTS was added after 3 days of culture in spheroid growth medium on ultra-low adherence substrate and spheroid
growth was tracked by imaging for 15 days. P-value is **<0.01, ***<0.001, n.s. = not significant. (B) Representative tumorsphere images from day 0 and
day 15 of DHTS treatment. Scale bar = 100 m. (C) Tumor growth of parental HCT116 and HuR-knockout cells (HCT116HuR) xenografts in nude
mice treated with 10 mg/kg DHTS or vehicle control every 48 h. P-value is ***<0.001, n.s. = not significant. (D) Representative tumors excised at day 31
are shown. (E) HuR-knockout cells (HCT116HuR) were transfected a HuR-expression construct (+HuR), along with empty vector transfected parental
HCT116 and HCT116HuR cells. Cells were treated with DHTS (10 M) or vehicle, and cell growth was assessed 6 days after the treatment using MTT
assay. Cell survival was normalized to the respective control and are the average of three experiments. P-value is **<0.01, ***<0.001. (F) Western blot
showing HuR complementation in HCT116HuR+HuR cells and absence of HuR in HCT116HuR cells. Actin was used as a loading control.
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tion of the two domains and establishing interactions with
the RNA strand. Addition of DHTS to unbound HuR re-
sults in a generalized decrease of the signal intensity of the
NMR resonances, with some residues experiencing larger
effects. It is likely that this behavior is due, at least in part,
to a change in the conformational dynamics of the protein.
Accordingly, upon complex formation with DHTS, in our
MD simulation we observed a rather limited inter-domain
flexibility, as a result of the shift in the conformational equi-
librium between HuR forms in favor of a closed conforma-
tion. This result was not anticipated since, at least in princi-
ple, a change in the conformational dynamics of HuR could
also have been achieved by stabilizing an open formofHuR.
Indeed, residues located on the -platforms of RRM1 and
RRM2domains, in the same regions involved in the binding
with the mRNA strand, experience a deep quenching.
In our MD simulation, we observed a further closure
of the RNA-binding groove, as compared to the RNA-
bound conformation of HuR, and an ensuing increase in
the number of inter-domain contacts, which could explain
why the largest decreases in signal intensity were observed
in residues belonging to these -platforms. Deletion of the
C-terminus region of RRM1 reduces the binding affinity
of RRM1 to the mRNA probe but, importantly, abolishes
the interaction between RRM1 and DHTS. This experi-
mental validation of the NMR data and molecular mod-
eling points to the residues next to the linker as being key
structural elements responsible of the interaction between
DHTS and HuR. Single aminoacid mutagenesis of Ser94,
Asn107, Ile133, and Asn134 into alanine highlighted the
importance of these residues in maintaining the equilib-
rium between the free protein in the monomer/dimer form
and the closed-bound-to-RNA protein dimer, avoiding its
aggregation on the RNA target. Interestingly, muteins are
fully resistant to DHTS, further supporting that this small
molecule competes for the same protein regions interact-
ing with the target RNA. Collectively, these results suggest
that DHTS stabilizes an unproductive ‘closed’ conforma-
tion of HuR and prevents the physiological re-orientation
of the two domains needed to bind the target mRNA. Sta-
bilization of such ‘closed’ conformation alters the protein
dynamics, producing the observed generalized decrease of
signal intensity of the resonances observed upon the addi-
tion of DHTS to the RRM1–RRM2 tandem domains. Un-
fortunately, the non-optimal solubility of DHTS hampered
the quantitative assessment of its Kd.
In other experiments, we characterized the ability of
DHTS to inhibit HuR activity in vitro, to modulate its
post-transcriptional function in cell models, and its speci-
ficity towards other RNA-binding proteins. Additionally,
we observed that DHTS inhibits the association step of
HuR to its target RNAs, and that its cytotoxicity against
cancer cells was HuR-dependent (31). The stable ‘closed’
form of the protein blocks the access to HuR for low affin-
ity target RNAs. Indeed, paradoxically, the mRNAs with
longer 3′UTR and higher U/AU content were more abun-
dantly loaded onHuR after DHTS treatment, as they likely
bind more avidly to HuR than DHTS itself. The levels of
HuR-target RNAs were not changed during DHTS treat-
ment, so a ‘post-binding’ mechanism of regulation can
be inferred. Nevertheless, DHTS-dependent HuR dysreg-
ulation has a strong anti-cancer activity in vivo, as ob-
served using a xenograft model of colon cancer (HCT116
cells). These findings are consistent with other results us-
ing colon, leukemia, cervical, and breast cancer cells, and
indicate that DHTS can penetrate tumors effectively (73–
76). The absence of systemic toxicity in treated animals
supports the idea that general inhibition of HuR by small
molecules can be a therapeutic avenue for future efforts, al-
though the effects on the immune system should be eval-
uated in a non-immuno-compromised mouse model. No-
tably, HCT116HuR knockout cells in vivo showed a lim-
ited ability to develop tumors, but the extent of DHTS
growth inhibition on these tumors did not match the effects
on WT tumors. While we cannot discount that loss of HuR
may impact cancer cell drug uptake, these results indicate in
vivo specificity of DHTS and support the view that DHTS
requires HuR for its antitumor influence. Finally, experi-
mental and theoretical studies here reported suggest that the
mechanism of action of DHTS is that of a competitive in-
hibitor of mRNA binding to HuR. These observations will
be the ground for a rational design and synthesis of more
potent small-molecule HuR disruptors.
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Dihydrotanshinone-I interferes 
with the RNA-binding activity 
of HuR affecting its post-
transcriptional function
Vito Giuseppe D’Agostino1, Preet Lal1, Barbara Mantelli1, Christopher Tiedje2, 
Chiara Zucal1, Natthakan Thongon1, Matthias Gaestel2, Elisa Latorre1, Luciana Marinelli3, 
Pierfausto Seneci4, Marialaura Amadio5 & Alessandro Provenzani1
Post-transcriptional regulation is an essential determinant of gene expression programs in 
physiological and pathological conditions. HuR is a RNA-binding protein that orchestrates 
the stabilization and translation of mRNAs, critical in inflammation and tumor progression, 
including tumor necrosis factor-alpha (TNF). We identified the low molecular weight compound 
15,16-dihydrotanshinone-I (DHTS), well known in traditional Chinese medicine practice, through 
a validated high throughput screening on a set of anti-inflammatory agents for its ability to 
prevent HuR:RNA complex formation. We found that DHTS interferes with the association step 
between HuR and the RNA with an equilibrium dissociation constant in the nanomolar range in 
vitro (Ki = 3.74 ± 1.63 nM). In breast cancer cell lines, short term exposure to DHTS influences 
mRNA stability and translational efficiency of TNF in a HuR-dependent manner and also other 
functional readouts of its post-transcriptional control, such as the stability of selected pre-mRNAs. 
Importantly, we show that migration and sensitivity of breast cancer cells to DHTS are modulated 
by HuR expression, indicating that HuR is among the preferential intracellular targets of DHTS. 
Here, we disclose a previously unrecognized molecular mechanism exerted by DHTS, opening new 
perspectives to therapeutically target the HuR mediated, post-transcriptional control in inflammation 
and cancer cells.
Post-transcriptional control of messenger RNA, coordinated by RNA-binding proteins (RBPs) and small 
or long non-coding RNAs, is an essential determinant of protein expression. Altered mRNA stability of 
pro-inflammatory cytokines tightly correlates with several pathological conditions such as inflammation, 
autoimmune disorders and cancer1. A prominent example of cytokine subjected to post-transcriptional 
control is tumor necrosis factor alpha (TNF-alpha or TNF), one of the main mediators of chronic 
inflammation associated with malignant cell transformation, growth and tumor progression2. Depletion 
of several RBPs can alter TNF protein production, leading to exacerbated chronic inflammatory dis-
ease both in mice and in humans3, supporting the relevance of in vivo post-transcriptional control on 
TNF mRNA. The half-life of this transcript is influenced by competitive binding of RBPs to adenylate- 
and uridinylate-rich elements (AU-rich elements or AREs) and by a constitutive decay element (CDE) 
in its 3′ -untranslated region (UTR)4,5. Notably, it has been shown that the stability and translational 
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efficiency of TNF mRNA is dependent on the p38 MAPK pathway, whose activation modulates the 
cytoplasmic equilibrium of tristetraprolin (TTP or Zfp36) and HuR/ELAVL1 proteins6. Whilst TTP is an 
anti-inflammatory RBP favoring rapid mRNA degradation, HuR stabilizes transcripts and promotes their 
poly-ribosomes engagement for active translation. This post-transcriptional function of HuR has been 
described for a wide number of transcripts bearing AU-rich elements, whose turnover is critical for cell 
proliferation, tumor cell survival, angiogenesis and metastasis7–10. Sporadically, anti-inflammatory agents 
have been reported to post-transcriptionally modulate cytokines, including TNF, with a variable involve-
ment of the p38 MAPK pathway, as in the case of KL-103711, s-curvularin12, LCY-2-CHO13. However, the 
direct and specific modulation of defined trans-acting factors has remained elusive. On the other side, 
systematic investigations, based on the direct evaluation of a post-transcriptional read-out have shown 
the feasibility of considering RBPs as potential drug targets14–16. Interestingly, resveratrol was found to 
suppress activation-induced gene expression in T-cell via a post-transcriptional mechanism and its effects 
were rescued by the RBP HuR. The same molecule was found to exert its post-transcriptional effects 
by regulating the RBP KSRP, suggesting that resveratrol changes the mRNA stability of HuR-targeted 
transcripts by enhancing the 3′ -UTR binding of KSRP and replacing HuR from the same 3′ -UTR 
sequences16. Here we demonstrate that 15,16-dihydrotanshinone-I (DHTS), identified through a bio-
chemical high-throughput screening among a set of anti-inflammatory agents, inhibits the HuR-RNA 
complex formation in vitro in low nanomolar range. DHTS belongs to the bioactive family of diterpenic 
tanshinones, extracted from the roots of Salvia miltiorrhiza and well-known in traditional Chinese med-
icine practice. Tanshinones are anti-inflammatory agents used for treatment of cardiovascular diseases17 
and during the last years they have been proposed as anti-cancer agents due their anti-proliferative, 
anti-angiogenic and pro-apoptotic activities against a broad spectrum of tumors18,19. We provide evi-
dences that interference of DHTS on HuR activity determines a post-transcriptional influence of TNF 
mRNA processing, showing a previously unrecognized molecular mechanism for this class of small mol-
ecules. In addition, we show that cytotoxicity and migration properties of breast cancer cell lines treated 
with DHTS are influenced by HuR dosage, supporting the post-transcriptional effect of this compound 
as a new, therapeutically relevant molecular mechanism.
Results
15,16-Dihydrotanshinone I (DHTS) interferes with HuR-RNA interaction in vitro. The mRNA 
stabilizing effects of HuR have been frequently investigated by studying the post-transcriptional control 
of key pro-inflammatory genes like COX-2, TNF or specific cytokines such as IL1720–22. We hypothe-
sized that anti-inflammatory small molecules could integrate a post-transcriptional layer of influence on 
mRNAs, in their mechanism of action, by interfering with HuR function. By using a previously validated 
biochemical approach23 involving the 3′ UTR ARE of TNF as RNA probe and a recombinant human HuR 
protein, we screened a set of commercially available anti-inflammatory compounds (a total of 107 listed 
in Supplementary Table S1) for their ability to prevent the rHuR-RNA complex formation. Eight posi-
tive hits were obtained (DHTS, hydrocortisone acetate, amiprilose, flurbiprofen, deracoxib, fluocinolone, 
triamcinolone, dexamethasone). The most potent hit, DHTS (CHEMBL227075 ID in ChEMBL database, 
Z-Score = − 2.69, Fig.  1A and Supplementary Table S1), among the other compounds, confirmed this 
inhibitory activity in RNA electrophoresis mobility shift assays. DHTS did not alter the electrophoretic 
mobility or the stability of the RNA probe even when a 200 fold molar excess (100 μ M) was used in the 
assay (Fig. 1B and Supplementary Fig. S1A), behaving as a validated hit. Saturation binding competitive 
experiments at equilibrium, either by REMSA (Fig.  1C) or AlphaScreen assays (Fig.  1D), indicated an 
equilibrium dissociation constant for DHTS (Ki) of 3.74 ± 1.63 nM, using a Kd equal to 2.5 nM23, and 
IC50 equaling 149 ± 34 nM and 68 ± 16 nM for REMSA or AlphaScreen assays, respectively and accord-
ing to the different concentration of the reagents used. The range of Ki values was also confirmed by 
competitive binding kinetics experiments (Fig.  1E), that revealed an association rate constant (k3) of 
5.38 ± 1.64*106 M−1 min−1 and a dissociation rate constant (k4) of 0.016 ± 0.01 min–1 for DHTS (k4/
k3 = 2.97 ± 0.7 nM). From these data, representing the law of mass action parameters of DHTS, it can 
be inferred that DHTS has a much higher probability to associate with one or both the free ligands, 
rather than to displace a pre-formed protein-RNA complex. Consistently, binding kinetic experiments 
performed either upon pre-incubation of rHuR with different concentrations of DHTS (Fig.  1F), or 
upon pre-incubation of protein and RNA (Fig. 1G), provided evidence that DHTS mainly prevents the 
association between the two ligands. Since the recognition of RNA substrate is determined by the RNA 
recognition domains (RRMs) of HuR, we purified two recombinant HuR isoforms (Supplementary Fig. 
S1B) retaining two different arrangements of RRMs, as depicted in Fig. 2A. As RRM1 and RRM2 are the 
rate-limiting domains for HuR binding activity24, the M1_M2 construct was expected to best recapitulate 
the ability of full-length HuR to bind to RNA, and to be the best target for DHTS. Accordingly, at equilib-
rium, M1_M2 isoform showed a Kd value (2.66 nM) similar to full-lenght HuR. DHTS similarly inhibited 
the M1_M2-RNA complex formation (Ki = 4.12 ± 0.81 nM). Notably, the M2_M3 construct expressed a 
labile protein characterized by higher Kd value (~24 nM) and only limited effects of DHTS were observed. 
In addition, we purified each single RRM domain (M1, M2, M3) from E. coli cells (Supplementary Fig. 
S1C) and analyzed their binding to the RNA probe in the presence of DHTS. The binding of M2 and M3 
was not affected even using 10 μ M of DHTS, while M1 was only marginally affected, being 74% of the 
protein still binding RNA with 5 μ M of DHTS (Supplementary Fig. S1C). Taken together, these results 
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suggest that the compound interferes with RNA binding by affecting a different site from the domain of 
RNA recognition. A putative explanation could reside in the interference by DHTS with the allosteric 
conformational changes of the first two RRMs, disturbing the additional contacts formed with the 
inter-domain linker region during RNA binding24. The in vitro activity of three commercially available 
members of the tanshinone family of compounds was evaluated in our biochemical model. Each tested 
tanshinone showed inhibitory activity (Supplementary Fig. S1D). However, while cryptotanshinone and 
tanshinone IIA were less potent (micromolar range), the potency of tanshinone I was comparable to 
DHTS at equilibrium (Fig. 2B). This indicates how this kind of interference requires either an aromatic 
furan ring (as in tanshinone I), or a reduced dihydrofuran (as in DHTS) on the right portion of the mol-
ecule. Conversely, the left side of tanshinones must contain a planar, aromatic methyl-substituted ring 
(as in DHTS and tanshinone I), rather than a non-planar, dimethyl-substituted cyclohexene ring (as in 
cryptotanshinone and tanshinone IIA). As tanshinone I is poorly soluble in buffers of biochemical assays 
(producing visible precipitates at the highest doses), we used DHTS as reference compound/inhibitor to 
exploit this bioactivity for further experiments.
Albeit the selective profile of DHTS and tanshinones has to be systematically characterized, we 
selected four other RBPs, i.e. Lin28b, TTP, TDP-43 and ELAVL4/HuD, with different structural simi-
larity compared with HuR and tested DHTS as a modulator of their specific protein-RNA interactions 
(Fig.  2C). As expected considering the 78% structural similarity with HuR, only HuD-RNA complex 
formation was affected by DHTS at the reference doses. Conversely, the binding of Lin28b, TTP, and 
TDP-43 to RNA did not appear substantially affected. Taken together, these biochemical data allowed to 
quantitatively determine the DHTS-mediated inhibition of the HuR-RNA complex formation in vitro, 
the highest potency of DHTS among the tested analogs and its selective profile towards other RBPs. 
Then, we decided to deeply investigate the post-transcriptional role of DHTS in a panel of breast cancer 
cell lines, characterized by HuR over-expression25.
DHTS down-regulates TNF mRNA and protein levels. Viability assays measuring intracellular 
ATP levels in different breast cancer cell lines (MCF-7, MDA-MB-231 and SKBR3), showed that about 
50% of cells were not viable after 24 h treatment with 1 μ M DHTS (MCF-7, IC50 = 0.84 μ M, Fig.  3A; 
MDA-MB-231, IC50 = 0.92 μ M, and SKBR3, IC50 = 1.2 μ M, graphs not shown). In MCF-7 cells, caspase 
activation was clearly visible after 24 h of treatment using as low as 0.5 μ M of DHTS. Conversely, at an 
Figure 1. DHTS is an inhibitor of the rHuR-RNA interaction. (A) AlphaScreen HTS carried out using 
1 nM of rHuR, 50 nM of BiTNF RNA probe and 50 nM of 107 anti-inflammatory compounds (see Table S1). 
(B) Representative REMSA performed with 0.5 μ M of rHuR and 0.5 μ M of Cy-3 RNA probe at equilibrium, 
showing the inhibitory activity of DHTS and its un-efficacy to electrophoretic mobility of the free RNA 
even at 100 μ M. (C) Saturation binding by REMSA or (D) by AlphaScreen assays evaluating DHTS activity 
in low micromolar or nanomolar range, respectively. (E) Kinetic experiments showing association (k3) and 
dissociation (k4) rate constants of DHTS. (F) Kinetic experiments performed upon pre-incubation of 1 nM 
of rHuR with different concentrations of DHTS before addition of 50 nM of BiTNF probe. (G) Dissociation 
experiments performed upon 30 min pre-incubation of 1 nM of rHuR and 50 nM of RNA (Ligands), or 
30 min pre-incubation of Ligands+beads, before addition of DHTS. Mean ± SD refers to three independent 
experiments (n = 3).
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earlier time point (3 h), no caspase activation was observed with 1 μ M of DHTS (Fig. 3B) and total RNA 
was actively transcribed (Fig. 3C and Supplementary Fig. S2A). Therefore, we used 1 μ M DHTS treatment 
at 3 h as reference condition to further characterize the impact of DHTS on HuR activity, and to reason-
ably exclude the induction of dramatic molecular events associated with cytotoxicity of the compound. 
DHTS alone or in combination with 3 h LPS stimulation (100 ng/ml) reduced TNF levels in stimulated 
Figure 2. DHTS inhibits HuR’s first RRMs and is not effective against other RBPs, HuD excluded; 
in vitro activity of other tanshinones. (A) Representative gels of at least three independent protein 
preparations of recombinant M1_M2 and M2_M3 HuR proteins. REMSAs were performed with 0.5 μ M of 
protein, 0.5 μ M of Cy-3 RNA probe and DMSO or DHTS at indicated doses. (B) Quantification of specific 
HuR-RNA binding challenged by indicated concentrations of commercially available tanshinones, including 
cryptotanshinone; TanI and TanII that were not included in the first screening. (C) Evaluation of DHTS 
activity at the indicated concentrations against Lin28b, TTP, HuD, and TDP-43 RNA-binding proteins tested 
by REMSA with 0.5 μ M of Cy-3 RNA as indicated in methods. Mean ± SD refers to three independent 
experiments (n = 3).
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mouse RAW264.7 cell line (Supplementary Fig. S2B)26. Since chronic production of TNF influences the 
phenotype of breast cancer cells by inducing secondary cytokines production and by impacting their 
growth and metastatic potential27, we studied the effect of DHTS on the regulation of TNF in human 
breast cancer cell lines. Exposure of breast cancer cells to 1 μ M of DHTS for 3 h significantly reduced 
total TNF mRNA levels to ≈ 40% (P < 0.05) of the control levels (Fig. 3D and Supplementary Fig. S2C). 
Treatment with 1 μ g/ml of LPS to MCF-7 (TLR4 positive) enhanced the TNF mRNA levels (P < 0.01), 
while treatment with DHTS counteracted the LPS-induced up-regulation (P < 0.001) (Fig. 3D). MCF-7 
cells expressed almost undetectable levels of TNF protein, and the endogenous (pro-TNF) protein could 
not be detected by immunoblotting in standard conditions. However, massive stimulation of pro-TNF 
production via exposure of MCF-7 cells to E. coli cells, and subsequent administration of DHTS, 
showed the efficacy of the compound in attenuating the production of pro-TNF (Supplementary Fig. 
S2D). Similarly, endogenous secreted TNF (sTNF, Fig. 3E) was hardly detectable under basal conditions, 
but protein level increased after LPS treatment and decreased markedly after 3 h treatment by DHTS 
(P < 0.01). These data show that DHTS first reduces the TNF mRNA expression level, and subsequently 
Figure 3. DHTS toxicity and inhibition of TNF in MCF-7 cells. (A) CellTiter-Glo assays upon exposure  
of MCF-7 cells to DHTS for 24 h. Relative IC50 was calculated by nonlinear regression curve fitting.  
(B) Apoptosis evaluation by 3/7 Caspase-Glo luminescent assays (Promega) and normalization to trypan 
blu negative cells (n = 3). (C) High content imaging quantification of fluorescence intensity/cell population 
of EU-conjugated Alexa-488 after 3 h treatment of MCF-7 cells with 1 μ M of DHTS or 2 μ M of actinomycin 
D. (D) Q-RT-PCR of TNF mRNA levels. Relative abundance was normalized with GAPDH mRNA in 
MCF-7 cells. (E) ELISA measuring secreted TNF protein levels. We detected in Mock condition an average 
of 15 pg/ml of sTNF as obtained by titration with standards. Where not indicated, mean ± SD refers to four 
independent experiments (n = 4).
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the translation and secretion of the encoded protein, confirming the anti-inflammatory properties of the 
compound in these cellular models.
DHTS inhibits post-transcriptional effects of HuR in MCF-7 cells. To test whether DHTS influ-
ences the post-transcriptional control of TNF mRNA mediated by HuR we performed ribonucleoproteic 
immunoprecipitation (RIP) analyses. DHTS reduced the number of copies of TNF mRNA selectively 
bound by HuR in MCF-7 cells (Fig. 4A). The strong enrichment observed in LPS-stimulated cell extracts 
confirmed the functional role of HuR in the post-transcriptional control of TNF in human cancer cells 
(P < 0.001). Notably, this effect is not specific for TNF mRNA, since RIP analysis on other HuR reg-
ulated transcript demonstrated that the copy number of ERBB2, VEGF, and CCND1 mRNAs bound 
by HuR in the presence of DHTS is, with different extent, significantly less with respect to the con-
trol (Supplementary Fig. S3A). RNA pull-down experiments in lysates from DHTS-treated MCF-7 cells 
confirmed the inhibition of the association step leading to the HuR:RNA complex formation (Fig. 4B), 
being the differences of precipitated HuR protein in DHTS treated cells statistically significant (P < 0.05) 
comparing DHTS vs Mock using the biotinylated probe. The same trend was observed for DHTS+LPS vs 
LPS condition, although with a non-significant effect in these experiments. Another ARE-binding RBP, 
hnRNP-D/AUF1, also displayed differential RNA-binding activity, however we observed these differences 
exclusively upon stimulation with LPS. To understand whether DHTS influences the stability of TNF 
mRNA in a HuR-dependent manner, we used both a stable HuR-silenced MCF-7 clone (siHuR) and 
transiently HuR over-expressing MCF-7 (HuROE) cells in actinomycin D chase experiments (Fig. 4C). 
The expression level of HuR positively correlated with the relative abundance of total TNF mRNA in 
MCF-7 cells, upon simultaneous transcriptional block. Interestingly, DHTS significantly reduced TNF 
mRNA stability compared with mock cells (P < 0.01 at 60 min time point), and caused a slightly addi-
tive effect in siHuR cells. On the contrary, DHTS displayed less efficacy in HuROE cells, suggesting 
that HuR expression is able to counteract the destabilizing effect of DHTS on mature TNF mRNA. To 
better understand these functional relationships, we evaluated the stability of nuclear immature (pre-) 
TNF transcripts, confirming, although with different kinetics, the HuR-dependency of mRNA stability 
and the same effects induced by DHTS on mature RNA transcripts; Similar effects were not observed 
for GAPDH mRNA under the same experimental conditions (Fig.  4C). Given the emerging evidences 
regarding HuR functionality in pre-mRNA processing events28, candidate HuR pre-mRNA targets were 
chosen according to Mukherjee et al.28, and CD14 was chosen as a negative control lacking AREs14. The 
mRNA stability of individual mRNAs, in actinomycin D chase experiment at single time point, was 
differently regulated by HuR expression and, except for pre-CTCF mRNA, HuR silencing caused a reduc-
tion of pre-BRCA1, pre-MDM2, pre-MYBL2 and pre-NFATC3 mRNA stability (Supplementary Fig. S3B, 
compare bar 1 and 3), in agreement with reported data28. To a different extent, DHTS diminished the 
stability of all the pre-mRNAs except the non-target, ARE-lacking, CD14 pre-mRNA (Supplementary 
Fig. S3B, compare bars 1 to 2). The compound exhibited further destabilization of pre-mRNAs in HuR 
depleted cells (siHuR), with the exception of pre-NFATC3 mRNA (Supplementary Fig. S3B, compare 
bars 3 to 4 and 5 to 6). Strikingly, over-expression of HuR in HuROE cells rescued the destabiliza-
tion effect of DHTS to control levels (Supplementary Fig. S3B, compare bars 7 and 8), supporting the 
idea that HuR RNA-binding activity is a target of DHTS, and that this compound early impacts this 
post-transcriptional modulation.
DHTS reduces polysomal recruitment of cytoplasmic TNF mRNA. To evaluate if DHTS modi-
fies the recruitment of TNF mRNA to the translational machinery, we performed nuclear and cytoplas-
mic RNA purifications from MCF-7 cells treated with DHTS and/or LPS, respectively, and evaluated 
TNF mRNA levels by real-time PCR (Fig. 5A). Nuclear levels of the transcript were significantly reduced 
by DHTS both in case-control and in LPS-treated cells (of ~55% and ~31%, P < 0.001 and P < 0.05, 
respectively). The relative amount of cytoplasmic TNF mRNA was unchanged in DHTS-treated versus 
control cells, but was significantly reduced by DHTS treatment (~44%, P < 0.01) in LPS-stimulated cells. 
Therefore, DHTS down-regulated nuclear TNF mRNA and reduced cytoplasmic TNF mRNA only after 
LPS stimulation.
To functionally investigate the translational efficiency of TNF mRNA, we performed sucrose-gradient 
fractionations of cytoplasmic sub-polysomal (representative of non-translating monosomes) and poly-
somal RNAs (representative of actively translating poly-ribosomes). DHTS treatment was performed 
on MCF-7 cells as such (Fig. 5B), and on LPS-treated MCF-7 and RAW264.7 cells (Supplementary Fig. 
S4A, S4B, S4C). Overall polysomal profiles showed no qualitative differences between the conditions 
analyzed, but the distribution analysis of single mRNAs, i.e. GAPDH and TNF (Fig. 5C) demonstrated 
that treatment with DHTS clearly reduced the polysomal loading of TNF mRNA paralleled by an 
increased amount in the sub-polysomal fractions. These data are also supported by the quantification of 
the TNF mRNA in collected sub-polysomal (fraction 1 to 6) and polysomal (fraction 7 to 12) compart-
ments (Supplementary Fig. S4B). Notably, the effect of DHTS on poly/sub ratios increased significantly 
with concomitant LPS stimulation (P < 0.001). Accordingly, polysomal loading of mouse TNF mRNA 
was also affected by DHTS in stimulated RAW264.7 cells (Supplementary Fig. S4C), supporting the 
hypothesis that DHTS interferes with the cytoplasmic TNF mRNA fraction loaded on polysomes for its 
translation. Extensive literature data show that HuR enhances the stability and translation of its bound 
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Figure 4. DHTS inhibits intracellular HuR-mRNA association, influencing mRNA stability. (A) RNA 
immunoprecipitation using MCF-7 lysates obtained after 3 h of treatment with DMSO, 1 μ M of DHTS, 
1 μ g/ml of LPS, or DHTS+LPS co-treatment. (B) RNA pull down assays on MCF-7 lysates obtained as in 
(A) after 2 h incubation with BiTNF (ARE+) or BiTNFneg (ARE-) exogenous RNA probes. Graph shows 
densitometric analyses by Image J software (NIH). (C) mRNA stability evaluation of TNF, pre-TNF, and 
GAPDH after co-treatment with actinomycin (D) and DHTS of scramble, vector, HuR silenced (siHuR) and 
HuR over-expressing (HuROE) MCF-7 cells. Relative HuR expression levels are shown in the representative 
WB. Residual mRNA, plotted in log scale, was normalized to relative RNA18S5 mRNA levels. Mean ± SD 
refers to three independent experiments (n = 3).
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mRNA by favoring the polysomal recruitment of the transcript21. Western blot analyses on protein sam-
ples precipitated from polysomal fractions revealed that DHTS displaces HuR from heavy polysomal 
fractions in un-stimulated and LPS-stimulated cells (Fig. 5D). Notably, we could not detect alterations 
in the activation of the p38 MAPK pathway in RAW264.7 cells (Supplementary Fig. S4D), which is 
responsible for cytoplasmic re-localization of HuR and stabilization of TNF mRNA upon LPS stimula-
tion6. Similarly, treatment of 3 h with 1 μ M of DHTS did not affect sub-cellular localization of HuR in 
MCF-7 cells (Fig. 6A) and did not change HuR protein expression level (Fig. 6B). Nucleo-cytoplasmic 
fractionation confirmed DHTS-induced HuR nuclear localization (Fig. 6C) further supporting the loss 
of function of HuR in the cytoplasm and its reduced polysomal loading. Our data suggests that, at early 
time points, pharmacological inhibition of RNA loading on HuR by DHTS confines HuR into the nuclear 
compartment.
HuR expression influences the sensitivity of breast cancer cells to DHTS. Dose-response assays 
on HuR-silenced or -over-expressing MCF-7 cells revealed a different sensitivity to DHTS (IC50 at 24 h of 
0.45 or 1.3 μ M compared with scramble or vector MCF-7 cells, respectively) (Fig. 7A), showing a com-
pensatory effect of HuR against DHTS. Interestingly, ectopic expression of TNF CDS alone, with 3′ UTR 
and ARE or with 3′ UTR but without ARE, did not influence the sensitivity of cells to 1 μ M of DHTS 
(Fig. 7B). This indicates that TNF itself is not responsible for this phenotypic response and that it can 
depend on the dysregulation of other factors regulated by HuR or, also, on independent events trigger-
ing the apoptotic pathways (Figs 3B, 7A). Real-time cell analysis assays demonstrated that DHTS exerts 
anti-proliferative effects at low doses (1 μ M), in MCF-7 cells after about 12 h of treatment (Fig. 7C). At 
Figure 5. DHTS decreases TNF mRNA translational efficiency in MCF-7 cells. (A) Q-RT-PCR showing 
relative nuclear or cytoplasmic amounts of TNF mRNA after 3 h treatment, normalized with GAPDH 
mRNA levels. (B) Polysomal profiles of cytoplasmic RNA of MCF-7 treated for 3 h with DMSO or 1 μ M of 
DHTS. (C) Q-RT-PCR analysis of GAPDH and TNF mRNA levels in single cytoplasmic RNA fractions.  
(D) Representative WB showing the distribution of HuR and RPL26 ribosomal protein in single fractions 
(left); densitometric analysis of relative cytoplasmic HuR protein levels in polysomal fractions. Mean ± SD 
refers to three independent experiments (n = 3).
www.nature.com/scientificreports/
9Scientific RepoRts | 5:16478 | DOI: 10.1038/srep16478
higher doses (10 μ M) cytotoxic effects of the compound appeared in this experimental system, and were 
confirmed by MTT (data not shown). HuR-silenced MCF-7 cells showed a decreased proliferative rate, 
and DHTS treatment completely blocked cell proliferation. Conversely, the proliferative potential of HuR 
over-expressing cells was considerably influenced by 1 μ M of DHTS compared with control (Fig.  7D), 
indicating that HuR dosage can modulate phenotypic response of these cells to low DHTS doses.
To better understand the phenotypic effect related with down-regulation of HuR-dependent and/or 
signaling molecules such as TNF, we then investigated the chemotactic potential of DHTS-treated, MCF-7 
conditioned medium using MDA-MB-231 trans-well migration as read-out, because the migration ability 
of MDA-MB-231 cells also depends on the presence of TNF and other cytokines in the surrounding 
environment29. DHTS treated medium strongly inhibited MDA-MB-231 migration more effectively than 
HuR depletion, whereas the DHTS treatment in siHuR cells produced an almost chemotactic inactive 
medium (Fig. 7E, left panel). Once again, HuR over-expression completely rescued DHTS efficacy and 
the corresponding medium was equally effective as the control medium. Notably, HuR over-expression 
per se did not produce an increased chemotactic medium (Fig. 7E, right panel). Taken all together, these 
data show that HuR completely rescues at least three phenotypic effects of DHTS, such as direct viability 
and proliferation inhibition on cancer cells and autocrine/paracrine inhibition of cancer cell migration. 
This suggests that HuR is a pivotal intracellular target of DHTS and that multi-target effects of DHTS, 
and eventually of tanshinones, can be explained by the inhibition of RNA-binding activity of HuR.
Discussion
In this study we show that DHTS is a potent inhibitor of the HuR:RNA interaction, active in the low 
nanomolar range, mainly by limiting the association rate of HuR with RNA. This inhibition is function-
ally recapitulated in our cellular models, in which the known, DHTS induced down-regulation of TNF 
expression can be largely ascribed to the loss of function of HuR, that no longer stabilizes TNF mRNA 
neither mediates its polysomal loading. This molecular mechanism of action has a therapeutic relevance, 
as shown by the inhibitory effect on viability, proliferation and chemotaxis of breast cancer cell lines and 
Figure 6. Effect of DHTS on HuR sub-cellular localization. (A) Representative immunofluorescence 
showing nuclei (Hoechst) or endogenous HuR (green) in MCF-7 cells treated with 1 μ M DHTS or 2 μ M 
of Actinomycin for 3 hD. (B) Representative western blot of total protein levels of HuR. (C) Western blot 
analysis on nuclear and cytoplasmic extracts of MCF-7 treated as in A. Densitometric analysis plot data of 
three independent experiments (n = 3).
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by the decreased TNF production in macrophages cells. Remarkably, the molecular and phenotypic 
effects induced by short-term and low doses of DHTS in breast cancer cell lines are rescued by the 
over-expression of HuR, confirming the cellular interaction between these two molecules. HuR 
over-expression in cancer tissues and the mechanistic role in mediating the inflammatory process has 
suggested that its inhibition could be beneficial in these pathologies22,30,31. In addition, HuR has been 
proposed as a drug target in cardiovascular diseases, nephropathy and diabetic retinopathy32–34. Several 
in vitro studies14,23,35 introduced some naturally occurring small molecule as HuR inhibitors, however the 
correlation among their post-transcriptional mechanism, biological effect and specificity, and therapeutic 
Figure 7. Efficacy of DHTS is dependent on HuR in breast cancer cell lines. (A) MTT assays on MCF-7 
cells genetically ablated or over-expressing HuR and treated for 24 h with DMSO or DHTS. (B) MTT assays 
on MCF-7 un-transfected or transfected with pUNO1-hTNFA (TNF), pUNO1-hTNFA/3′ UTR (TNF+3′), 
or pUNO1-hTNFA/3′ UTR-ARE (TNFΔ ARE) plasmids, then treated as in A. Western blot shows relative 
amount resulting from ectopic expression of TNF. (C,D) RTCA proliferation assays. Arrows indicate 
the treatment point with DMSO or the indicated doses of DHTS (symbol of vector DMSO condition is 
behind HuROE DHTS in the figure). (E) RTCA migration assays. Complete media of SCR, vector, siHuR, 
and HuROE MCF-7 cells treated for 3 h with DMSO, 1 μ M of DHTS 1 μ g/ml of LPS (vector cells only 
for positive control) were diluted to obtain 1% FBS final concentration. MDA-MB-231 cells were equally 
seeded (20,000/well) in each well of the upper chamber. SCR; stably transfected cells with non targeting 
shRNA, siHuR; stably transfected cells with HuR targeting shRNA, vector; transient transfected cells with 
empty vector, HuROE; transient transfected cells with HuR expressing vector. Mean ± SD refers to three 
independent experiments (n = 3).
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usefulness remains elusive. The most noteworthy example is the naphthofuranone MS-444, that was 
identified by a screening campaign on ≈ 50,000 natural product extracts using confocal fluctuation spec-
troscopic assays14. MS-444 has been shown to inhibit the HuR:RNA interaction by blocking the dimeri-
zation of HuR upon binding to the target RNA with a Kd around 40 nM. We did not investigate if DHTS 
acts via a similar inhibition of HuR dimerization. MS-444 has been recently used as a mechanistic tool 
to prevent HuR binding to miR-1636 and to TDP-43 and FUS mRNA37, although at higher concentrations 
than DHTS. In a recent effort compounds with a coumarin-derived core, which interfere with the func-
tion of HuR in the nanomolar range, have been identified using fluorescence polarization. This class of 
compounds shows anticancer properties in cell lines by inhibition of the expression of anti-apoptotic 
HuR targets, such as Bcl-2, Msi1 and XIAP38. In our case, having RNA-binding activity as functional 
read-out, we measured a strong, nanomolar inhibition of the association rate constant between HuR and 
RNA in vitro that was also specific to HuR and not to other RBPs as Lin28b, TDP-43 and TTP. In par-
ticular, we observed a ≈ 60% reduction in the number of TNF mRNA copies, as well as, with different 
extent, for ERBB2, VEGF, and CCND1 transcripts, using 1 μ M of DHTS by RIP experiments. Consistently, 
pull down experiments confirmed this effect although the magnitude of the interference was smaller 
(~40%), being limited by the use of a competitive exogenous RNA probe. The inhibitory effect of DHTS 
on AUF1 protein upon stimulation with LPS (Fig. 4B) could be ascribed to different mechanisms such 
as a diminished affinity for RNA or to an increased affinity for DHTS due to post-translational modifi-
cations, therefore we can not exclude a multi-targeting effect of DHTS in this condition. We did not 
observe a DHTS-induced activation of the p38 MAPK pathway nor HuR localization to the cytoplasm, 
further supporting the DHTS-induced HuR inhibition within cells and the utilization of DHTS in those 
cancer where HuR cytoplasmic localization plays a relevant role31. DHTS belongs to a family of natural 
diterpenes called tanshinones. Their anti-inflammatory, anti-atherosclerosis, cardioprotective and 
anti-cancer properties have been exploited in traditional Chinese medicine and are now under clinical 
investigation, but their exact mechanism of action is still unclear17,39. In this context we disclose a previ-
ously unrecognized molecular mechanism of action, involving post-transcriptional regulation, that might 
contribute to explain the wide spectrum of activities of DHTS correlated with their well-known inhibi-
tion of TNF. In particular, tanshinone I inhibits growth, invasion and angiogenesis on human breast 
cancer cells MDA-MB-231, both in vitro and in vivo, by decreasing the TNF-induced VEGF production. 
Moreover it reduces the MDA-MB-231 adhesion properties by decreasing the TNF dependent pivotal 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (V-CAM) of endothelial 
cells29. The efficacy of tanshinones has also been related with reduced expression of interleukins such as 
IL-618, MMPs40, VEGF41 and COX-242. There are also indications that the modulatory properties on an 
inflammatory state upon administration of tanshinones occurs via post-transcriptional repression of spe-
cific miRNAs, as in the case of miRNA-155 in colon cancer cells43. Interestingly, many of these key 
mRNAs and miRNAs are post-transcriptionally regulated by HuR8,20,44–47. Tanshinones have been shown 
to target or modulate several transcription factors, ion channels or hormone receptors within the cell39. 
We show that an intriguing explanation to the multi-target spectrum of tanshinones, could rely on the 
inhibition of the post-transcriptional function of HuR. Importantly resveratrol that has been shown to 
post-transcriptionally modulate TNF through KSRP regulation, providing a valuable example of the 
importance of post-transcriptional modulation of mRNA processing in the control of inflammation16. 
We provide mechanistic data indicating that HuR-mediated post-transcriptional inhibition is a major 
component of the cellular response to DHTS and that its relevance is shown by the HuR dosage modu-
lation of cytotoxicity and migratory potential in breast cancer cells in response to DHTS. These findings 
suggest several important avenues for further research: (i) HuR-dependent regulation of TNF expression 
levels. Modulation of cytokines is a validated therapeutic strategy for the treatment of inflammatory 
disorders, and due to its predicted post-transcriptional regulation, it might be expected that administra-
tion of DHTS could attenuate the TNF protein levels rather than deplete TNF at systemic levels, such as 
a consequence of antibody-based therapeutic strategies48; (ii) DHTS as a tool to investigate the connections 
between cancer and inflammation based on modulation of post-transcriptional events. Once validated in 
vivo, the use of DHTS (or of some of its analogues with a better drug-like profile) for therapeutic pur-
poses could be conceived. A functional screening of anti-inflammatory agents allowed the identification 
of 15,16-dihydrotanshinone-I (DHTS) for its ability to inhibit a specific protein-RNA interaction. First, 
we have characterized the biochemical parameters of DHTS in virtue of its interference on the dynamic 
of HuR-RNA binding and anticipated a new molecular scaffold exerting a previous unrecognized bioac-
tivity. Second, we have reported mechanistic evidences, in human tumor and mouse macrophages cell 
lines, suggesting HuR among the early intracellular targets of DHTS. The loss of function of HuR in 
response to this agent explains the modulation of the stability and translational efficiency of target 
mRNAs. Third, we have shown that phenotypic response, in terms of migration and sensitivity, of breast 
cancer cells to DHTS is remarkably influenced by HuR expression. Overall, these findings advance the 
understanding of contribution of post-transcriptional control in mediating anti-inflammatory and 
anti-cancer effects of a class of natural compounds and expand the concept of “genome druggability” by 
adding the post-transcriptional activity of the RNA binding protein HuR as feasible event that can occur 
during a pharmacological treatment. Finally, we suggest a novel rationale for the use of tanshinones in 
human diseases where HuR is deregulated or has prognostic significance, as breast, colon or ovarian 
cancers.
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Methods
Cell culture. Human breast adenocarcinoma MCF-7 (ICLC; HTL95021), SKBR3 (ICLC; HTL03005), 
and MDA-MB-231 (ICLC; HTL99004) cell lines were cultured in standard DMEM medium and growth 
conditions. Stable HuR-silenced (siHuR) and scramble (SCR) MCF-7 cells were obtained by infection 
with HuR shRNA- (ELAVL1 MISSION, Sigma, TRCN0000285492) and control shRNA (plasmid 1864, 
Addgene)-containing lentiviral particles, respectively; clones were selected with 5 μ g/ml puromycin. 
MCF-7 over-expressing (HuROE) cells were obtained by transient transfection with Lipofectamine 2000 
(Life Technologies; 11668-019) of pCMV6-HuR vector23. For endogenous TNF, MCF-7 cells (5*10^4/
well) were seeded in 6-well plates and grown under standard conditions for 24 h. Approximately 10^3 
DH5α E. coli cells were then inoculated for overnight co-culture in DMEM without antibiotics. After PBS 
washing steps, MCF-7 cells were treated for 3 h in complete medium with DHTS or DMSO. RAW264.7 
monocytes were grown as MCF-7 but in DMEM plus 0.1 mM non-essential amino acids mixture (Life 
Technologies, 11140).
Compounds and primary antibodies. Anti-inflammatory drugs used in the screening were 
cherry picked from the Spectrum Collection (MicroSource Discovery). Dihydrotanshinone I (D0947), 
Tanshinone I (T5330), Tanshinone IIA (T4952), Cryptotanshinone (C5624), and actinomycin D (A9400) 
were purchased from Sigma and dissolved in ultrapure dimethylsulfoxide (DMSO, Amresco, N182) to 
10 mM final concentration. List of antibodies: anti-HuR (sc-71290), anti-TNF (sc-1351), anti-Actin (sc-
1616) from Santa Cruz Biotechnology; mouse anti-GAPDH (MAB374) from EMD/Millipore; anti-RPL26 
(ab59567) and anti-6x His (ab1187) from Abcam; TTP antiserum (SAK21B) was a kind gift from Dr. 
A.R. Clark49 (Centre for Translational Inflammation Research, University of Birmingham, Birmingham, 
UK).
Expression and purification of HuR isoforms. The full-lenght sequence of HuR (NP_001410.20) 
in pCMV-HuR recombinant vector50 was used as template for PCR using M1_M2 
(5′ -CCCGCATATGATGTCTAATGGTTATG and 5′ -TATACTCGAGGCGAGAGGAGTGCC) and M2_
M3 (5′ - CCGCATATGATGACCCAGAAGGACGTA and 5′ - GGCCTCGAGTTTGTGGGACTTGT) 
primers. Inserts were sub-cloned in NdeI/XhoI-digested pET-42a vector (kindly provided by dr. Filipowicz’s 
lab, FMI, Basel, Switzerland) to produce M1_M2 (aa 1 to 197; predicted molecular weight: 22 kDa) and M2_
M3 (aa 117 to 326; predicted molecular weight: 24 kDa) His-tagged proteins, respectively. Sub-cloning of 
single domains was obtained with the following primers: M1 (5′ -CCCGCATATGATGTCTAATGGTTATG 
and 5′ -CCGCTCGAGTACGTCCTTCTGGG); M2 (5′ -CCGCATATGATGACCCAGAAGGACGTA and 
5′ -GGCTCGAGTCGCGCTGGCGAGT); M3 (5′ -GGCATATGTCCTCCGGCTGGTGCAT and 5′ -GGCC 
TCGAGTTTGTGGGACTTGT). Protein expression and purifications were performed as already 
described51. Purity of eluates was evaluated by 15% SDS-PAGE and Coomassie staining; single bands 
were quantified using ImageJ 1.4 software (NIH) with respect to known amount of loaded BSA.
AlphaScreen and electrophoresis mobility shift (REMSA) assays. Recombinant HuR-cMyc- 
His protein preparation, REMSAs with a fluorescent RNA probe (5′ -Cy3-AUUAUUUAUUAUU 
UAUUUAUUAUUUA), AlphaScreen with a 5′ -biotinylated RNA probe (BiTNF, 5′ -AUUAUUUAUUAUU 
UAUUUAUUAUUUA), and screening assays were carried out as already described23. Equilibrium disso-
ciation constants (Ki) of DHTS were fitted according to 1-site competition model in GraphPad Prism® , 
version 5.0 (GraphPad Software, Inc., San Diego, CA), keeping constant the RNA concentration (50 nM) 
and the Kd of the reaction at equilibrium (2.5 nM). IC50 values were obtained by nonlinear regression 
of log(dose)-response fit using the same software. Time course experiments were performed by reacting 
ligands and DHTS simultaneously, or by pre-incubating DHTS with rHuR or RNA. Dissociation exper-
iments were performed upon 30 min pre-incubation of 1 nM of rHuR and 50 nM of RNA plus beads 
(“Ligands+beads” in Fig. 1G), before addition of DHTS. To exclude possible interference of beads on dis-
sociation kinetics protein and RNA (“Ligands” in Fig. 1G) were pre-incubated for 30 min, then DHTS, at 
the indicated concentrations, and, finally, beads were added. Curves were fitted according to the kinetics of 
competitive binding model in GraphPad software, keeping constant the kon (2.76 ± 0.56*10^6 M–1 min–1) 
and koff (0.007 ± 0.005 min–1) of the reaction. DHTS analogs were tested by REMSA at the indicated con-
centrations and at equilibrium52. Plasmids encoding recombinant Lin28b-cMyc-His, TDP-43-His, and 
HuD-His were kindly provided by Prof. Quattrone’s lab (CIBIO, University of Trento, Italy). TTP, Lin28b, 
and HuD were expressed in HEK293T cells and purified following the protocols reported in23, with 
exception of buffers for Lin28b purification that were supplemented with 15 μ M ZnCl2. REMSAs were 
performed using the fluorescent AU-rich RNA probe to test TTP and HuD protein activities, whereas 
Lin28b binding was tested against pre-let7g (5′ -Cy3-GUCUAUGAUACCACCCGGUACAGGAGAU)53 
and TDP-43 against the 5′ -Cy3-CCGGGGCCGGGGCCGGGGCCGGGG RNA probes. Further details 
about biochemical experiments in the supplemental information.
Nucleo-cytoplasmic cell fractionation and qPCR. For nucleo-cytoplasmic fractionation, cells 
(4–6*10^6/sample) were re-suspended in buffer C (20 mMTris-HCl pH 7.5, 75 mM NaCl, 5 mM MgCl2, 
0.5% p/w sodium deoxycholate, 0.2% Triton, 1 mM DTT, 0.5% glycerol) plus protease inhibitor cock-
tail (Sigma, P8340) and 1 U/μ l RNAse inhibitor (Thermo Scientific, EO0381). After centrifugation 
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supernatants were collected (cytoplasmic lysates), whereas pelleted nuclei were re-suspended in buffer N 
(10 mM Tris-HCl pH 8, 25 mM NaCl, 5 mM MgCl2, 1% p/w sodium deoxycholate, 1% Triton, 0.2% SDS, 
1 mM DTT) plus protease and RNAse inhibitors and sonicated as above. TRIzol reagent (Life Technologies, 
12183-555) was used for RNA isolation. Quantitative PCRs, after cDNA Synthesis (Thermo Scientific, 
K1612) with equimolar mix of random and oligo-dT primers and two micrograms of template RNA, 
were performed using Universal SYBR Master Mix (KAPA Biosystems, KR0389) on CFX-96/384 thermal 
cyclers (BIO-RAD). 2−ΔΔCt method was used for quantification of mRNAs. Forward and reverse prim-
ers used: RNA18S5 (GCAGCTAGGAATAATGGAATAG and TGGCAAATGCTTTCGCTCTG), TNF 
(5′ -GGGACCTCTCTCTAATCAGC and 5′ -TCAGCTTGAGGGTTTGCTAC), GAPDH (5′ -CAAGGTCA 
TCCATGACAACTT and 5′ -GTCCACCACCCTGTTGCTGTA), CD14 (5′ -GAAGCT AAAGCACTTCCA 
GAGC and 5′ -TTCATCGTCCAGCTCACAAG), ERBB2 (GGTACTGAAAGCCTTAGGGAAGC and AC 
ACCATTGCTGTTCCTTCCTC), VEGF (CCGCAGACGTGTAAATGTTCCT and CGGCTTGTCACAT 
CTGCAAGTA), and CCND1 (CAGAACACGGCTCACGCTTAC and CTTGCCCCATCACGACAGAC). 
Primers for pre-TNF, pre-BRCA1, pre-CTCF, pre-MDM2, pre-MYBL2, and pre-NFATC3 are described 
elsewhere28.
Polysomal profiling and protein/RNA isolation. For polysomal RNA profiling, cytoplasmic lysates 
of 2*10^7 MCF-7 cells/sample were subjected to 15–50% sucrose gradient ultracentrifugation and frac-
tionation following reported protocols6,54,55. Aliquots of cytoplasmic lysates were considered for normal-
ization. From each sub-polysomal or polysomal fraction, protein samples were obtained by precipitation 
with 10% final concentration of trichloroacetic acid (TCA), while RNAs were isolated by TRIzol reagent 
(1:5 v/v). Fractions 1 to 6 were pooled to represent sub-polysomal RNA samples, while pooling of frac-
tions 7 to 12 represented polysomal RNA samples.
RNA immunoprecipitation (RIP) and RNA pull-down assays. Five*10^6 cells/sample were used 
for each RIP experiment, performed as described in56 without cross-linking steps and using 0.8 μ g/
ml of anti-Hu antibody or of mouse IgG isotype (negative control). TRIzol reagent was added directly 
to the beads for HuR-bound RNA isolation. Fold enrichment was calculated as 2e-Δ Ct, Δ Ct = target 
mRNA IP HuR/(target mRNA IgG). For RNA pull-down assays, MCF-7 cells were lysed in buffer R 
(20 mM HEPES pH 7.5, 50 mM KCl, 0.5 μ g BSA, 0.25% Glycerol, + protease and RNAse inhibitors) by 
sonication (80 amplitude with 6–7 cycles of 7” on and 45” off) at 4 °C. Clear lysates (0.2 μ m-filtered) 
were incubated for 1 h at 4 °C with 0.5 μ M of positive (BiTNF) or negative biotinylated (BiTNFneg, 
5′ -ACCACCCACCACCCACCCACCACCCA) RNA probes23. Solutions were incubated for further 2 h 
with 30 μ l/samples of streptavidin magnetic beads (Life technologies, 11205D). Specific protein enrich-
ments in beads-precipitated samples were analyzed by immunoblotting and densitometric analysis 
obtained using Image J 1.4 software (NIH).
RNA stability assays. SCR, siHuR, vector, and HuROE MCF-7 cells were co-treated with Act-D 
(2 μ M) and DMSO or DHTS for 3 h. Kinetics for mRNA stability evaluation has been carried out by 
extracting RNA in five time points (0, 30, 60, 120, 240 min) to be used for cDNA synthesis and quanti-
tative PCR analyses. Residual levels of target mRNAs were normalized to those of RNA18S5, and data 
were plotted as function of time with respect 0 min condition.
Cytotoxicity, Click-iT and RTCA assays. Sensitivity to DHTS was evaluated by CellTiter-Glo® 
(Promega, G7570), alamarBlue or MTT reagents following suggested protocols.
Ectopic expression of human TNF has been obtained with the pUNO1-hTNFA (Invivogen) plas-
mid. Inserts for recombinant pUNO-hTNFA/3′ UTR and pUNO-hTNFA/3′ UTRΔ ARE plasmids have 
been obtained by digestion of pBS vectors57,58, respectively, with XbaI and then blunt-end ligated in 
pUNO1-hTNFA vector digested with NheI restriction enzyme. Sequencing confirmed the results.
Apoptosis was evaluated by Caspase-Glo® 3/7 luminescent assay (Promega, G8090) upon normaliza-
tion to the number of trypan blue negative cells. RNA transcription was assessed using Click-iT® RNA 
Alexa Fluor® 488 Imaging Kit (Life Technologies, C10330). EthynylUridine (EU) was added 30 min 
before fixation, permeabilization and Click-iT reaction. Fluorescence signals relative to nascent RNA 
and nuclei (Hoechst 33342) were detected with Operetta instrument (PerkinElmer)and analyzed with 
Harmony 3.5.2 software (PerkinElmer). Proliferation assays were carried out with the xCELLigence 
RTCA DP Instrument (Roche) by plating 5,000 cells/well at t0 in E-Plate-16 format. Parallel plates were 
used to check the magnitude of HuR silencing or over-expression. Migration assays were performed 
using the same instrument and settings for CIM-Plates-16 (Roche), using media (1% FBS) of MCF-7 cells 
in the lower chamber and MDA-MB-231 cells equally seeded (20,000/well/160 μ l) in the upper chamber.
Immunoblotting and Enzyme-linked immunosorbent (ELISA) assay. Total, nuclear, and cyto-
plasmic cell extracts were subjected to 15%-SDS-PAGE and resolved proteins were transferred to nitro-
cellulose membrane (Millipore, IPVH00010) as previously described59. ELISA assays were carried out 
using Human TNF kit (Thermo Scientific, EH3TNFA) and the suggested protocol using surnatants of 
95%-confluent MCF-7 cells at time of treatment, seeded in 12-well plates.
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Statistical analysis. All data are expressed as means ± SD from three to four independent experi-
ments and statistics was performed using one-way ANOVA with Bonferroni’s multiple comparison test 
and Alpha level of 0.05. Magnitude of significance was also evaluated by student t-test and probability 
(P) values <0.05, <0.01, and <0.001 were indicated with *, **, *** symbols, respectively.
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